



Swedish Radiobiological Society

Svensk förening för radiobiologi



# Programme and abstract book

45th Annual Meeting of the European Radiation Research Society

September 13 - 17 2020 Lund, Sweden

Copenhagen

Lund

Malmö

### **Commercial Sponsors**









### **Support from**





Mrs. Berta Kamprad's Cancer Foundation



The John and Augusta Persson Foundation



### **Table of Contents**

Commercial Sponsors	2
Support from	2
Table of Contents	3
Welcome	10
Committees	11
The Local Organizing Committee (LOC)	11
Scientific Committee	11
ERRS meetings	12
Awards	13
Bacq & Alexander Award	13
Young investigator awards	13
Scientific Program	14
Sunday 13: Conference opening and opening lecture	14
Monday 14: Molecular and cellular effects	15
Monday 14: Molecular and cellular effects, continued	16
Tuesday 15: Translational and clinical research	17
Tuesday 15: Translational and clinical research, continued	18
Wednesday 16: Health effects and radiation protection	19
Wednesday 16: Health effects and radiation protection, continued	20
Thursday 17: Radiation physics and chemistry	21
Thursday 17: Radiation physics and chemistry, continued	22
Abstracts	23
Opening Lecture - The Linear No-Threshold (LNT) Dose-Response Model-A Never-Ending Controversy in Low-Dose Risk Assessment	24
Bacq&Alexander Award Lecture - Premature Chromosome Condensation as a powerful to dose estimation and individualised long-term risk assessment following exposure	
Abstracts – Keynotes	26
K1 - Induction and repair of oxidative clustered DNA damage and its biological importance	
K2 - Non-targeted Effects and Advanced Radiotherapy	29
K3 - Targeting Hypoxia-induced single stranded DNA: an underlying vulnerability	30

	K4 - FLASH radiobiology	. 31
	K5 - Effects of low versus high doses of radiation on the immune system	. 32
	K6 - Radionuclide therapy: biological, physical and medical aspects in preclinical and clinical	
	settings	. 33
Abs	tracts – Invited	34
	I1 - Computational Biology towards Personalizing Radiation Oncology	. 35
	I2 - Genome-wide multi-omics profiling in radionuclide therapy	. 36
	13 - Radiation-induced genomic instability as a driver for environmental evolution	. 37
	14 - Relative Biologial Effect (RBE) for alpha, beta and Auger emitters - implication for         radionuclide therapy	. 38
	I5 - Systemic effects of microbeam radiotherapy	. 39
	16 - Vascular effects of Microbeam Radiation Therapy	. 40
	17 - Microbeams, Organs at Risk and Radiobiology: Bench to Bedside	. 41
	I8 - Imaging tumour of biology	. 42
	19 - Preclinical Models of Precision Radiotherapy	. 43
	I10 - FLASH Radiotherapy	. 44
	I11 - Electron dose rate and oxygen depletion protect zebrafish embryo from radiation dama	ge
		. 45
	I12 - Combined radiotherapy and immunotherapy	. 47
	I13 - Neurocognitive effects of radiation	. 48
	I14 - Unwanted doses from stray radiation in proton therapy	. 49
	I15 - Genetics of Subsequent Neoplasms after Radiotherapy: Biological Insights into Radiation Carcinogenesis and Clinical Implications	
	I16 - Biodosimetry and internal dosimetry in Nuclear Medicine	. 51
	I17 - Radioecology or environmental radioactivity – past present and the future	. 52
	I18 - Ethics in an Crisis: Comparison of COVID-19 and Nuclear Emergencies	. 53
	I19 - Boron neutron capture therapy (BNCT): Technological and physical prospects	. 54
	I20 - Mechanistic Modelling of Intrinsic Radiation Sensitivity	. 55
	I21 - Progress towards using laser wakefield accelerators for radiotherapy	. 56
	I22 - Virtual Study Visit at MAX IV	. 57
	I23 - Life science at ESS	. 58
٩bs	tracts - Oral	59
	O1 - Impact of ATM and DNA-PK inhibition on gene expression and individual response of	60

or BRCA2 mutation
O3 - Chromosome aberration complexity revealed in proton-irradiated cells treated with boron carriers supports Proton-Boron Capture Therapy
O4 - Endometrial stem cells isolated from menstrual blood - A better model for the radiobiology of mesenchymal stem cells?
O5 - Blocking Connexin43 hemichannel alleviates radiation-induced endothelial cell damage . 65
O6 - Cell membrane and lipid raft are involved in targeted and non-targeted effects of Auger and alpha molecular radiotherapy
O7 - Combination therapy: particle irradiation with the Hedgehog inhibitor GANT61 differently modulates the radiosensitivity and migration of cancer cells
O8 - Identification of linear and circular RNA biomarkers of radiation resistance in MCF7 breast cancer cells
O9 - Study of cytotoxic effects induced by carbon ions irradiation on U-251 Glioblastoma cell line after treatment with a new platinum(IV)-based prodrug
O10 - Influence of Alpha-particle Radiation on Intercellular Communication Networks of Tunneling Nanotubes in U87 Glioblastoma Cells
O11 - Targeting NRF2, regulator of antioxidant system, to sensitize glioblastoma neurosphere cells to radiation-induced oxidative stress
O12 - CREB signalling in the irradiated hippocampus
O13 - Role of cellular senescence in radiation-induced cognitive dysfunction
O14 - Role of microenvironment on the post-irradiation regenerative potential of salivary gland stem cells
O15 - Communication of radioprotective effects by TGF-β3
O16 - FLASH-effect observed under normoxic conditions in vitro – mechanisms other than oxygen depletion?
O17 - Reversing cold tumor microenvironment with targeted alpha-therapy 80
O18 - RIBE induction using human ex vivo explants causes alterations in mitochondrial metabolism in bystander cells
O19 - First pre-clinical study for lung carcinoma employing Synchrotron Microbeam  Radiotherapy at the Australian Synchrotron
O20 - Proteomic expression analysis of rat thyroid tissue 12 months after low-intermediate 131I exposure
O21 - Normal tissue reaction following proton irradiation of the mouse brain
O22 - Differential neurocognitive response after partial brain proton irradiation 85
O23 - The new experimental beam line and research facility at CNAO for radiobiological studies with charged particles

ord - RBE-dependence on LET and fractionation in the rat cervical spinal cord after helium ion irradiation
O25 - Proton-FLASH – Radiation effects of ultrahigh dose-rate irradiation
O26 - Investigating FLASH irradiation on acute normal tissue toxicity in the murine gastrointestinal system
O27 - First veterinary patient treated with electron FLASH radiotherapy at a clinical linear accelerator
O28 - Immunomodulatory effects of external and targeted radiotherapy depend on radiation type
O29 - Examining the effect of radiation on the secretome of normal and rectal cancer tissue and how this secretome interacts with the innate immune system
O30 - Clinical Trial Evaluating the Efficacy of Mesenchymal Stromal Cell Injections for the Treatment of Radiation Induced Chronic Pelvic Complications
O31 - Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up97
O32 - Decision tool for radiotherapy compliance in elderly cancer patients
O33 - Characterization of monocytes-endothelium interactions after radiotherapy 100
O34 - Colonic and microbial alterations in a colorectal cancer mouse model provoked by pelvic fractionated X-ray treatment
O35 - p53 drives premature neuronal differentiation in response to radiation-induced DNA damage during early neurogenesis
O36 - NOTCH inhibition promotes bronchial stem cell renewal and epithelial barrier integrity after irradiation
O37 - Preclinical study of Chronic radiocystitis and cell therapy treatment
O38 - Can rosiglitazone protect endothelial cells from irradiation-induced mitochondiral dysfunction?
O39 - Evaluation of the radioprotective potential of a PTEN inhibitor bpV(HOpic)
O40 - Cardiomyocyte dysfunction upon radiation
O41 - Early-life X-ray exposure accelerates brain aging in a 3xTg-AD mouse model 109
O42 - The time-dependence of radiological benefit of decontamination of residential areas after a nuclear fallout for newborn and adults
O43 - Improved patient dosimetry at radioiodine therapy by combining the ICRP iodide compartment model and the EANM pre-therapeutic standard procedure
O44 - Coadministration of three antioxidants did not influence the tumour response to radiotherapy in GOT1 neuroendocrine tumour model
O45 - Effects of α-particles and X-rays on human lung epithelium
O46 - G2/M checkpoint abrogation with selective inhibitors results in chromosome break repair defects in RPE and 82-6 hTERT cells

	radiation doses in interventional cardiology
	O48 - Mathematical modelling of radiation-induced acute myeloid leukaemia incidence 117
	O49 - Modeling early radiation damage occurring during [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy with the Geant4-DNA toolkit
	O50 - RBE prediction by the BIANCA model for in vitro and in vivo irradiation by different hadron therapy ion-beams
	O51 - Development of a new microdosimetric biological weighting function for the RBE assessment in case of the V79 cell line exposed to ions from 1H to 238U
	O52 - EURADOS WG10 and RENEB WG2 exercise on retrospective dosimetry methods in a simulated small scale incident involving ionising radiation
	O53 - About the Absence of Reactive Oxygen Species Overproduction in the Presence of Gold Nanoparticles
	O54 - Azide and hydroxyl radicals induce several di-tyrosine bridge isomers from the amino acid to the protein scale
	O55 - Presolvated electron attachement towards nucleotides in liquids: pulsed radiolysis studies
	O56 - UrMAX - the light from Lund. Preservation of epoch-making scientific equipment illustrated by the evolution from UrMAX to MAX IV.
Abs	tracts - Posters130
	P1 - Development of a low-energy proton beamline for studies on the biological effectiveness of Proton-Boron Capture Therapy
	P2 - Establishing a method for commissioning and validation of the micro-RayStation beam model of a 220 kV XenX small animal irradiator
	P3 - Evaluating the impact of gamma sterilization on calcium phosphates composites with different TiO2 nanomaterials
	P4 - Machine learning for automated assessment of in vitro T-47D colonies using principal component based watershed segmentation
	P5 - Modeling of the radiation situation in the rooms at BNCT research post using the MCNP code
	P6 - Up to speed – Real-time dosimetry for FLASH radiotherapy
	P7 - A lineage tracing tool to map the fate of hypoxic tumour cells
	P8 - A novel EdU-based protocol for the investigation of cell cycle kinetics of irradiated human lymphocytes
	P9 - A Raman spectroscopy-based alternative approach for the analysis of X-ray irradiated SH-SY5Y human neuroblastoma cells
	P10 - Bi-modal treatment using radiation therapy and drug delivery nano-systems for enhanced
	cytotoxicity in radio-resistant tumor models

P11 - Causes and Consequences of telomere instability
P12 - Cell-cycle perturbation, atypical mitosis and micronuclei in Caco-2 cells as indicator of radiation-induced genomic instability
P13 - Cytotoxicity study of peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
P14 - Deep learning-based approach for the segmentation of human carcinoma cells 145
P15 - Ephrin receptors take part in cellular DNA damage response after ionizing radiation and regulate cell viability of non-small lung cancer cells
P16 - Experimental database for research on low dose hyper-radiosensitivity and induced radioresistance
P17 - Gene expression during radiation-induced differentiation of human fibroblasts in vitro 149
P18 - Identifying the cellular response to complex DNA damage induced by high-LET protons 150
P19 - Increased immunogenic signaling in terms of calreticulin expression after x-ray irradiation
P20 - Ionizing radiation, psychological stress, and microgravity in space: hind limb unloading animal model in mice
P21 - Melanin production and radiobiological features of mucosal melanoma cells 153
P22 - Microbeam radiation therapy shows a sparing effect in normal tissue cells 154
P23 - Mitochondria nucleus communication is involved in DNA damage response following exposure to genotoxic stress
P24 - On to the molecular mechanisms of therapeutic and toxic responses of prostate cancer targeted radionuclide therapy
P25 - Proteomic analysis of bystander effects in chondrosarcoma cells
P26 - Proton boron capture therapy (PBCT) approach to enhance radiobiological effectiveness of proton beams on cell culture models
P27 - Puzzling enhancement of proton-induced cellular damage by boron 160
P28 - Quantitative Modelling of Bystander Effects Within Spatially Fractionated Exposures 161
P29 - Response of medulloblastoma cells to ionizing radiation
P30 - Side effects of scattered versus scanned proton beams on normal tissues in total body irradiated mice: preliminary results
P31 - Small is beautiful: low activity alpha and gamma sources for small-scale radiation protection research experiments
P32 - The cytokinesis-block micronucleus assay on isolated fresh and frozen peripheral blood mononuclear cells
P33 - The influence of MGMT expression on radiation responses in human glioblastoma multiforme cell lines
P34 - The specific role of DNA-PKcs in DNA-DSBs repair induced by the neutron-mixed beam 167

	P35 - The temperature effect at the level of DNA damage foci and micronucleus frequency i U2OS-53BP1 and U2OS-NBS1 cells.	
	P36 - Therapeutic potential of Hedgehog signaling pathway modulation for muscular repair after high local dose radiation exposure	169
	P37 - Unravelling the potential interplay of simulated spaceflight conditions: how is the skin affected?	
	P38 - Comparison of the immuno-biological response in the tumor microenvironment after FLASH or conventional electron irradiation	171
	P39 - Identification of Raman spectral biomarkers of treatment response in high risk localise prostate cancer patients receiving SABR.	
	P40 - Nomogram for predicting overall survival in patients diagnosed with spinal bone metastases	173
	P41 - Search for Biomarkers of Radiation-Induced Cardiovascular Disease and Pediatric Tum	
	P42 - Gene expression based signatures to predict the acute radiation syndrome after ionizi radiation - developments and challenges	_
	P43 - Health effects of cardiac fluoroscopy and modern radiotherapy in paediatrics; Harmor	
	P44 - Inter-comparison of OSL response of irradiated salted crackers between Croatian and Italian laboratories for retrospective dosimetry purposes	178
	P45 - Investigation of the Self-cleaning Processes in Lake Drūkšiai from Anthropogenic Origin 14C in the Cooling Pond of the Ignalina Nuclear Power Plant	
	P46 - Long-Term 14C Activity Measurements in Tree Rings Near Ignalina Nuclear Power Plan How it Helps to Monitor Safety of Our Environment	
	P47 - Low dose alpha, gamma and mixed beam radiation gene expression effects at low and high dose rates in human VH10 fibroblasts and AHH1 lymphoblasts	
	P48 - Macrophage subpopulations in stereotactic radiation-induced lung injury in mice	182
	P49 - The competitive relationship between cell killing and induction of carcinogenic mutati in normal cells exposed to fractionated radiation	
	P50 - The "BioPhyMeTRE" project: novel biological and physical methods for triage in radiological and nuclear (R/N) emergencies	184
Autl	hor Index	.185

### Welcome

We are delighted to welcome you to the 45th Annual Meeting of the European Radiation Research Society (ERRS2020)!

The ERRS meeting series belongs to a tradition of European conferences on radiation research initiated already in 1953. This year's meeting is jointly organised by the Swedish Radiobiological Society and Lund University.

With the pandemic situation in mind it was decided to reformat this year's meeting into a digital conference. As organizers, we are committed to bring you an enjoyable experience in an immersive and interactive meeting space. During the organization we have been excited to see the scientific programme grow into a list of contributions that we find truly state-of-the art, covering a wide range of aspects in the fields of radiobiology and radiation sciences, and with representation from about 30 different countries and five continents.

Many meetings were cancelled this year, and we are happy that it was possible to arrange the ERRS2020 event in an alternative manner. We would already now like to thank all participants for submitting their abstracts and adapting to this format. Please take this opportunity to interact with colleagues and friends around the globe, to engage and contribute to a pleasant and rewarding experience. We look forward to your contribution during live discussions, chats around posters and within the sponsor area. Enjoy!

Sincerely,

The Local Organizing Committee

### **Committees**

### The Local Organizing Committee (LOC)

Crister Ceberg (chair), Lund University
Bo Baldetorp, Lund University
Sophie Eriksson, Lund University
Siamak Haghdoost, Stockholm University
Bo-Anders Jönsson, Lund University
Lovisa Lundholm, Stockholm University
Kristoffer Petersson, Skåne University Hospital
Katarina Sjögreen Gleisner, Lund University
Sven-Erik Strand, Lund University

### Scientific Committee

Sarah Baatout, Belgian Nuclear Research Centre, Mol

Bo Baldetorp, Lund University, Lund

Marc Benderitter, Institute for Radiological Protection and Nuclear Safety, Fontenay-aux-Roses

Peter Bernhardt, University of Gothenburg, Gothenburg

Crister Ceberg, Lund University, Lund

Sophie Eriksson, Lund University, Lund

Micael Granström, Swedish Defence Research Agency, Umeå

Siamak Haghdoost, Stockholm University, Stockholm/University of Caen Normandy, Caen

Ester Hammond, Oxford University, Oxford

Michal Hofer, Academy of Sciences of the Czech Republic, Brno

Marek Janiak, Military Institute of Hygiene and Epidemiology, Warsaw

Bo-Anders Jönsson, Lund University, Lund

Gerhard Kraft, GSI Helmholzzentrum für Schwerionenforschung, Darmstadt

Lovisa Lundholm, Stockholm University, Stockholm

Fiona Lyng, Dublin Institute of Technology, Dublin

Lorenzo Manti, University of Naples, Naples

Marjan Moreels, Belgian Nuclear Research Centre, Mol

Kristoffer Petersson, Oxford University, Oxford

Geza Safrany, National Research Institute for Radiobiology and Radiohygiene, Budapest

Katarina Sjögreen Gleisner, Lund University, Lund

Peter Sminia, VU University Medical Center, Amsterdam

Bo Stenerlöw, Uppsala University, Uppsala

Sven-Erik Strand, Lund University, Lund

Soile Tapio, Helmholtz Zentrum, Munich

Georgia Terzoudi, Institute of Nuclear & Radiological Sciences & Technology, Athens

Kristina Viktorsson, Karolinska Institutet, Stockholm

Andrzej Wojcik, Stockholm University, Stockholm

### **ERRS** meetings

Tuesday 15, 11:00 – 12:00: ERRS Council meeting

Wednesday 15, 11:00 – 12:00: ERRS General Assembly

### **Awards**

### Bacq & Alexander Award

Gabriel Pantelias: Premature Chromosome Condensation as a powerful tool for dose estimation and individualised long-term risk assessment following exposure to different radiation qualities

Award lecture is held Wednesday 17, 15:30 - 16:10

### Young investigator awards

Chiara Feoli

Annemarie Schröder

Verdiana Trappetti

Lisa Hintz

**Biche Osong** 

Ségolène Ladaigue

**Shari Wouters** 

Timo Smit

Aggeliki Nikolakopoulou

Martha Habibi

Alessio Parisi

Viacheslav Shcherbakov

Samia Chaouni

Sandra Bicher

Isabella Guardamagna

Anna Kirstein

Lorain Geenen

Magdalena Płódowska

Simon Sioen

Evi Duthoo

Valerio Ricciardi

Jade Monaghan

Milagrosa Lopez Riego

**Delmon Arous** 

Gaia Pucci

Award ceremony is held Thursday 17, 15:30 – 16:10 Poster award ceremony is held Thursday 17, 16:50 – 17:10

### Scientific Program

Sunday 13: Conference opening and opening lecture

15:00 - 15:30	Opening Session  Mats Helmfrid: Lund City Welcome Fiona Lyng: ERRS President's Address Siamak Haghdoost: Swedish Radiobiological Society How to access the ERRS2020 Digital Conference
15.30 - 16.10	Opening Lecture - Pat Zanzonico: The Linear No-Threshold (LNT) Dose- Response Model-A Never-Ending Controversy in Low-Dose Risk Assessment
16.10 - 17.00	Mingle in the Lounge

# Monday 14: Molecular and cellular effects

12.00 - 12.40	Keynote 1 - Alexandros G. Georgakilas: Induction and repair of oxidative clustered DNA damage and its biological importance for humans		
12.40 - 13.00	Invited 1 - Kristian Unger: Computational Biology towards Personalizing Radiation Oncology		
13.00 - 13.20	Invited 2 - Eva Forssell-Aronsson: Genome-wide multi-omics profiling in radionuclide therapy		
13.20 - 13.40	Invited 3 - Carmel Mothersill: Radiation-induced genomic instability as a driver for environmental evolution		
13.40 - 14.00	Coffee Break		
14.00 - 14.40	Main Stage  O1 - Lovisa Lundholm: Impact of ATM and DNA-PK inhibition on gene expression and individual response of human lymphocytes to mixed beams of alpha particles and X-rays  O2 - Stephanie Vermeulen: RAD51 foci as biomarkers for HR efficiency and radiosensitivity in individuals with a BRCA1 or BRCA2 mutation  O3 - Chiara Feoli (YIA): Chromosome aberration complexity revealed in proton-irradiated cells treated with boron carriers supports Proton-Boron Capture Therapy  O4 - Annemarie Schröder (YIA): Endometrial stem cells isolated from menstrual blood - A better model for the radiobiology of mesenchymal stem cells?	O5 - Raghda Ramadan: Blocking Connexin43 hemichannel alleviates radiation-induced endothelial cell damage  O6 - Jean-Pierre Pouget: Cell membrane and lipid raft are involved in targeted and non-targeted effects of Auger and alpha molecular radiotherapy  O7 - Bjorn Baselet: Combination therapy: particle irradiation with the Hedgehog inhibitor GANT61 differently modulates the radiosensitivity and migration of cancer cells  O8 - Auchi Inalegwu: Identification of linear and circular RNA biomarkers of radiation resistance in MCF7 breast cancer cells	
14.40 - 15.00	Panel Discussion		
	Poster Viewing		

# Monday 14: Molecular and cellular effects, continued

15.30 - 16.10	Keynote 2 - Kevin Prise: Non-targeted Effects and Advanced Radiotherapy		
16.10 - 16.30	Invited 4 - Roger Howell: Relative Biologial Effect (RBE) for alpha, beta and Auger emitters - implication for radionuclide therapy		
16.30 - 16.50	Invited 5 - Olga Martin: Systemic effects of microbeam radiotherapy		
16.50 - 17.10	Invited 6 - Valentin Djonov: Vascular effects of micro-beam radiotherapy		
17.10 - 17.30	Coffee Break		
	Main Stage	Breakout Stage	
	O9 - Federica Ciamarone: Study of cytotoxic effects induced by carbon ions irradiation on U-251 Glioblastoma cell line after treatment with a new platinum(IV)-based prodrug	O13 - Yuting Jiang: Role of cellular senescence in radiation-induced cognitive dysfunction	
17.30 - 18.10	O10 - Nicole Matejka: Influence of Alpha-particle Radiation on Intercellular Communication Networks of Tunneling Nanotubes in U87 Glioblastoma Cells	O14 - Yi Wu: Role of microenvironment on the post- irradiation regenerative potential of salivary gland stem cells	
	O11 - Paulo Godoy: Targeting NRF2, regulator of antioxidant system, to sensitize glioblastoma neurosphere cells to radiation-induced oxidative stress	O15 - Ingunn Hanson: Communication of radioprotective effects by TGF-β3	
	O12 - Soile Tapio: CREB signalling in the irradiated hippocampus	O16 - Gabriel Adrian: FLASH-effect observed under normoxic conditions in vitro – mechanisms other than oxygen depletion?	
18.10 - 18.30	Panel Discussion		

Tuesday 15: Translational and clinical research

11:00 - 12:00	ERRS Council meeting		
12.00 - 12.40	Keynote 3 - Ester Hammond: Tumour hypoxia and radiosensitivity		
12.40 - 13.00	Invited 7 - Elisabeth Schültke: Microbeams, Organs at Risk and Radiobiology: Bench to Bedside		
13.00 - 13.20	Invited 8 - Bart Cornelissen: Imaging of tumour biology		
13.20 - 13.40	Invited 9 - Karl Butterworth: Preclinical Models of Precision Radiotherapy		
13.40 - 14.00	Coffee Break		
	Main Stage	Breakout Stage  O21 - Elke Beyreuther: Normal tissue reaction following	
	O17 - Justine Perrin: Reversing cold tumor microenvironment with targeted alpha-therapy	proton irradiation of the mouse brain	
14.00 - 14.40	O18 - Aisling Heeran: RIBE induction using human ex vivo explants causes alterations in mitochondrial metabolism in bystander cells	O22 - Daniëlle Voshart: Differential neurocognitive response after partial brain proton irradiation	
	O19 - Verdiana Trappetti (YIA): First pre-clinical study for lung carcinoma employing Synchrotron Microbeam Radiotherapy at the Australian Synchrotron	O23 - Angelica Facoetti: The new experimental beam line and research facility at CNAO for radiobiological studies with charged particles	
	O20 - Malin Larsson: Proteomic expression analysis of rat thyroid tissue 12 months after low-intermediate 1311	O24 - Lisa Hintz (YIA): RBE-dependence on LET and fractionation in the rat cervical spinal cord after helium	
	exposure	ion irradiation	
14.40 - 15.00		ion irradiation	
14.40 - 15.00 15:00 - 15:30	Panel Di		

Tuesday 15: Translational and clinical research, continued

15.30 - 16.10	Keynote 4 - Marie-Catherine Vozenin: FLASH radiobiology		
16.10 - 16.30	Invited 10 - Kristoffer Petersson: FLASH radiotherapy		
16.30 - 16.50	Invited 11 - Elke Beyreuther: Electron dose rate and oxygen depletion protect zebrafish embryo from radiation damage		
16.50 - 17.10	Invited 12 - Ana Carneiro: Combined radiotherapy and immunotherapy		
17.10 - 17.30	Coffee Break		
	Main Stage	Breakout Stage	
	O25 - Sarah Rudigkeit: Proton-FLASH – Radiation effects of ultrahigh dose-rate irradiation	O29 - Aisling Heeran: Examining the effect of radiation on the secretome of normal and rectal cancer tissue and how this secretome interacts with the innate immune system	
17.30 - 18.10	O26 - Jia-Ling Ruan: Investigating FLASH irradiation on acute normal tissue toxicity in the murine gastrointestinal system	O30 - Alain Chapel: Clinical Trial Evaluating the Efficacy of Mesenchymal Stromal Cell Injections for the Treatment of Radiation Induced Chronic Pelvic Complications	
	O27 - Elise Konradsson: First veterinary patient treated with electron FLASH radiotherapy at a clinical linear accelerator	O31 - Anna Sundlöv: Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up	
	O28 - Julie Constanzo: Immunomodulatory effects of external and targeted radiotherapy depend on radiation type	O32 - Biche Osong (YIA): Decision tool for radiotherapy compliance in elderly cancer patients	
18.10 - 18.30	Panel Discussion		

# Wednesday 16: Health effects and radiation protection

11:00 - 12:00	ERRS General Assembly		
12.00 - 12.40	Keynote 5 - Udo Gaipl: Effects of low versus high doses of radiation on the immune system		
12.40 - 13.00	Invited 13 - Charles Limoli: Neurocognitive effects of radiation		
13.00 - 13.20	Invited 14 - Pawel Olko: Unwanted doses from stray radiation in proton therapy		
13.20 - 13.40	Invited 15 - Lindsay Morton: Genetics of Subsequent Neoplasms after Radiotherapy: Biological Insights into Radiation Carcinogenesis and Clinical Implications		
13.40 - 14.00	Coffee Break		
	Main Stage	Breakout Stage	
	O33 - Ségolène Ladaigue (YIA): Characterization of monocytes-endothelium interactions after radiotherapy	O37 - Clément Brossard: Preclinical study of Chronic radiocystitis and cell therapy treatment	
14.00 - 14.40	O34 - Shari Wouters (YIA): Colonic and microbial alterations in a colorectal cancer mouse model provoked by pelvic fractionated X-ray treatment	O38 - Bjorn Baselet: Can rosiglitazone protect endothelial cells from irradiation-induced mitochondiral dysfunction?	
	O35 - Roel Quintens: p53 drives premature neuronal differentiation in response to radiation-induced DNA damage during early neurogenesis	O39 - Ankit Chauhan: Evaluation of the radioprotective potential of a PTEN inhibitor bpV(HOpic)	
	O36 - Lorena Giuranno: NOTCH inhibition promotes bronchial stem cell renewal and epithelial barrier integrity after irradiation	O40 - Timo Smit (YIA): Cardiomyocyte dysfunction upon radiation	
14.40 - 15.00	Panel Discussion		
15:00 - 15:30	Poster Viewing		

# Wednesday 16: Health effects and radiation protection, continued


15.30 - 16.10	Bacq & Alexander Award - Gabriel Pantelias: Premature Chromosome Condensation as a powerful tool for dose estimation and individualised long-term risk assessment following exposure to different radiation qualities		
16.10 - 16.30	Invited 16 - Uta Eberlein: Biodosimetry and internal dosimetry in nuclear medicine		
16.30 - 16.50	Invited 17 - Per Roos: Radioecology or environmental radioactivity – past present and the future		
16.50 - 17.10	Invited 18 - Deborah Oughton: Science, Ethics and Society: Comparison of Nuclear Emergencies and COVID-19		
17.10 - 17.30	Coffee Break		
17.30 - 18.10	Main Stage	Breakout Stage	
	O41 - Mieke Verslegers: Early-life X-ray exposure accelerates brain aging in a 3xTg-AD mouse model	O45 - Kim Carola Roeder: Effects of α-particles and X- rays on human lung epithelium	
	O42 - Christopher Rääf: The time-dependence of radiological benefit of decontamination of residential areas after a nuclear fallout for newborn and adults	O46 - Aggeliki Nikolakopoulou (YIA): G2/M checkpoint abrogation with selective inhibitors results in chromosome break repair defects in RPE and 82-6 hTERT cells	
	O43 - Martin Andersson: Improved patient dosimetry at	O47 - Martha Habibi (YIA): Detection of DNA damage and chromosomal aberrations after exposure to low ionizing radiation doses in interventional cardiology	
	radioiodine therapy by combining the ICRP iodide compartment model and the EANM pre-therapeutic standard procedure	chromosomal aberrations after exposure to low ionizing	
	compartment model and the EANM pre-therapeutic	chromosomal aberrations after exposure to low ionizing	

### Thursday 17: Radiation physics and chemistry

12.00 - 12.40	Keynote 6 - Mark Konijnenberg: Radionuclide therapy: biological, physical and medical aspects in preclinical and clinical settings		
12.40 - 13.00	Invited 19 - Sauli Savolainen: Boron neutron capture therapy (BNCT) : Technological and physical prospects		
13.00 - 13.20	Invited 20 - Stephen McMahon: Mechanistic Modelling of Intrinsic Radiation Sensitivity		
13.20 - 13.40	Invited 21 - Olle Lundh: Progress towards using laser wakefield accelerators for radiotherapy		
13.40 - 14.00	Coffee Break		
14.00 - 14.40	Main Stage  O49 - Giulia Tamborino: Modeling early radiation damage occurring during [177Lu]Lu-DOTA- [Tyr3]octreotate radionuclide therapy with the Geant4-DNA toolkit  O50 - Mario P. Carante: RBE prediction by the BIANCA model for in vitro and in vivo irradiation by different hadron therapy ion-beams  O51 - Alessio Parisi (YIA): Development of a new microdosimetric biological weighting function for the RBE assessment in case of the V79 cell line exposed to ions from 1H to 238U  O52 - Lovisa Waldner: EURADOS WG10 and RENEB WG2 exercise on retrospective dosimetry methods in a simulated small scale incident involving ionising radiation	O53 - Viacheslav Shcherbakov (YIA): About the Absence of Reactive Oxygen Species Overproduction in the Presence of Gold Nanoparticles  O54 - Anouchka Gatin: Azide and hydroxyl radicals induce several di-tyrosine bridge isomers from the amino acid to the protein scale  O55 - Sergey Denisov: Presolvated electron attachement towards nucleotides in liquids: pulsed radiolysis studies  O56 - Sverker Werin: UrMAX - the light from Lund. Preservation of epoch-making scientific equipment illustrated by the evolution from UrMAX to MAX IV	
14.40 - 15.00	Panel Discussion		
15:00 - 15:30	Poster Viewing		

### Thursday 17: Radiation physics and chemistry, continued

15.30 - 16.10	Young Investigator Awards
16.10 - 16.30	Invited 22 - Sverker Werin: Virtual Study Visit at MAX IV
16.30 - 16.50	Invited 23 - Sindra Petersson Årsköld: Opportunities for Life Sciences at ESS, the European Spallation Source
16.50 - 17.10	Best Poster Award and Closing the Conference



# Opening Lecture - The Linear No-Threshold (LNT) Dose-Response Model-A Never-Ending Controversy in Low-Dose Risk Assessment

#### Pat Zanzonico<sup>1</sup>

The Linear No-Threshold, or LNT, dose-response model in the assessment of low-dose radiation risk remains one of the great scientific controversies. The most important low-dose effect, at least hypothetically, is carcinogenesis. The most extensive and reliable dose-response data for radiation carcinogenesis are the A-bomb survivor data, but with many of these data lying in a high-dose range (> 1 Sv) and with the doses delivered at a high dose rate. The challenge, then, is: How do we mathematically model these fairly noisy, high dose-rate data to estimate the low-dose, low-dose rate cancer risk (<0.1 Sv)? There are four possible dose-response models, or mathematical functions, for fitting these data: the supra-linear model, the linear no-threshold (LNT) model, the sub-linear (linear-quadratic, LQ) model, and the hormesis model. The debate has been and largely remains between the LNT and the LQ models, with the LNT-derived lifetime risk of fatal cancer being ~0.05 /Sv. Importantly, studies of occupationally exposed individuals to date have yielded a notable, and unexpected, lack of mitigation of cancer risk associated with the lower dose rates from occupational exposures. However, the cancer risk associated with diagnostic and occupational radiation doses, if any, is not only far smaller than that of other common cancer risk factors but also is so small that it is likely undetectable among a general population. While the LNT model is likely not a mechanistically valid model of low-dose radiation action and while it is not appropriate for patient management, it provides a systematic basis for formulating radiation protection standards.

<sup>&</sup>lt;sup>1</sup> Memorial Sloan Kettering Cancer Center, New York, NY


Bacq&Alexander Award Lecture - Premature Chromosome Condensation as a powerful tool for dose estimation and individualised long-term risk assessment following exposure

#### Gabriel Pantelias<sup>1</sup>

<sup>1</sup> Institute of Nuclear and Radiological Sciences, Energy, Technology and Safety (I.N.RA.S.T.E.S.), National Center for Scientific Research Demokritos, Athens, Greece

Chromosomal aberrations analyzed in blood lymphocytes at metaphase are of interest for Radiation Protection purposes. Specifically, dicentrics and ring chromosomes are used to obtain early absorbed dose estimates; reciprocal chromosome exchanges are valuable for retrospective dosimetry of past exposures; and radiation-induced chromatid breaks during the G2-M-phase transition are examined for intrinsic individual radiosensitivity testing. Even though the results obtained with conventional metaphase analyses are very important for personalized risk assessment, a major shortcoming is that the blood lymphocytes must be cultured for 2 to 3 days to reach mitosis. In addition, the G2-block induced by exposure to high doses retard the entry of damaged cells into metaphase. To overcome these shortcomings, I developed the premature chromosome condensation (PCC)-assay for non-stimulated blood lymphocytes, which not only allows visualization of 46 G0-lymphocyte prematurely condensed chromosomes (PCCs) within 2 hours, but also a timely dose estimation based on radiation-induced excess (over 46) PCCs.

In the present 2020 Bacq & Alexander award lecture, I will focus on the fascinating features and potential of premature chromosome condensation as a powerful research tool in biodosimetry, radiobiology, and cell biology. Specifically, I will describe briefly our most recent achievements using PCC to: 1) improve biodosimetry and health risk monitoring methods, combining PCC fragment analysis and FISH techniques to detect and quantitate inter- and intra-chromosome rearrangements; 2) develop a micro-PCC assay for early triage biodosimetry; 3) study the conversion mechanism of radiation-induced DNA lesions into chromosome fragments; 4) investigate the mechanisms underlying the phenomenon of chromothripsis, an alternative mechanism to the stepwise induced carcinogenesis; 5) obtain RBE values, identify specific fingerprints of exposure to particle radiation, and elucidate the mechanistic origin of chromothripsis-like alterations induced by high-LET irradiation.



# K1 - Induction and repair of oxidative clustered DNA damage and its biological importance for humans

### Alexandros G. Georgakilas<sup>1</sup>

Ioanna Tremi¹, Spyridon A. Kalospyros¹, Maria P. Souli¹,², Theodora-Dafni Michalettou¹, Christine Vasileiou¹, Ifigeneia V. Mavragani¹, Antonio Pantelias³, Georgia I. Terzoudi³, Zacharenia Nikitaki¹¹ DNA damage laboratory, Physics Department, School of Applied Mathematics and Physical Sciencies, National Technical University of Athens, Iroon Polytechneiou 9, Zografou 15780, Greece² Atominstitut, Technische Universität Wien, Stadionallee 2, Wien 1020, Austria³ Laboratory of Health Physics, Radiobiology & Cytogenetics, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Centre for Scientific Research "Demokritos", Athens, Greece

Exposure to ionizing radiation (IR) of low—to-high linear energy transfer (LET) inflicts a variety of pernicious effects to biological systems. But which is considered the main instigator of these effects? With increasing LET, like when a charged particle traverses a cell, the induced-DNA damage is dense in space and time and it's called clustered or complex DNA damage. Both types of cells (malignant and normal) and across species, respond to IR-induced complex DNA damage by activating a multifaceted network of initial DNA damage response signaling cascade, which along with its subsequent damage processing (repair) pathways are called DNA damage response and repair (DDR/R) [1]. Clustered DNA damage hobbles cellular repair machinery leading to cell death or to misrepair DNA, causing in turn, genomic instability [2]. Upon irradiation, the underlying biological processes that determine cellular fate (cell death, senescence or survival with mutations) are practically the complexity of DNA damage and fidelity of repair.

In this presentation, we will discuss: the importance of clustered DNA lesions comprised strand breaks and oxidative base damage, available DNA damage prediction tools based on Monte Carlo simulations [3] as well as DNA damage detection strategies along with the state of the art microscopy advantages and the resolution limit [4]. At the same time, a historical perspective on the progress of understanding the repair mechanisms used to confront this severe type of cellular stress and the need for systemic biology approaches needed to tackle the problem better. Last but not least, we will briefly present latest data from our laboratory on the above topics and conclude underscoring the IR-systemic effects triggered by complex DNA damage and implications for cancer treatment using radiation therapy (RT).

#### **Selected references**

- 1. Mavragani, I.V.; Nikitaki, Z.; Kalospyros, S.A.; Georgakilas, A.G. Ionizing Radiation and Complex DNA Damage: From Prediction to Detection Challenges and Biological Significance. *Cancers* **2019**, *11*, 1789.
- 2. Pantelias, A.; Karachristou, I.; Georgakilas, A.G.; Terzoudi, G.I. Interphase Cytogenetic Analysis of Micronucleated and Multinucleated Cells Supports the Premature Chromosome Condensation Hypothesis as the Mechanistic Origin of Chromothripsis. *Cancers* **2019**, *11*, 1123.
- 3. Chatzipapas, K.P.; Papadimitroulas, P.; Emfietzoglou, D.; Kalospyros, S.A.; Hada, M.; Georgakilas, A.G.; Kagadis, G.C. Ionizing Radiation and Complex DNA Damage: Quantifying the Radiobiological Damage Using Monte Carlo Simulations. *Cancers* **2020**, *12*, 799.

4.	Nikitaki, Z.; Nikolov, V.; Mavragani, I.V.; Plante, I.; Emfietzoglou, D.; Iliakis, G.; Georgakilas, A.G. Non-DSB clustered DNA lesions. Does theory colocalize with the experiment? <i>Radiation Physics and Chemistry</i> <b>2016</b> , <i>128</i> , 26-35.

#### K2 - Non-targeted Effects and Advanced Radiotherapy

#### Kevin M. Prise<sup>1</sup>

<sup>1</sup> Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7AE

The delivery of radiotherapy has rapidly advanced into an extremely precise and effective treatment in around 50% of all cancers. Much of this is a technological evolution from large field conformal treatments to voxel-based painting of dose linked to image guidance. Advances, such as the increased use of charged particles and combining MRI imaging with photon-based RT, have the potential to further accelerate its utility and precision. Our understanding of how radiation interacts at a biological level is also evolving from one where direct radiation damage is key to one where non-targeted effects, involving signalling, tissue interactions and immune responses have the potential to impact clinical utility. These have developed from an understanding of bystander responses at the cellular level to longer range abscopal or out-of-field effects which impact clinically. Although mechanisms underpinning these effects are being elucidated, they involve a complex interplay between stress response and immune signalling which is likely to be highly patient specific. The advent of Microbeam Radiotherapy (MRT), building on historical grid therapy approaches has shown that the spatial effects that these patterend irradiations deliver at the tissue level are important. Recently the use of high dose-rate FLASH approaches has also highlighted that dose-rate is critical, particularly for normal tissue response. Overall, this suggests that our understanding of the fundamental role of spatial and temporal responses in biological systems needs more focussed research.

#### K3 - Targeting Hypoxia-induced single stranded DNA: an underlying vulnerability

#### **Ester Hammond**

<sup>1</sup> MRC Oxford Institute for Radiation Oncology, Department of Oncology, The University of Oxford, Oxford, OX3 7DQ, UK

Exposure to severe levels of hypoxia, often referred to as radiobiological hypoxia, leads to the induction of the DNA damage response. As cancer cells in radiobiological hypoxia are significantly more resistant to radiation-induced DNA damage they negatively impact radiotherapy response. A number of clinical studies have demonstrated that hypoxia is a significant indicator of poor patient response. The aim of our work is to investigate the biological response and adaptation by cancer cells to hypoxia, with the ultimate aim of developing new therapeutic strategies through the identification of critical molecular targets. The levels of hypoxia associated with resistance to radiotherapy initiate a unique transcriptional response including the rapid response of numerous transcription factors in a background of global repression of transcription. Here, we show that the biological response to radiobiological hypoxia includes the induction of the DNA/RNA helicase SETX. In the absence of hypoxia-induced SETX, R-loop levels increase, DNA damage accumulates and DNA replication rates slow. Together, these data demonstrate a key role for SETX in protecting cells from DNA damage induced either through R-loop accumulation or replication stress. Interestingly, we show that the mechanism of SETX induction is reliant on the PERK/ATF4 arm of the unfolded protein response. These data highlight the unique biological response to radiobiological hypoxia which include the DNA damage and unfolded protein response and suggest functional links between them.

K4 - FLASH radiobiology			
Marie-Catherine Vozenin			
	31		


### K5 - Effects of low versus high doses of radiation on the immune system

#### Udo Gaipl<sup>1</sup>

<sup>1</sup> Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

The immune system protects the body from illness by recognizing and killing of invaders such as bacteria and viruses. It further assures homeostasis and is central in controlling cancer. A dedicate balance of the regulation of immune responses does exist, since on the one hand immune reactions against the own body (autoimmunity) have to be avoided and on the other hand cancer cells and invaders have to be recognized and killed. This is assured by the immediate and non-specific action of components of the innate immune system and over time by the specific, acquired immunity, the so-called adaptive immune response. Radiation as stressor acts directly on cells of the innate and adaptive immune system and does indirectly modulate the immune system as reaction on radiation exposed normal tissue and cancer cells. This talk will deal with radiosensitivity of immune cells, anti-tumor immune responses induced by local irradiation of tumor tissues as applied in radiotherapy of cancer, and with the impact of lower doses of radiation on amelioration of existing inflammation. In the latter context, the evidence of low-dose radiation therapy for COVID-19 pneumopathy will shortly be discussed. Clinical trials that were developed based on pre-clinical immune biological findings of immune modulation by radiation will be introduced, such as the IMMO-LDRT01, RAD-ON02, ST-ICI, GLIO-CMV-01, and CheckRad-CD8 studies. It will become clear that radiation triggers the immune systems in dependence of many factors such as radiation dose, fractionation of radiation, combination with additional immune modulators, and basal inflammatory status. Furthermore, the dynamics of the immune system and non-linear dose effect relationships have always to be considered when examining radiation effects on the immune system. One can conclude that the effects of radiation on the immune system are manifold and that targeted DNA damaging effects of radiation should always be viewed in conjunction with stress responses and subsequent immune modulations.

K6 - Radionuclide therapy: biological, physical and medical aspects in preclinical and clinical settings
Mark Konijnenberg



### 11 - Computational Biology towards Personalizing Radiation Oncology

### Kristian Unger<sup>1, 2, 3</sup>

- <sup>1</sup> Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany
- <sup>2</sup> Clinical Cooperation Group Personalized Radiotherapy in Head and Neck Cancer, Helmholtz Zentrum München, Neuherberg, Germany

In oncology one of the major challenges is the heterogeneity of the treatment response in the frame of standard therapy regimens. I present the concept of computational biology with the main aim to identify prognostic rules in the form of molecular signatures for the prognostic substratification of patients as a first step. In the second step the biological specifics of substrata are investigated towards personalization of treatment options.

The "computational biology towards personalizing radiation oncology" concept uses multi-omics big data sets in from oncology-treated patient cohorts in combination with clinical follow-up data to be subjected to machine learning in order to identify prognostic signatures. I present two examples of a successful application of this approach. In the first we used a multi-center cohort of locally advanced radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC) patients from which we generated global miRNA-expression data. A 5-miRNA signature was identified that predicts local control (freedom from recurrence) and survival endpoints. Integration of the 5-miRNA signature with T-stage, N-stage Ai3nd extracapsular extension by recursive partitioning decision tree analysis allowed the definition of prognostically relevant subgroups. The second example is application of the concept on standard-treated (surgery followed by radiochemotherapy) glioblastoma in which a prognostic (overall survival) 4-miRNA signature was identified. The signature in combination with *MGMT*-promoter methylation status allows the definition of subgroups with particularly unfavorable, intermediate and favorable outcome.

Computational biology on big omics data from clinically ongologically treated cohorts can identify prognostic rules for the potential used in precision medicine.

<sup>&</sup>lt;sup>3</sup> Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

#### 12 - Genome-wide multi-omics profiling in radionuclide therapy

#### Eva Forssell-Aronsson<sup>1</sup>

<sup>1</sup> Dept of Radiation Physics, Inst of clinical Sciences, Sahlgrenska Academy, Universitty of Gothenburg, Gothenburg, Sweden, and Dept of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden

Systemic targeted radionuclide therapy (RNT) offers a possibility for treatment of patients with metastatic tumour diseases, patients who otherwise have poor prognosis. Much research involves development of more specific radiopharmaceuticals, and some have recently been FDA and EMA approved, demonstrating successful results regarding tumour regression, increased overall survival, and improved quality of life. However, the cure rate is still low, and many strategies are proposed to optimised treatment protocols and individualised treatment planning. Such strategies include combination therapy with radiosensitisers (to increase effect on tumour tissue) or radioprotectors (to reduce side effects) together with new fractionation schedules.

To improve RNT the molecular mechanisms (signalling pathways) behind the radiation response need to be known. Biomarkers to predict/prognose late side effects on critical organs and tumour response are needed for individualised treatment. Omics methods are then needed to fully understand the signalling pathways behind the treatment effects. Omics platforms offer whole genome, transcriptome, proteome, metabolome or epigenetic analysis.

The presentation will demonstrate examples of genome-wide multi-omics data from our recent studies on radionuclide therapy or radiation exposure of tumour-bearing mice and normal mice and rats. Omics analyses were performed on tumour and various normal tissue samples, including plasma and urine. Transcriptomic and proteomic data from studies of new fractionation schedules, combination therapies, and side effects are shown.

So far we have found effects related to radionuclide, absorbed dose, dose rate, time after administration, tissue type, animal species or strain, age, and sex. Differential response related to fractionation, combination therapy, systemic effects, and circadian rhythm were detected. Radiation associated biomarkers have been proposed for solid tissue, plasma and urine. Furthermore, deconvolution of microarray data from samples with multiple cell types were tested and resulted in higher detection rate and lower number of false negatives. Results were reproducible and could be validated by other methods.

There are methods to evaluate several omics data sets from different platforms in a concerted way, using e.g. machine learning or deep learning in a systems biology way. Such methods are intriguing, but also connected to challenges including experimental limitations, differences in data between the platforms, integration, handling of large amount of data, and interpretation of data into biologically and clinically useful results. Multi-omics techniques offer a great basis for improved RNT.

# 13 - Radiation-induced genomic instability as a driver for environmental evolution

## Carmel Mothersill<sup>1</sup>

Colin Seymour<sup>1</sup>

The "non-targeted effects" of ionizing radiation including bystander effects and genomic instability predominate after low dose exposures and dominate response outcomes. These effects are unique in that no classic mutagenic event occurs in the cell showing the effect. In the case of bystander effects, cells which were not in the field affected by the radiation show high levels of mutations, chromosome aberrations, ROS and membrane signaling changes (horizontal transmission of mutations and information which may be damaging) while in the case of genomic instability, generations of cells derived from an irradiated progenitor appear normal but then lethal and nonlethal mutations appear in distant progeny (vertical transmission). The phenomena are characterized by high yields of mutations and distant occurrence of events both in space and time. This precludes a mutator phenotype or other conventional explanation and appears to indicate a generalized form of ROS mediated stress induced mutatgenesis which is well documented in bacteria. The nature of the signal travelling between irradiated and unirradiated cells and organisms is currently unknown but our recent experiments suggest that there may be a physical component such as a vibration wave involved. UV photon mediated transmission has also been documented and the latter mechanisms can induce the release of exosomes which by themselves can induce bystander effects when added to recipient cells. This review will discuss the phenomenology of non-targeted effects both in vitro and in vivo, including recent data suggesting that excitation decay-induced photons in the UVA range lead to exosome release and consequent mitochondrial malfunction and elevated ROS in recipient cells. Photons, calcium, and neurochemicals are important in signal production while the exosome cargo, and cytokine mediated pathways especially TGFb determine response to the signal. By highlighting some key challenges and controversies, concerning the mechanisms and more importantly, the reason these effects exist, current ideas about the wider implications of non-targeted effects in evolution and biology will be discussed.

<sup>&</sup>lt;sup>1</sup> Environmental Radiobiology, McMaster University, Canada

Roger Howell		

# 15 - Systemic effects of microbeam radiotherapy

# Olga Martin<sup>1</sup>

<sup>1</sup> Peter MacCallum Department of Oncology, University of Melbourne

Radiotherapy, a major contributor to cancer cures, is a localized treatment that is directed at the tumor. It is generally believed that the only normal tissues at risk are those that are in the irradiated volume, and the problem will diminish as the targeting technology improves. One example is synchrotron-generated microbeam radiotherapy (MRT) utilizing high intensity X-rays collimated into planar microbeams. It is a promising novel cancer treatment due to its reported ability to ablate tumours with less damage to normal tissues compared to conventional broadbeam radiotherapy techniques. However, toxicities associated with cancer radiotherapy extend beyond the focal volume. Some toxicities are due to lower doses delivered to normal surrounding tissues, others arise from the stress of the treatment propagated systemically far from the irradiated areas, and are associated with nontargeted (or abscopal) effects.

Accumulated unrepaired systemic DNA damage underlies radiotherapy-induced pathologies. We demonstrated that in lung cancer patients treated with curative intent radiotherapy, dose-dependent radiation-induced DNA damage was induced in lymphocytes circulating through the irradiated thorax, while dose-independent abscopal DNA damage accumulated in out-of-field normal tissues. For a mechanistic insight, we examined abscopal effects in mice that were locally exposed to MRT or broadbeam radiation at the Australian Synchrotron in Melbourne. Complex DNA damage, apoptosis, immune responses, senescence were elevated in unirradiated normal tissues. These genotoxic events were accompanied by changes in concentrations of several plasma cytokines. Overall, systemic radiation responses were independent of dose, time post-irradiation, and radiation modality. Strikingly, these effects were completely or partially abrogated in the mice with various immune deficiencies, highlighting the role of the functional immune system in propagation of systemic genotoxic effects of localized irradiation. This study opens an opportunity to monitor individual real-time biologic effects of various radiotherapy protocols, and may inform new strategies for prevention and mitigation of radiotherapy-related morbidities, to improve the quality of life of the increasing numbers of cancer survivors.

# 16 - Vascular effects of Microbeam Radiation Therapy

# Valentin Djonov<sup>1</sup>

<sup>1</sup> Institute of Anatomy, University of Bern, Switzerland

The Microbeam Radiation Therapy (MRT) technique uses synchrotron-generated X-rays to produce a spatially fractioned beam of alternating regions of high and low doses in the target tissue. The underlying radiobiology of MRT appears to follow a different paradigm of radiation tissue interactions in which tumour tissue is highly sensitive and normal, healthy tissues exhibit remarkably high resistance even when irradiated with peak doses of hundreds of Grays. Our preliminary data employing different animal models, indicate that the vascular alterations induced by MRT could explain its remarkable therapeutic index:

(i) With 'peak' doses in the range of 400-600 Gy, MRT could be used as a completely <u>novel antiangiogenic</u>, <u>tumor-vascular disrupting strategy</u> due to its unique, selective destruction of tumourvessels. Normal tissue, with mature vasculature, can restore MRT-damaged capillaries using its robust basal membrane and extracellular matrix as a scaffold. In contrast, the immature tumor vasculature with an irregular or missing basal membrane and an abnormal extracellular matrix is unable to repair such damage and tumour blood supply is abolished. (ii) MRT in a range of 100-150 Gy causes a partial disintegration of the endothelium, which leads to a temporally significant increase in tumor blood vessel permeability without disrupting perfusion. An MRT induced "transpermeability window" has been identified as a potent <u>drug delivery system</u>. This highly efficient therapeutic window could be applied for combined/double treatment: MRT plus hemotherapy /Nanoparticles /Antibodies /etc... (iii) Tumor vessels disintegrated by MRT could serve as homing gate for circulating inflammatory and immune cells and thus have the potential to modulate anti-tumor immune responses.

Depending of the dose, MRT could be considered either as a novel angiodisruptive agent in tumors at high doses or as a potent and unique drug delivery system for combined tumor treatment at lower doses. This will help to create new, more efficient treatment strategies against cancer and angioproliferative vascular diseases.

# 17 - Microbeams, Organs at Risk and Radiobiology: Bench to Bedside

## Elisabeth Schültke<sup>1</sup>

<sup>1</sup> Klinik und Poliklinik für Strahlentherapie, Universitätsmedizin Rostock, Südring 75, 18059, Rostock

Microbeam radiotherapy (MRT) is a still experimental concept of spatial dose fractionation. In order to conduct MRT, a multislit collimator is inserted into an X-ray beam generated by a synchrotron. An array of quasi-parallel microbeams is produced which results in an inhomogeneous dose distribution in the target tissue, with a regular sequence of peak dose (high dose) and valley dose (low dose) zones. The peak doses are typically higher by one or even two orders of magnitude, compared to a single fraction dose in clinical radiotherapy. The results of pre-clinical studies suggest that MRT could help to improve tumour control, especially in malignant tumours which are considered radioresistant with current clinical concepts of radiotherapy. Radiobiology studies suggest that tissue responses are different for broad beam and microbeam radiotherapy.

The first two decades of MRT research have focused almost entirely on models of malignant brain tumours and normal brain tissue response. More recently, also tumours in organs outside the CNS are considered as potential targets. In an international collaborative effort, we have been studying the response of lung tissue to MRT and initiated studies in organs of risk with irradiation targets in the lung.

With view on the first clinical MRT trials, which are hoped to be conducted within the next 6-10 years at international synchrotron facilities in Grenoble (France) and Melbourne (Australia), the results of key experiments in pre-clinical MRT research will be presented.

# *18 - Imaging tumour of biology*

# Bart Cornelissen<sup>1</sup>

<sup>1</sup> Oxford Institute for Radiation Oncology, UK

The outcome of cancer therapy using ionising radiation heavily depend on the (radio)biology of the tumour tissue. Non-invasive interrogation of this biology, using molecular imaging, provides vital information regarding the molecular processes underpinning tumour response. This not only provides excellent research tool for studying the effects of experimental treatment regimens, but can be translated to the clinic to allow for patient selection and fast treatment evaluation.

# 19 - Preclinical Models of Precision Radiotherapy

## Karl T. Butterworth<sup>1</sup>

<sup>1</sup> Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland, UK

Animal models continue to play a critical role in our understanding of radiotherapy response and are evolving to better recapitulate the underlying biology of humans. In addition, recent developments in small animal precision radiotherapy have significantly improved in vivo irradiation techniques, allowing previously unimaginable experimental approaches to be explored in the laboratory. Currently, we are applying small animal precision radiotherapy to challenge conventional dose-volume/dose relationships in critical organs at risk, including the heart, which is considered a uniformly radiosensitive organ. Despite whole-heart dose constraints, emerging evidence suggests that higher doses to radiosensitive cardiac substructures located in the base of the heart may lead to poorer survival outcomes.

C57BL/6 mice were irradiated with a single fraction of 16 Gy to the base, middle or apex of the heart using a small animal radiotherapy research platform. Cone beam CT and echocardiography were performed at baseline, and at 10 week intervals until 50 weeks post-treatment. Structural and functional parameters including fractional shortening, ejection fraction and myocardial performance index were correlated with mean heart dose (MHD) and volume of heart receiving 5 Gy (V5). Statistically different functional effects (p < 0.01) were observed in base-irradiated animals which showed the most significant decreases compared to controls. The observed functional changes did not correlate with MHD and V5 ( $R^2$  < 0.1), indicating that whole heart dosimetry parameters do not predict physiological changes resulting from cardiac sub-volume irradiation.

This is the first report demonstrating the structural and functional consequences of sub-volume irradiation in the mouse heart that validates the heart base as a critical radiosensitive region. Our study exemplifies how recent developments in preclinical radiotherapy technology are now enabling advanced studies in the laboratory, and may directly inform the development of new treatment paradigms exploiting optimised beam modalities and avoidance of critical substructures.

# 110 - FLASH Radiotherapy

# Kristoffer Petersson<sup>1, 2</sup>

- <sup>1</sup> Oxford Institute for Radiation Oncology, UK
- <sup>2</sup> Department of Radiotherapy, Skåne University Hospital, Lund, Sweden

FLASH radiotherapy (FLASH-RT) is a new technique which involves treatment of tumours at ultrahigh dose rates which actually reduces normal tissue toxicity with a dose modifying factor of approximately 1.2-1.5, whilst equalling the anti-tumour effect of conventional dose rate radiotherapy (CONV-RT). Another potentially large benefit with FLASH-RT is the quick delivery, allowing for the full dose to be delivered in a fraction of a second. With such a quick delivery, there is no target motion during treatment, i.e. motion due to respiration or any other involuntary movement. If a new image-guidance and positioning strategy is implemented, target margins related to motion could likely be minimized, leading to less normal tissue being exposed to the treatment dose. However, very little is known about the mechanisms behind the FLASH effect or how it should be used in an optimal way in a clinical setting to treat cancer patients.

One human patient with an aggressive form of lymphoma has been treated with FLASH-RT. The treatment was successful with complete tumour response, while the patient only experienced mild redness and inflammation in the treated volume. A first clinical *veterinarian* study has been performed; a phase I dose-escalation trial treating feline patients suffering from squamous cell carcinoma on their noses. Currently, several veterinarian clinical studies are ongoing, treating canine and feline cancer patients.

Prototype electron linear accelerators have been used in most studies demonstrating a FLASH effect. Clinical linear accelerators can be modified to deliver FLASH-RT with electrons, simplifying the translation into clinical trials. However, a limitation of these electron beams is the depth of tissue which can be treated, which is restricted to a few centimetres. A solution could be to use higher energy electron beams with improved depth penetration or proton beams. Nevertheless, these beams come with a new set of challenges that needs to be solved before FLASH-RT can be used clinically.

FLASH-RT has been studied across various species and has been shown to result in superior tissue protection in comparison to CONV-RT, without compromising on tumour response. While its mechanism of action is likely to in part involve oxygen depletion, it is not fully understood and therefore requires further studies. How this technology should be optimally introduced and utilized in the clinic for treating cancer patients is another main topic of our continued research into FLASH-RT, at the Oxford Institute for Radiation Oncology.

# 111 - Electron dose rate and oxygen depletion protect zebrafish embryo from radiation damage

# Elke Beyreuther<sup>1, 2</sup>

Michael Brand<sup>3</sup>, Stefan Hans<sup>3</sup>, Leonhard Karsch<sup>2, 4</sup>, Elisabeth Lessmann<sup>1</sup>, Steffen Löck<sup>2, 5, 6</sup>, Michael Schürer<sup>2, 7</sup>, Jörg Pawelke<sup>2, 4</sup>

- <sup>1</sup> Helmholtz-Zentrum Dresden Rossendorf (HZDR), Institute of Radiation Physics, Dresden, Germany
- <sup>2</sup> OncoRay National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden; Helmholtz-Zentrum Dresden Rossendorf, Dresden, Germany
- Technische Universität Dresden, Center for Molecular and Cellular Bioengineering (CMCB),
   CRTD Center for Regenerative Therapies Dresden, Fetscherstraße 105, 01307 Dresden, Germany
   Helmholtz-Zentrum Dresden Rossendorf, Institute of Radiooncology—OncoRay, 01328
   Dresden, Germany
- <sup>5</sup> Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, D-01062 Dresden, Germany
- <sup>6</sup> German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- <sup>7</sup> National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and; Helmholtz Association / Helmholtz-Zentrum Dresden Rossendorf (HZDR), Dresden, Germany

The combination of the beneficial effects of high dose-rate Flash-RT and proton depth dose distribution promise the differential sparing of normal tissue under similar tumour treating efficacy. However, of the two published attempts [1,2] made at clinical proton facilities, one in vivo study on zebrafish embryo was not able to measure a Flash effect [2]. In the discussion of this experiment, the zebrafish model, a non-ideal pulse-time-regime and an uncertain oxygen level during irradiation were identified as potential explanations for the missing Flash effect. In order to investigate these parameters in detail an experiment was scheduled at the research electron accelerator ELBE at HZDR, because an electron Flash effect was already demonstrated for zebrafish embryo [3]. The highly variable pulse structure of ELBE enables to deliver the dose either in therapy like quasicontinuous (cw) beams or as electron Flash irradiation.

Zebrafish embryo were irradiated with 40 Gy with pulse dose rates of  $10^9$  Gy/s and mean dose rates of  $10^6$  Gy/s in comparison to 0.1 Gy/s with cw irradiation. In addition to this, the Oxylite system was applied to measure and control oxygen depletion kinetics in sealed embryo samples. A protective Flash effect was seen for most endpoints ranging from 4 % less reduction in embryo length to about 20-25 % less embryo with spinal curvature and pericardial oedema, relative to cw-irradiation. The reduction of partial oxygen pressure below atmospheric levels results in higher protection, the more the lower the oxygen level.

In conclusion, the Flash experiment at ELBE show that the zebrafish embryo model is appropriate for the study of the radiobiological response of high dose rate irradiation. A sufficiently pulse dose seems to be more important than pulse dose rate and the partial oxygen pressure during irradiation plays a pivotal role.

# **Selected references** $[1]\ Diffenderfer\ et\ al.: \underline{https://doi.org/10.1016/j.ijrobp.2019.10.049}$ [2] Beyreuther et al.: <a href="https://doi.org/10.1016/j.radonc.2019.06.024">https://doi.org/10.1016/j.radonc.2019.06.024</a> [3] Vozenin et al.: <a href="https://doi.org/10.1016/j.clon.2019.04.001">https://doi.org/10.1016/j.clon.2019.04.001</a>

I12 - Combined radiotherapy and immunotherapy
Ana Carneiro
47

# 113 - Neurocognitive effects of radiation

## Charles L. Limoli<sup>1</sup>

Ron J. Leavitt<sup>1</sup>, Munjal M. Acharya<sup>1</sup>, Janet E. Baulch<sup>1</sup>

Radiation-induced cognitive dysfunction (RICD) is a progressive and debilitating health issue facing patients following cranial radiotherapy to control CNS cancers. This talk will provide a brief backdrop of the causes of RICD, and overview some of the past work using stem cell and extracellular vesicle (EV) based grafting strategies to resolve certain adverse side effects of brain tumor therapy. A focus of this session will be on recent data from our group defining further the mechanisms underlying the neuroprotective benefits of EV grafting in the irradiated brain.

As nano-scale membrane-bound structures, EV contain biological contents including mRNA, microRNA, proteins, and lipids that can be readily isolated from conditioned culture media. Immuno-competent wild type mice were used to demonstrate that hNSC-derived EV treatment administered either intravenously via retro-orbital vein injection or via intracranial transplantation can ameliorate cognitive deficits following 9 Gy head-only irradiation. Cognitive function assessed on the Novel Place Recognition, Novel Object Recognition, and Temporal Order tasks was not only improved at early (five weeks) but also at delayed (six months) post-irradiation times with just a single EV treatment. Improved behavioral outcomes were also associated with reduced neuroinflammation as measured by a reduction in activated microglia. To identify the mechanism of action, analysis of EV cargo implicated miRNA (miR-124) as a potential candidate in the mitigation of RICD. Furthermore, viral vector-mediated overexpression of miR-124 in the irradiated brain ameliorated RICD and reduced microglial activation. Our findings demonstrate for the first time that systemic administration of hNSC-derived EV abrogates RICD and neuroinflammation in cranially irradiated wild type rodents through a mechanism involving miR-124.

<sup>&</sup>lt;sup>1</sup> Department of Radiation Oncology, University of California Irvine, CA 92697-2695, USA

# 114 - Unwanted doses from stray radiation in proton therapy

# Pawel Olko<sup>1, 2</sup>

<sup>1</sup> Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland

Unwanted patient exposure due to the stray radiation during radiation therapy was intensively investigated by Working Group 9 "Dosimetry in Radiation Therapy" of the European Radiation Dosimetry Group EURADOS. In several experimental campaigns in proton therapy centres at Kraków and Trento systematic measurements of in-phantom and ambient doses were performed. Broad spectrum experimental techniques was applied including passive (TLD, OSL, RPL, CR-39, bubble detectors) and active detectors (REM counters, TEPC, Boner spheres). The results demonstrate that for modern Pencil Scanning Beam technology without beam modifiers and for typical range of target parameters (dose, volume) unwanted organ doses for the entire course of treatment are typically not exceeding a few mSv. Ambient doses within the gantry vault depend on the target volume, proton energy and direction of the primary proton beam and for distances of 2 m from the isocenter are not usually exceeding a few mSv per Gy in target. In conclusion, in modern Pencil Scanning Beam facilities the radiation exposure from scattered radiation remains at the very moderate level, as compared to other sources of exposure.

<sup>&</sup>lt;sup>2</sup> EURADOS Working Group 9 "Dosimetry in Radiotherapy"

# 115 - Genetics of Subsequent Neoplasms after Radiotherapy: Biological Insights into Radiation Carcinogenesis and Clinical Implications

# Lindsay Morton<sup>1</sup>

<sup>1</sup> Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

With advances in treatment and early detection, as well as aging of the population, the number of cancer survivors continues to expand rapidly, and the long-term health of this population is of increasing clinical and public health importance. The development of a subsequent neoplasm is a major cause of morbidity and mortality among cancer survivors. Decades of research have demonstrated that radiotherapy is an important contributor to subsequent neoplasm risk in certain cancer survivors. With advances in genomic technologies, research is increasingly aimed toward identifying genetic variants that confer susceptibility to radiotherapy-related subsequent neoplasms and other adverse outcomes. Recent studies have investigated not only rare genetic variants that are typically associated with cancer predisposition or clinical radiation sensitivity syndromes but also common genetic variants in novel pathways. This talk will review new discoveries in this research area and identify the key next steps that are needed in order for these discoveries to be translated into new biological insights and clinical practice.

# 116 - Biodosimetry and internal dosimetry in Nuclear Medicine

## Uta Eberlein<sup>1</sup>

- S. Schumann<sup>1</sup>, H. Scherthan<sup>2</sup>, M. Lassmann<sup>1</sup>
- <sup>1</sup> Department of Nuclear Medicine, University of Würzburg, Würzburg Germany
- <sup>2</sup> Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, Germany

For diagnostic procedures in nuclear medicine, mostly  $\gamma$ - and  $\beta^+$ -emitters are administered, whereas for radionuclide therapies,  $\beta^-$  or  $\alpha$ -labelled radiopharmaceuticals are applied. The radionuclides irradiate the body internally with time-dependent dose-rates, which can cause DNA double strand breaks (DSBs). The aim of our research is to analyse the time- and dose-dependent induction and repair of the radiation-induced DSBs with the biomarkers  $\gamma$ -H2AX+53BP1 in peripheral blood mononuclear cells (PBMCs) in-vivo and ex-vivo after internal irradiation with  $\beta$ - and  $\alpha$ -emitters.

For the ex-vivo study, blood samples were taken from volunteers and activity of different concentrations of radionuclides (<sup>131</sup>I, <sup>177</sup>Lu, <sup>223</sup>Ra, <sup>224</sup>Ra) were added. The blood aliquots were incubated for 1 h to reach absorbed doses to the blood up to 150 mGy.

For the in-vivo studies, radiation-induced DSBs were quantified in blood samples of patients receiving a therapy with either [131]NaI, [177Lu]Lu-DOTA-TATE/TOC or [177Lu]Lu-PSMA taken before, and 1h, 2h, 3h, 4h and up to 168h after radionuclide administration. For the [68Ga]Ga-PSMA PET/CT study blood samples (n=5) were taken up to 2h after the PET/CT examination. For all studies, the time-dependent absorbed dose to the blood was calculated.

In all blood samples, PBMCs were directly isolated, ethanol-fixed and stored until analysis. All samples were immuno-stained with  $\gamma$ -H2AX+ 53BP1 antibodies and co-localized foci/ $\alpha$ -tracks were counted manually. To determine the average number of radiation-induced foci (RIF)/ $\alpha$ -tracks per cell, the number of individual baseline foci/ $\alpha$ -tracks per cell was subtracted from the number of counted foci/ $\alpha$ -tracks per cell in all irradiated samples. Ex-vivo a linearity between the number of RIF/ $\alpha$ -tracks and the absorbed dose to the blood below 150 mGy after internal irradiation could be established.

For the  $\beta$ -labelled radiopharmaceuticals the average number of RIF in-vivo showed a linear dose-response relationship within the first hours after administration. At later time points (> 4 h) a diminishing number of radiation-induced foci was observed in accordance with the progression of DNA repair and declining dose rates. For <sup>68</sup>Ga we observed that even at very low absorbed doses to the blood of less than 3 mGy, the number of DSBs in the blood was still significantly increased compared to baseline. The observed RIF numbers were higher as expected from the extrapolation of the results of the ex-vivo studies.

Overall, we can provide evidence that the biomarkers  $\gamma$ -H2AX+53BP1 in conjunction with internal dosimetry quantify ex-vivo and in-vivo the induction of DSBs and repair of simple DSBs by radiopharmaceuticals.

# 117 - Radioecology or environmental radioactivity – past present and the future

### Per Roos<sup>1</sup>

<sup>1</sup> European Spallation Source, Lund, Sweden

Radioecology or environmental radioactivity has gone through a number of phases largely defined by various accident scenarios. To a large extent radioecology was initiated with the atmospheric nuclear weapons tests in the sixities. The complex content of this intense fallout forced a multitude of research in analytical science of both instrumentation, data handling and chemistry to be initiated. This was a very fruitful period which established a number of highly competent laboratories worldwide. The analytical competence that was built up acted as one of important pillars upon which radioecological investigations could be formed. Later events like the Chernobyl and Fukushima accidents further boosted radioecology but they also acted as double-edged swords in the sense that radioecological studies of these accidents demanded much less analytical competence. The reduced need for advanced method development, complex instrumentation and radiochemistry resulted in a gradual reduction in hands-on experience of several techniques deemed not to be of interest again. Not only were the techniques made obsolete but also the collected mentality of applying new techniques in existing fields. Funding opportunities for maintaining or developing this leg of radioecology became scarce. Following the increased demand of closing and decommissioning of nuclear installations after the Fukushima accident power plant operators and authorities became aware of the lack of qualified laboratories capable performing analysis of hard-to-measure radioisotopes. On top of this handling and storing of radioactive materials following the 9/11 attacks made development work more cumbersome. As an example can be mentioned that test material containing trace actinides may take months or more than a year to send across borders due to extensive paper handling. However, taking into account that decommissioning of the world NPP's is a process that will last for several decades it is worth the effort to again establish laboratories and skills needed to comply with authority demands, this will bring funding which not only may be used to improve the analytical capability but can also be used to perform radioecological studies connected to decommissioning which include a number of interesting challenges.

I18 - Ethics in an Cris	is: Comparison of CC	VID-19 and Nucl	ear Emergencies	
<b>Deborah Oughton</b>				

# 119 - Boron neutron capture therapy (BNCT): Technological and physical prospects

# Sauli Savolainen<sup>1, 2</sup>

In Finland, clinical BNCT trials were initiated by applying BPA as a <sup>10</sup>B carrier and epithermal neutrons from Finnish Research Reactor 1 (FiR 1, Otaniemi, Espoo, Finland), 249 patients have been treated with BNCT in 308 sessions, since some patients have received two or three treatments.

Before initializing the clinical trials, the epithermal neutron beam was reconstructed at the 250 kW FiR 1 Training, Research, Isotopes, General Atomics (TRIGA) MARK II reactor, and

- beam characteristics and intensity were confirmed
- procedures for primary beam dosimetry (measurements and MC simulation)
- patient position system was developed
- treatment planning system was tested
- blood 10B concentration evaluation was established
- complimentary dosimetric methods were examined
- radiobiological studies were carried out

The talk is focused on the dosimetry issues of BNCT concept: from beam characterization to dose measurements of the treated patients.

## **Selected references**

Ref.: Serén et al. 1999, Aschan 1999, Kosunen 1999, Benczik 2000, Auterinen et al. 2001, Seppälä 2002, Kortesniemi 2002, Ryynänen 2002, Vähätalo 2004, Karila 2006, Kotiluoto 2007, Uusi-Simola 2009, Koivunoro 2012, Savolainen et al. 2012, Winkler 2017

<sup>&</sup>lt;sup>1</sup> Department of Physics, University of Helsinki, Finland

<sup>&</sup>lt;sup>2</sup> Medical Imaging Center, Helsinki University Hospital, Finland

# 120 - Mechanistic Modelling of Intrinsic Radiation Sensitivity

## Stephen McMahon<sup>1</sup>

<sup>1</sup> Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, UK

Prediction of individual sensitivity to ionising radiation remains challenging. While it is well-established both *in vitro* and *in vivo* that different cell lines have significantly different responses to the same radiation exposures, this factor is typically not taken into account in clinical practice. Instead, most tumours of the same origin receive the same treatment dose. While is typically effective, a better understanding of the causes of individual sensitivity may enable better clinical outcomes through the delivery of personalised radiotherapy.

However, myriad factors can impact on radiation sensitivity, including tissue of origin, the genetic mutations particular to that tumour, and microenvironmental factors among others. And while these individual radiosensitivity mechanisms have been extensively studied *in vitro* and *in vivo*, translation of this extensive pre-clinical knowledge of radiation responses into a predictive tool is not straightforward.

Mechanistic modelling offers a tool to address this need. By building computational models, integrating the key aspects of the underlying radiation response pathways, we can begin to combine our knowledge of radiation sensitivity into tools that can offer the first steps towards individual radiation sensitivity predictions. This remains a challenging task, requiring the integration of physical, chemical, and biological modelling spanning a range of spatial and temporal scales.

In this talk, in addition to a brief summary of some of the challenges in this area, we will present ongoing work on our mechanistic modelling tool, MeDRaS (Mechanistic DNA Repair and Survival model). This tool describes the key cellular aspects of response to ionising radiation, including DNA damage repair and misrepair, together with relevant cell death pathways, to enable prediction of a range of common experimental endpoints. Significantly, it has been shown that this model can accurately reproduce a range of observed biological variability between cell lines, including the differences in intrinsic radiation sensitivity driven by modifications in key radiation response pathways.

Such modelling approaches have the potential to accelerate the translation of our preclinical knowledge into clinical predictive tools, but demand increased collaboration and sharing between experimentalists and modellers to deliver the most effective tools and greatest clinical impact in the future.

I21 - Progress towards using laser wakefield accelerators for radiotherapy	
Olle Lundh	


I22 - Virtual Study Visit at MAX IV		
Sverker Werin		
57		

# 123 - Life science at ESS

# Sindra Petersson-Årsköld

<sup>1</sup> European Spallation Source ERIC, Lund, Sweden

ESS is an international research infrastructure under construction outside Lund, Sweden. Out of the 15 neutron instruments currently being built, 6 of them have clear life science applicability. I will present some examples where neutrons have been key in resolving life science questions and discuss what ESS, which will provide novel capabilities, will be able to contribute.



# O1 - Impact of ATM and DNA-PK inhibition on gene expression and individual response of human lymphocytes to mixed beams of alpha particles and X-rays

Lei Cheng<sup>1</sup>

Beata Brzozowska<sup>2</sup>, Halina Lisowska<sup>3</sup>, Andrzej Wojcik<sup>1, 3</sup>, **Lovisa Lundholm**<sup>1</sup>

**Introduction:** Accumulating evidence suggest a synergistic effect in cells exposed to different ionising radiation qualities with varying damage complexity and linear energy transfer (LET), originating from natural or medical exposure.

**Methods:** Here we aimed to analyse the effect of mixed beams on the expression of selected genes involved in DNA damage response in peripheral blood lymphocytes (PBL) isolated from 4 donors. Two donors were compared upon inhibition of ATM or DNA-PK and at different sampling times. qPCR was used to measure the relative expression levels of the genes FDXR, GADD45a, BBC3, MDM2, CDKN1A and XPC 24 hours following exposure to alpha particles, X-rays or mixed beams (1:1 dose of alpha particles and X-rays).

**Results:** Generally, alpha particles and mixed beams were stronger inducers of gene expression compared to X-rays and this difference was largest at low doses, displaying saturated versus linear dose response curves, respectively. Gene expression levels in three out of four donors showed a significant synergistic effect of mixed beams. Interestingly, when two of the donors were sampled again one year later, the former additive effect of mixed beams in one donor was now synergistic and the donors displayed no significant difference in intrinsic radiosensitivity as determined by gamma radiation-induced micronuclei. ATM, but not DNA-PK inhibition, reduced the radiation-induced gene expression, but differently for alpha radiation between the two donors.

**Conclusion:** In conclusion, synergy was present for all donors but the results suggest individual variability in the response to mixed beams, most likely due to life style changes.

<sup>&</sup>lt;sup>1</sup> Centre for Radiation Protection Research, Department of Molecular Biosciences - The Wenner-Gren Institute, Stockholm University, Sweden

<sup>&</sup>lt;sup>2</sup> Biomedical Physics Division, Faculty of Physics, University of Warsaw, Warsaw, Poland

<sup>&</sup>lt;sup>3</sup> Institute of Biology, Department of Radiobiology and Immunology, Jan Kochanowski University

# O2 - RAD51 foci as biomarkers for HR efficiency and radiosensitivity in individuals with a BRCA1 or BRCA2 mutation

# Stephanie Vermeulen<sup>1, 2</sup>

Valerie De Mey<sup>1</sup>, Evi Duthoo<sup>1, 2</sup>, Anne Vral<sup>1, 2</sup>, Ans Baeyens<sup>1, 2</sup>

**Introduction:** Breast cancer is the most common cancer in females. Known breast cancer predisposition genes are *BRCA1* and *BRCA2*. These genes are involved in the DNA damage response pathway, more specifically in homologous recombination (HR). HR is a DNA double strand break repair pathway active in S- and G2-phase of the cell cycle. Accumulation of RAD51 at the double strand break site is a hallmark of HR and could therefore be used to assess HR functionality and radiosensitivity in mutation carriers. A recent study performed by our group showed that *in vitro* irradiation of MCF10A breast epithelial cells with reduced BRCA1 and BRCA2 protein levels resulted in a significant decrease in RAD51 foci.

<u>Aim:</u> Investigate if RAD51 foci can be used as biomarkers to assess HR functionality in peripheral blood mononuclear cells (PBMCs) of healthy and *BRCA1/BRCA2* mutation carriers.

**Methods:** PBMCs were isolated by density gradient centrifugation and cultured for 72h. The cells were irradiated with 5 Gy (220 kV X-rays). Identification of cells in S-phase at time of irradiation was achieved by EdU pulse-labelling. Thereafter RAD51 foci were detected by immunofluorescent staining and automatically scored by Metacyte software (Metafer 4, Metasystems).

**Results:** The functional RAD51 foci assay was optimized. Preliminary results comparing RAD51 foci between healthy individuals and mutation carriers will be presented.

**Conclusion:** As *BRCA1/BRCA2* mutation carriers might show increased risk for radiation-induced carcinogenesis, these results can ultimately contribute to personalized radiation regimens, both therapeutic as diagnostic.

<sup>&</sup>lt;sup>1</sup> Ghent university, department of human structure and repair, radiobiology group, Ghent, Belgium

<sup>&</sup>lt;sup>2</sup> Cancer research institute Ghent, Ghent, Belgium

# O3 - Chromosome aberration complexity revealed in proton-irradiated cells treated with boron carriers supports Proton-Boron Capture Therapy

### Chiara Feoli<sup>1</sup>

Pavel Bláha<sup>1</sup>, Roberto Catalano<sup>2</sup>, Mario Ciocca<sup>3</sup>, Angelica Facoetti<sup>3</sup>, Giada Petringa<sup>2</sup>, Valerio Ricciardi<sup>1, 4</sup>, Enrico Rosa<sup>5</sup>, Lorenzo Manti<sup>1, 5</sup>

- <sup>1</sup> Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Napoli, Naples, Italy
- <sup>2</sup> Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali del Sud (LNS), Catania, Italy
- <sup>3</sup> Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy
- <sup>4</sup> Dipartimento di Matematica e Fisica, Università della Campania "L. Vanvitelli", Caserta, Italy.
- <sup>5</sup> Dipartimento di Fisica "E. Pancini", Università di Napoli Federico II, Naples, Italy

**Introduction:** We investigated chromosome aberrations (CA) induced by the  $p+^{11}B\rightarrow 3\alpha$  reaction (p-B). We already demonstrated enhancement of proton biological effectiveness by p-B [1]. The rationale underlying Proton-Boron Capture Therapy (PBCT) as a strategy to increase protontherapy tumour local control [2] hinges on the highly DNA-damaging high-LET  $\alpha$ -particles from p-B, whose cross section peaks at 675 keV [3], i.e. for slowing down protons. To prove this, we analyzed the yield of complex CAs, a biomarker of high-LET exposure [4], in boron-treated cells along clinical proton Spread-Out Bragg Peaks (SOBPs).

Methods: MCF10A cells were irradiated at the SOBP entrance, mid and distal positions at two Italian protontherapy facilities, INFN-LNS and CNAO, with proton energies of 62 MeV and 131.5-164.8 MeV, respectively. In separate experiments, cells were treated with Sodium Boroncaptate BSH (80 ppm) or Boronophenylalanine BPA (120 ppm). After 36-48 h, chromosome spreads were obtained by calyculin A-induced Premature Chromosome Condensation [5]. Whole Chromosome Painting and mFISH karyotype reconstructions (Metafer, Metasystems, Germany) were performed. All aberration types were scored. Complex aberrations were classified as previously defined [6] and the degree of exchange complexity was evaluated by overall number of chromosome and breaks involved [7].

**Results:** CA frequency and degree of exchange complexity were consistently greater in boron-treated samples at all proton doses; more importantly, the proportion of complex exchanges increased moving from mid to the distal SOBP positions, with no effect observed at beam entrance. **Conclusion:** Our findings confirm p-B-mediated enhancement of proton biological effectiveness and point to DNA damage complexity as the plausible explanation.

## **Selected references**

- [1] G. A. P. Cirrone, et al., First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness. Sci. Rep., 8, 1141 (2018).
- [2] Y. Do-Kun, et al., Application of proton boron fusion reaction to radiation therapy: A Monte Carlo simulation study. Appl. Phys. Lett. 105, 223507 (2014)
- [3] M. H. Sikora, M. H. & H. R. Weller, A new evaluation of the  $11B(p, \alpha)\alpha\alpha$  reaction rates. J. Fusion. Energ. 35, 538–543 (2016).
- [4] R. M. Anderson, et al. *Complex chromosome aberrations in peripheral blood lymphocytes as a potential biomarker of exposure to high-LET alpha particles.* Int. J. Radiat. Biol. 76, 31–42 (2000).
- [5] L. Manti et al., *Chromosome aberrations in human lymphocytes from the plateau region of the Bragg curve for a carbon-ion beam.* Nucl. Instr. Meth B, 259, 884-888 (2007).
- [6] M. N. Cornforth, Analyzing Radiation-Induced Complex Chromosome Rearrangements by Combinatorial Painting. Radiat. Res., 155, 643-659 (2001)

et al., Complex exch o X-rays at the first			

# O4 - Endometrial stem cells isolated from menstrual blood - A better model for the radiobiology of mesenchymal stem cells?

### Annemarie Schröder<sup>1</sup>

Guido Hildebrandt<sup>1</sup>, Katrin Manda<sup>1</sup>

**Introduction:** The endometrium is a highly remodeling tissue characterized by a large number of adult stem cells localized not only in the basalis but also in the functionalis. Due to its rejection during menstruation, it is possible to isolate mesenchymal stem cells (MSCs), here called Endometrial Regenerative Cells (ERCs) from the menstrual blood - a non-invasive, monthly repeatable, high-yield source of MSCs. These conditions are optimal and unique in stem cell research. Therefore, the aim of this study is to characterize ERCs for the first time in terms of their radiation response and to examine donor-specific influencing factors.

**Methods:** The successful isolation of ERCs was confirmed on the basis of their differentiation capacity and the panel of surface proteins. The donor-dependent proliferation rate, clonogenicity and differentiability were then examined. To assess radiation sensitivity, the clonogenic survival and the ability to repair DNA double-strand breaks were examined after irradiation.

**Results:** A total of 23 donors were registered. Donor-specific differences in growth kinetics and radiation sensitivity could not be attributed to the determined factors: body mass index, age, smoking behavior and number of pregnancies or miscarriages. Overall, the ERCs were characterized by a robust growth kinetic under norm- as well as hypoxic conditions with a population doubling time of 48 hours and a high repair capacity of DNA double-strand breaks leading to a moderate radiation sensitivity with an SF2 (survival fraction at 2Gy) of 34 %.

**Conclusion:** ERCs isolated from menstrual blood are very suitable as a model for the analysis of radiological examinations of MSCs.

<sup>&</sup>lt;sup>1</sup> Department of Radiotherapy and Radiation Oncology, University Medical Centre Rostock, Suedring 75, 18059 Rostock, Germany.

# 05 - Blocking Connexin43 hemichannel alleviates radiation-induced endothelial cell damage

# Raghda Ramadan<sup>1, 2</sup>

Els Vromans<sup>3</sup>, Dornatien Chuo Anang<sup>4</sup>, Ines Goetschalckx<sup>5</sup>, Delphine Hoorelbeke<sup>2</sup>, Elke Decrock<sup>2</sup>, Sarah Baatout<sup>1, 6</sup>, Luc Leybaert<sup>2</sup>, An Aerts<sup>1</sup>

- <sup>1</sup> Radiobiology Unit, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium;
- <sup>2</sup> Department of Basic Medical Sciences, Physiology group, Ghent University, Ghent, Belgium;
- <sup>3</sup> Centre for Environmental Health Sciences, Hasselt University, Hasselt, Belgium;
- <sup>4</sup> Biomedical Research Institute, Hasselt university, Hasselt, Belgium;
- <sup>5</sup> Protein Chemistry, Proteomics and Epigenetic Signaling Group, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium.
- <sup>6</sup> Department of Molecular Biotechnology, Ghent University, Ghent, Belgium

**Introduction:** Emerging evidence indicates an excess risk of late occurring cardiovascular diseases, especially atherosclerosis, after thoracic cancer radiotherapy. Ionizing radiation (IR) induces cellular effects which induces endothelial cell dysfunction, an early marker for atherosclerosis. In addition, intercellular communication through channels composed of transmembrane connexin proteins (Cxs), i.e. gap junctions (direct cell-cell coupling) and hemichannels (paracrine release/uptake pathway) can modulate radiation-induced responses and therefore the atherosclerotic process. However, the role of endothelial hemichannel in IR-induced atherosclerosis has never been described before. **Methods:** Telomerase-immortalized human Coronary Artery/Microvascular Endothelial cells (TICAE/TIME) were exposed to X-rays (0.1 and 5 Gy). Production of reactive oxygen species (ROS), DNA damage, cell death, inflammatory responses, and senescence were assessed with or without applying a Cx43 hemichannel blocker (TAT-Gap19).

**Results:** We report here that IR induces an increase in oxidative stress, cell death, inflammatory responses (IL-8, IL-1β, VCAM-1, MCP-1, and Endothelin-1) and premature cellular senescence in TICAE and TIME cells. These effects are significantly reduced in the presence of the Cx43 hemichannel-targeting peptide TAT-Gap19.

**Conclusion:** Our findings suggest that endothelial Cx43 hemichannels contribute to various IR-induced processes, such as ROS, cell death, inflammation, and senescence, resulting in an increase in endothelial cell damage, which could be protected by blocking these hemichannels. Thus, targeting Cx43 hemichannels may potentially exert radioprotective effects.

### **Selected references**

Ramadan, R., Vromans, E., Anang, D.C., Decrock, E., Mysara, M., Monsieurs, P., Baatout, S., Leybaert, L., and Aerts, A. (2019). Single and fractionated ionizing radiation induce alterations in endothelial connexin expression and channel function. *Scientific Reports* 9, 4643.

Decrock, E., Hoorelbeke, D., Ramadan, R., Delvaeye, T., De Bock, M., Wang, N., Krysko, D.V., Baatout, S., Bultynck, G., Aerts, A., Vinken, M., and Leybaert, L. (2017). Calcium, oxidative stress and connexin channels, a harmonious orchestra directing the response to radiotherapy treatment? *Biochim Biophys Acta* 1864, 1099-1120.

# O6 - Cell membrane and lipid raft are involved in targeted and non-targeted effects of Auger and alpha molecular radiotherapy

### Jean-Pierre POUGET<sup>1</sup>

Riad Ladjohounlou<sup>1</sup>, Alexandre Pichard<sup>1</sup>, Julie Constanzo<sup>1</sup>, Jihad Karam<sup>1</sup>, Sara Marcatili<sup>2</sup>, Manuel Bardiès<sup>2</sup>, Frank Bruchertseifer<sup>3</sup>, Alfred Morgenstern<sup>3</sup>, Julien Torgue<sup>4</sup>, Isabelle Teulon<sup>1</sup>

- <sup>1</sup> IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, F-34298, France
- <sup>2</sup> UMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie de Toulouse, Toulouse F-31062, France
- <sup>3</sup> Directorate for Nuclear Safety and Security, European Commission Joint Research Centre, Karlsruhe, Germany
- <sup>4</sup> AREVA Med, 4800 Hampden lane, Bethesda, MD 20814, USA

**Introduction:** With the development of new therapeutic radiopharmaceuticals in oncology, it is important to determine the contribution of targeted and non-targeted (bystander and systemic) effects of targeted radionuclide therapy.

**Methods:** Here, we investigated the contribution of non-targeted cytotoxic and genotoxic effects *in vitro* and *in* vivo (WT C57BL/6J and athymic nude mice) during alpha (<sup>212</sup>Pb/<sup>212</sup>Bi, <sup>213</sup>Bi) and Auger (<sup>125</sup>I) radioimmunotherapy (RIT).

**Results:** *In vitro*, we showed that bystander effects contributed to 7-36% and 27-29% cell killing during alpha RIT and Auger RIT, respectively. We demonstrated that the bystander cell response was partly mediated by lipid raft-mediated activation of p38 kinase and c-JUN N-terminal kinases (JNK). We then showed that RIT efficacy was reduced *in vitro* and *in vivo* when RIT was combined with ASMase inhibitor (imipramine) or with drugs modifying cholesterol metabolism such as filipin, methyl-beta-cyclodextrin (or pravastatin). Reactive oxygen species also played a significant role in these bystander effects. Using autoradiography and voxel dosimetry, we confirmed the occurrence of bystander effects *in vivo* also, during Auger and alpha RIT. We isolated extracellular vesicles from the secretome of cells exposed to RIT and showed that they were responsible for clonogenic survival decrease *in vitro* and for tumor growth delay *in vivo* after intratumoral injection. We also showed that the latter therapeutic efficacy was enhanced in immune competent mice suggesting a role of immune cells.

**Conclusion:** We confirmed that non-targeted effects play a central role in Auger and alpha RIT and that drugs modifying cholesterol metabolism can modify RIT efficacy.

### **Selected references**

- Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I and Pouget J-P. Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and off-target response to alpha and Auger radioimmunotherapy Clin Cancer Res. 2019 May 6. 25(15):4775-4790.
- 2. Pouget JP, Georgakilas A, Ravanat J-L. Targeted and off-Target (bystander and abscopal) effects of radiation therapy: redox mechanisms and risk/benefit analysis. Antioxid Redox Signal. 2018 Nov 20;29(15):1447-1487.
- 3. Paillas S, Ladjohounlou R, Lozza C, Pichard A, Deshayes E, Jarlier M, Sevestre S, Le Blay M, Boudousq V, Sosabowski J, Chardes T, Teulon I, Mairs R, Pouget JP. Localized irradiation of cell membrane by Auger electrons is cytotoxic through oxidative stress-mediated non-targeted effects. Antioxid Redox Signal. 2016 Sep 10;25(8):467-84.

# O7 - Combination therapy: particle irradiation with the Hedgehog inhibitor GANT61 differently modulates the radiosensitivity and migration of cancer cells

# Bjorn Baselet<sup>1</sup>

Katrien Konings<sup>1</sup>, Marjan Moreels<sup>1</sup>, Sarah Baatout<sup>1</sup>

<sup>1</sup> Radiobiology unit, Interdisciplinary biosciences, Institute for environment, health and safety, SCK CEN, Mol, Belgium

**Introduction:** Due to the improved dose deposition and increased biological effectiveness advantage of charged particles, an increase is noted in the use of particle therapy in the clinic. Metastasis is an important cause of mortality in cancer patients and evidence has shown that conventional radiotherapy can increase the formation of metastasizing cells. An important pathway involved in the process of metastasis is the Hedgehog signaling pathway. Recent studies have demonstrated that activation of the Hedgehog pathway in response to X-rays, can lead to radioresistance and increased migratory and invasive capabilities of cancer cells.

**Methods:** The effect of X-rays, protons and carbon ions was investigated on cell survival, migration and Hedgehog pathway gene expression in prostate cancer (PC3) and medulloblastoma (DAOY) cell lines. In addition, the modulation of cell survival and migration by the Hedgehog pathway inhibitor GANT61 was investigated.

**Results:** We found that in both cell lines, carbon ions were more effective in decreasing cell survival and migration as well as inducing more significant alterations in the Hedgehog pathway genes compared to X-rays or protons. In addition, we show here for the first time that the Hedgehog inhibitor GANT61 is able to sensitize medulloblastoma cells to particle radiation (proton and carbon ion) but not to conventional X-rays.

**Conclusion:** This finding demonstrates that the results of combination treatment strategies with X-ray radiotherapy cannot be automatically extrapolated to particle therapy and should be investigated separately. In conclusion, combining GANT61 with particle radiation could offer a benefit for specific cancer types with regard to cancer cell survival.

# O8 - Identification of linear and circular RNA biomarkers of radiation resistance in MCF7 breast cancer cells

# Auchi Inalegwu<sup>1, 2</sup>

Bart Cuypers<sup>3</sup>, Jürgen Claesen<sup>4</sup>, Sarah Baatout<sup>1</sup>, Kris Laukens<sup>3</sup>, Winnok H. De Vos<sup>5</sup>, Roel Quintens<sup>1</sup>

- <sup>1</sup> Radiobiology Unit, SCK•CEN, Belgian Nuclear Research Centre, 2400 Mol, Belgium.
- <sup>2</sup> Department of Biomedical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, 2610 Antwerp, Belgium.
- <sup>3</sup> Adrem Data Lab, Department of Mathematics and Computer Science, University of Antwerp, 2020 Antwerp, Belgium.
- <sup>4</sup> Microbiology Unit, SCK•CEN, Belgian Nuclear Research Centre, 2400 Mol, Belgium.
- <sup>5</sup> Department of Veterinary Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, 2610 Antwerp, Belgium.

**Introduction:** Insights into the molecular mechanisms that determine radiation sensitivity of tumours can help optimize patient-specific treatment. The goal of the present study was to identify transcriptional biomarkers of radiation resistance in MCF7 breast cancer cells.

**Methods:** We generated a radiation resistant MCF7 breast cancer cell line (FIR20) through fractionated 2-Gy X-ray exposure of the parental (PAR) cell line. The radiation response of FIR20 cells was subsequently analysed with respect to a culture age-matched, sham-irradiated control (AMC) and PAR cells using the clonogenic survival assay, and live-cell fluorescence imaging. RNA-seq was also performed for linear and circular RNA (circRNA) detection.

Results: FIR20 cells showed increased clonogenic survival after irradiation as compared to PAR and AMC cells. Live-cell imaging revealed a reduction in proliferation and decreased susceptibility of FIR20 cells to radiation-induced apoptosis. RNA-seq analysis identified over 550 significantly differentially expressed genes (DEGs) in FIR20 cells, of which the up-regulated DEGs were mainly involved in inflammatory pathways, hypoxia, P53 signaling and epithelial-mesenchymal transition (EMT). In contrast, the down-regulated DEGs were mainly E2F and MYC targets and G2M checkpoint and mitotic spindle-associated genes indicating cell cycle deregulation; a common hallmark of human malignancies. Additionally, using the CIRI2 and CircExplorer pipelines we detected ~40 differentially expressed circRNAs between FIR20 and the control cell lines.

**Conclusion:** The molecular mechanisms of radioresistance in the FIR20 cell line potentially attributable to the modulation of various immunoprotective pathways, altered proliferation and cell cycle deregulation may present an opportunity for therapeutic interventions.

# O9 - Study of cytotoxic effects induced by carbon ions irradiation on U-251 Glioblastoma cell line after treatment with a new platinum(IV)-based prodrug

## Federica Ciamarone<sup>1, 2</sup>


Beatrice Ferrari<sup>1</sup>, Mario Ciocca<sup>2</sup>, Federica Carnevale<sup>2</sup>, Chiara Rita Inguscio<sup>1</sup>, Angelica Facoetti<sup>2</sup>, Maria Grazia Bottone<sup>1</sup>

**Introduction:** The use of carbon ions for the treatment of high-grade cancer cells, has further advantages compared to protons, including a Bragg peak with a smaller width and better radiobiological effects. Cell apoptosis is one of the key mechanisms through which ionizing radiation kills tumour cells via the extrinsic or the intrinsic death pathway. The highly resistance and the unsuccessful treatment of Glioblastoma, remains a significant therapeutic challenge. The introduction of Pt(IV)-based compounds in combination with heavy charged particles, to overcome the gliomas intrinsic resistance, is still under investigation.

**Methods:** The U-251 glioblastoma cell line was treated with 48h-continuous treatment of cisplatin or with a new platinum(IV)-based prodrug, Pt(IV)Ac-POA, followed by 0, 2 or 4 Gy carbon ions irradiation. The cytotoxic effects induced by two different carbon ion doses and by the Pt(IV)Ac-POA, the morphological cell alterations and the activation of apoptotic mechanisms, trigger through caspase-3 and PARP1 activity, involved in several crucial cellular processes, were analysed by Western blotting and immunocytochemical techniques.

**Results:** The cytotoxic effect observed demostrated a caspase-dependent cell apoptosis in glioblastoma cell death involving the PARP1 signaling pathway not only at 48 h after carbon ions irradiation but even after 7 days, demonstrating a prolonged antitumor effect of the Pt(IV)Ac-POA. The efficacy was detected more intensely after combined treatment with carbon ion irradiation, showing a long-term cytotoxic effect.

**Conclusion:** The combined treatments with the Pt(IV)Ac-POA and carbon ions irradiation could be an important contribution to emerging therapeutic approaches in glioblastoma treatment and discusses the future challenges in improving antitumor directions.



<sup>&</sup>lt;sup>1</sup> Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy

<sup>&</sup>lt;sup>2</sup> CNAO National Center for Oncological Hadrontherapy, Pavia, Italy

# O10 - Influence of Alpha-particle Radiation on Intercellular Communication Networks of Tunneling Nanotubes in U87 Glioblastoma Cells

# Nicole Matejka<sup>1</sup>

Judith Reindl<sup>1</sup>

<sup>1</sup> Institut für angewandte Physik und Messtechnik, Universität der Bundeswehr München, Werner-Heisenberg-Weg 39, 85577 Neubiberg, Germany

Introduction: Cellular communication plays a crucial role in the coordination and organization of cancer cells. Especially processes such as uncontrolled cell-growth, invasion and therapy resistance, which are features of malignant tumors as glioblastomas, are supported by an efficient cell-to-cell communication. One powerful way for cells to communicate are tunneling nanotubes (TNTs). These tiny cytoplasmic membrane bridges with a diameter from 50 to 1500 nm directly connect cells over long distances up to several cell diameters and serve as highways for information and material exchange between them. We study the response of TNT communication networks in glioblastoma cells on radiative stress induced by  $\alpha$ -particle radiation. The aim was to figure out whether cell-to-cell connections via TNTs are influenced by radiation and if cellular communication was enhanced upon irradiation.

**Methods:** U87 glioblastoma cells were irradiated using high-LET α-particles to a dose of 1.2 Gy. After irradiation cells were labeled with CellMask<sup>TM</sup> Orange plasma membrane stain. The TNT network was examined using live-cell confocal microscopy up to 72 h after irradiation and compared to sham irradiated controls. We quantify the development of TNT networks and suggest an evaluation method to characterize these communication networks.

**Results:** Our results show that irradiated cells establish their network faster and have more cell-to-cell connections with a high TNT content than sham irradiated controls within the first 24 h. **Conclusion:** These findings suggest that there is an additional trigger upon radiation damage which results in fast and intensive network formation by TNTs as a radiation damage response mechanism.

# O11 - Targeting NRF2, regulator of antioxidant system, to sensitize glioblastoma neurosphere cells to radiation-induced oxidative stress

# Paulo Godov<sup>1, 2</sup>

Ali Pour Khavari<sup>1</sup>, Marzia Rizzo<sup>1</sup>, Elza Sakamoto-Hojo<sup>2, 3</sup>, Siamak Haghdoost<sup>1, 4, 5</sup>

- <sup>1</sup> Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University
- <sup>2</sup> Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo
- <sup>3</sup> Department of Genetics, Faculty of Medicine of Ribeirão Preto
- <sup>4</sup> University of Caen Normandy
- <sup>5</sup> Advanced Resource Center for HADrontherapy in Europe (ARCHADE)

**Introduction:** The presence of glioma stem cells (GSCs), which are enriched in neurospheres, may be connected to the radioresistance of glioblastoma (GMB) due to their enhanced antioxidant defense and elevated DNA repair capacity. The role of ROS in GSCs still needs better characterization in response to different qualities of radiation.


**Methods:** U87MG cells were cultured in a 3D model and irradiated with low (24 mGy/h) and high (0.39 Gy/min) dose rates of low LET gamma and high LET carbon ions (1-2 Gy/min). Thereafter, expression of proteins related to oxidative stress response (NRF2, hMTH1, PRDX2, GSTO1, APE1, SOD1 and SOD2), stemness marker (MUSASHI-1), extracellular 8-oxo-dG, and neurospheres were determined. The NRF2 gene was knocked down by CRISPR/Cas9.

**Results:** LD50 for carbon ions was significantly lower compared to LD50 of high and low dose rate gamma radiation. A significantly higher level of 8-oxo-dG was detected in the media of cells exposed to a low dose rate as compared to a high dose rate of gamma or carbon ions. A downregulation of oxidative stress proteins was also observed (NRF2, hMTH1, and SOD1). The NRF2 gene was knocked down by CRISPR/Cas9 in neurosphere cells, resulting in less self-renewal, more differentiated cells, and less proliferation capacity after irradiation with low and high dose rate gamma rays.

**Conclusion:** NRF2 knockdown exerted a great impact in cellular responses to irradiation by decreasing the antioxidant properties of neurospheres leading to a lesser self-renewal capacity and increasing differentiation, thus indicating NRF2 as a molecular target for reducing GBM cell survival.

#### **Selected references**

- S. Bao, Q. Wu, R. E. McLendon et al., "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response," Nature, vol. 444, no. 7120, pp. 756–760, 2006.
- S. Haghdoost, L. Sjolander, S. Czene, and M. Harms-Ringdahl, "The nucleotide pool is a significant target for oxidative stress," Free Radical Biology and Medicine, vol. 41, no. 4, pp. 620–626, 2006.
- P. R. D. V. Godoy, A. P. L. Montaldi, and E. T. Sakamoto-Hojo, "HEB silencing induces anti-proliferative effects on U87MG cells cultured as neurospheres and monolayers," Molecular Medicine Reports, vol. 14, no. 6, pp. 5253–5260, 2016.
- C. R. R. Rocha, G. S. Kajitani, A. Quinet, R. S. Fortunato, and C. F. M. Menck, "NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells," Oncotarget, vol. 7, no. 30, pp. 48081–48092, 2016.



### 012 - CREB signalling in the irradiated hippocampus

### Soile Tapio<sup>1, 2</sup>

Daniela Hladik<sup>1, 2</sup>, Claudia Dalke<sup>3</sup>, Christine von Törne<sup>4</sup>, Omid Azimzadeh<sup>1, 2</sup>

**Introduction:** The impact of low-dose radiation on human brain has recently attracted attention due to its increasing medical use for diagnostic purposes. High doses of ionizing radiation are known to induce harmful effects in the central nervous system, whilst the effects of low doses are still controversial.

**Methods:** Female B6C3F1 mice were total body irradiated at the age of 10 weeks with doses of 0 (control), 0.063, 0.125 or 0.5 Gy ( $^{60}$ Co). Hippocampus was analysed 24 months post-IR by quantitative label-free proteomics. The results were validated by western blotting. The oxidative stress level was determined using carbonylation assay.

**Results:** The proteomics data showed that CREB signalling was affected at all doses. Notably, the lower doses of 0.063 Gy and 0.125 Gy seemed to induce the CREB pathway, whereas the exposure to 0.5 Gy deactivated CREB. Similarly, the lowest dose (0.063 Gy) had an anti-inflammatory effect reducing the number of activated microglia (IBA-1), whereas an induction of both activated microglia and reactive astroglia (GFAP) was found at the 0.5 Gy dose suggesting inflammation and astrogliosis, respectively. Apoptotic and oxidative stress markers were increased only at the highest dose (0.5 Gy).

**Conclusion:** The CREB pathway plays a central role in long-term memory formation. These data suggest neuroprotection at 0.063 Gy, but neurodegeneration at 0.5 Gy. These effects become significant first in old animals and support the hypothesis of radiation-induced accelerated aging in the brain.

The research received funding from the Federal Ministry of Education and Research (BMBF) under the reference number 02NUK045C (INSTRA).

### Selected references


Hladik D. et al. J Proteome Res. 2020 Jan 3;19(1):337-345.

<sup>&</sup>lt;sup>1</sup> Institute of Radiation Biology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH (HMGU), 85764 Neuherberg, Germany

<sup>&</sup>lt;sup>2</sup> Technical University Munich (TUM), 80333 Munich, Germany

<sup>&</sup>lt;sup>3</sup> Institute of Developmental Genetics, HMGU

<sup>&</sup>lt;sup>4</sup> Research Unit Protein Science, HMGU



### O13 - Role of cellular senescence in radiation-induced cognitive dysfunction

### Yuting Jiang<sup>1, 2</sup>

Daniëlle Voshart<sup>1, 2</sup>, Fabian Hobbie<sup>2</sup>, Maarten Hamberg<sup>2</sup>, Fleur van Buuren-Broek<sup>1, 2</sup>, Steven Bergink<sup>2</sup>, Rob Coppes<sup>1, 2</sup>, Lara Barazzuol<sup>1, 2</sup>

**Introduction:** Radiotherapy causes cognitive dysfunction in 50-90% of brain tumour surviving patients. However, the underlying mechanisms are still unclear. Recently, cellular senescence has been reported to be involved in the pathogenesis of age-related neurodegenerative diseases by promoting protein aggregation. Thus, in this study we investigated the connection between cellular senescence and protein aggregation after irradiation.

**Methods:** Senescence and protein aggregation were measured both *in vivo* in 14 Gy irradiated rat brains and *in vitro* in mouse primary neurons/astrocytes and pluripotent stem cell-derived human cortical brain organoids after 5 or 10 Gy irradiation. The senolytic drug ABT-263 was used to selectively kill the senescent cells. β-Galactosidase staining and qPCR analysis of p16, p21 and senescence-associated secretory phenotype genes were used to evaluate cellular senescence. Accumulation of protein aggregates was assessed by immunofluorescence staining of markers like the autophagy receptor p62, the RNA/DNA-binding protein TDP43 and the aggresome dye Proteostat. Neuronal function was measured using live calcium imaging.

**Results:** Senescent cells and protein aggregates accumulated in the cortex of irradiated rat brains and in human brain organoids. Astrocytes accounted for about 60% of radiation-induced senescent cells. In a co-culture system of senescent astrocytes and non-irradiated neurons, astrocytes were shown to mediate neuronal protein aggregation. Additionally, treatment with ABT-263 could remove radiation-induced senescent cells and partially relieve the accumulation of protein aggregates improving calcium dynamics.

**Conclusion:** Our study suggests that cellular senescence plays a role in radiation-induced cognitive decline and senolytic drugs may be a promising therapeutic strategy.

<sup>&</sup>lt;sup>1</sup> Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

<sup>&</sup>lt;sup>2</sup> Department of Biomedical Sciences of Cells and Systems, Section of Molecular Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

# O14 - Role of microenvironment on the post-irradiation regenerative potential of salivary gland stem cells

### Yi Wu<sup>1, 2</sup>

Sarah Pringle<sup>3</sup>, Uilke Brouwer<sup>1, 2</sup>, Xiaohong Peng<sup>1, 2</sup>, Arjan Vissink<sup>4</sup>, Lara Barazzuol<sup>1, 2</sup>, Rob Coppes<sup>1, 2</sup>

<sup>1</sup>University medical center Groningen, dept. of biomedical sciences of cells & systems, Groningen, Netherlands


<sup>2</sup>University medical center Groningen, dept. of radiation oncology, Groningen, Netherlands

<sup>3</sup>University medical center Groningen, dept. of rheumatology and clinical immunology, Groningen, Netherlands

<sup>4</sup>University medical center Groningen, dept. of oral and maxillofacial surgery, Groningen, Netherlands

Introduction: Radiotherapy of head and neck cancer involves co-irradiation of salivary glands,

often resulting in hyposalivation and consequential reduced quality of life. Radiation-induced microenvironmental changes may be unfavorable for regenerative potential of the tissue. The aim was to assess how these changes affects regenerative potential of salivary gland stem cells (SGSCs). Methods: Mice were locally irradiated (IR) with 15 Gy on the salivary glands and salivary secretion was measured at distinct time points. Morphological changes and level of senescence were determined using IHC and SGSC organoid formation efficiency (OFE) was assessed up on several passages. Irradiated organoids derived conditioned medium was tested for naïve SGSC OFE. **Results:** Hyposalivation, gland weight reduction, morphology decline and infiltration of inflammatory cells increased progressively from 30 days after IR onwards. The number of acini declined and an enhanced number of p21+ senescent cells were observed. The irradiated glands exhibited a lower number of CD24hi/CD29hi stem cells than the control. Interestingly, the OFE of SGSCs obtained up to 30-days post-irradiation was initially reduced but recovered at later passages. However, SGSCs obtained from 90 days irreversibly lost potential to form organoids, indicative of loss of regenerative potential. After incubation with the conditioned medium, OFE was significantly decreased, indicating the irradiated microenvironment compromised SGSC self-renewal potential. Conclusion: The regenerative potential of surviving SGSCs early after irradiation seems to be comparable to unirradiated stem cells when taken out of a deleterious environment. However, at late phases, stem cells have lost regenerative potential indicating permanent environmental-related changes in stemness.



Cells isolated from irradiated salivary glands lose self-renewal capacity over time after IR

### O15 - Communication of radioprotective effects by TGF-83

### Ingunn Hanson<sup>1</sup>

Ursula Altanerova<sup>1</sup>, Bernd Thiede<sup>2</sup>, Nina F. J. Edin<sup>1</sup>

- <sup>1</sup> Department of Physics, University of Oslo
- <sup>2</sup> Department of Biosciences, University of Oslo


**Introduction:** TGF- $\beta$ 3 is induced by low dose-rate priming irradiation (0.06-0.3 Gy/h) and removes low dose hyper-radiosensitivity (HRS) both in primed cells, and in un-primed reporter cells.

**Methods:** To examine whether TGF- $\beta$ 3 was transported between irradiated and reporter cells via exosome secretion, we isolated these from primed and wild-type T-47D cells. The exosomes were cocultured with reporter cells to determine their radioresponse, and MS was performed on the contents. To elucidate the mechanism with which TGF- $\beta$ 3 removed HRS from reporter cells, we added recombinant TGF- $\beta$ 3 together with inhibitors of various TGF- $\beta$ 7 receptors to reporter cell medium.

**Results:** Exosomes from primed, but not unprimed, cells removed HRS in reporter cells. Addition of TGF- $\beta$ 3 inhibitor to the medium restored HRS, indicating that active TGF- $\beta$ 3 is responsible for removal of HRS and is contained in exosomes from primed cells only. Exosome-specific proteins were confirmed present in the exosomes. Exosomes from both groups contained similar amounts of TGF- $\beta$ 3, along with inactivating latency-associated protein (LAP), indicating that TGF- $\beta$ 3 is secreted in inactive form in exosomes from primed and unprimed cells, and that the primed exosomes contains an un-identified activator of TGF- $\beta$ 3.

Inhibition of ALK5 did not affect removal of HRS in primed cells. Inhibition of ALK1 retained HRS in reporter cells, indicating that ALK1 alone mediates the removal of HRS by TGF-β3. Other results indicated a competition between ALK5 and ALK1 for TGF-β3 binding, where ALK5 has higher affinity, but ALK1 mediates removal of HRS.

Conclusion: TGF- $\beta$ 3 removes HRS in reporter cells by secretion in exosomes and binding to ALK1.



# O16 - FLASH-effect observed under normoxic conditions in vitro — mechanisms other than oxygen depletion?

### Gabriel Adrian<sup>1, 2</sup>

Karl Butterworth<sup>3</sup>, Elise Konradsson<sup>4</sup>, Crister Ceberg<sup>4</sup>, Mihaela Ghita<sup>3</sup>, Stephen J. McMahon<sup>3</sup>, Kristoffer Petersson<sup>2, 5</sup>

- <sup>1</sup> Division of Oncology and Pathology, Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden
- <sup>2</sup> Department of Haematology, Oncology and Radiation Physics, Radiation Physics, Skåne University Hospital, Lund, Sweden
- <sup>3</sup> Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland
- <sup>4</sup> Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden
- <sup>5</sup> Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom; Department of Haematology, Oncology and Radiation Physics, Radiation Physics

Introduction: Radiotherapy at ultra-high dose rates (FLASH) have been shown in pre-clinical studies to spare normal tissues while maintaining efficient tumor control, compared with conventional radiotherapy (CONV). Oxygen depletion has been suggested as an underlying mechanism for the observed FLASH-sparing effect. Previously, we have shown that FLASH-sparing was apparent when cells were irradiated under hypoxic (1.6% oxygen) and physoxic (2.7, 4.4, and 8.3% oxygen) conditions, whereas we did not find a significant effect in normoxia (20% oxygen), comparing CONV to FLASH. In the current project, we aimed to expand our studies investigating any FLASH-sparing effect for several established cell lines, starting in normoxic conditions.

Methods: Breast cancer, glioblastoma, cervix cancer and fibroblasts cell lines were irradiated in normoxia with doses of 0-12Gy with an electron beam from a modified linear accelerator, providing dose rates of 14Gy/min (CONV) and 600Gy/s (FLASH). Survival was determined by colony formation assays.


**Results:** Surprisingly, we found a higher survival after FLASH compared with CONV irradiation in normoxia. For some cell lines, a low variability in the survival data allowed for this difference to be significant (Figure). The separation between FLASH and CONV survival curves was seen already seen at 3Gy and was significant at 6Gy and 9Gy, where oxygen depletion in normoxic cells is estimated to have no effect on cell survival (according to published models).

**Conclusion:** The FLASH-sparing effect occurs at moderate doses for cells in normoxic conditions. Consequently, oxygen depletion does not seem to be the sole underlying mechanism for the FLASH-sparing effect.

### **Selected references**

Adrian G, Konradsson E, Lempart M, Bäck S, Ceberg C, Petersson K. The FLASH effect depends on oxygen concentration. *Br J Radiol*. 2020;93:20190702.

Petersson K, Adrian G, Butterworth K, McMahon SJ. A quantitative analysis of the role of oxygen tension in FLASH radiotherapy. *Int J Radiat Oncol*. March 2020.



Figure

Cell survival after irradiation in normoxia with FLASH (blue line and circles) compared with conventional dose-rate (red line and squares).  $\underline{n}_{S}$ : not significant,\*\* p < 0.01, \* p <0.05.

### 017 - Reversing cold tumor microenvironment with targeted alpha-therapy

### Justine Perrin<sup>1</sup>

Marisa Capitao<sup>1</sup>, Sebastien Gouard<sup>1</sup>, Catherine Maurel<sup>1</sup>, Cedric Louvet<sup>2</sup>, Mélanie Lancien<sup>2</sup>, Franck Bruchertseifer<sup>3</sup>, Alfred Morgenstern<sup>3</sup>, Michel Chérel<sup>1, 4</sup>, Joëlle Gaschet<sup>1</sup>, Yannick Guilloux<sup>1</sup>

- <sup>1</sup> CRINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
- <sup>2</sup> Centre de Recherche en Transplantation et Immunologie, INSERM, Université de Nantes, Nantes, France
- <sup>3</sup> European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany
- <sup>4</sup> Nuclear Medicine Unit, ICO Cancer Center Gauducheau, Saint Herblain, France

**Introduction:** Cancer therapies are facing challenges towards tumor cell destruction: tumor microenvironment (TME) involves immunoregulatory cells and cytokines, preventing anti-tumoral immune response. Therapeutic combination could turn these « cold » TME into « hot » ones. Therefore, this project focus on combining targeted alpha-therapy (TAT) and adoptive T-cells transfer (ACT).

This combination was conducted in a Multiple Myeloma murine model using a cell line expressing the CD138 antigen and H<sub>2</sub>K<sup>b</sup>/OVA<sub>257-264</sub> complexes grafted subcutaneously to mice. TAT was delivered through i.v. injection of a 213-bismuth radiolabelled anti-CD138 antibody. To reinforce its efficiency, TAT was combined with an ACT of tumor specific OT-1 T-cells. This combination resulted in a delayed tumor growth (1).

**Methods:** Based on these results, this project aims to understand the impact of TAT on the "cold" TME and on ACT efficacy. Tumor infiltrated cells were analysed by flow cytometry to identify *in situ* immune populations, and cytokines production were assessed by RT-qPCR on tumor fragment.

**Results:** Although OT-1 T cells infiltrated the tumor after ACT, only combination with TAT resulted in regulatory CD4 T cell drop and production of IL-2 and IFNg within the tumor. Futhermore, OT-1 T cells motility was increased on TAT treated tumor slices as observed by *ex vivo* time lapse.

**Conclusion:** Combining TAT and ACT appears to turn this "cold" tumor model into a "hot" one with regulatory T cells depleted, proportion and motility of tumor-specific CD8 T cells increased and IL-2 and IFNg increased production. Next, we will investigate impact of this combination on metabolism and hypoxia.

### **Selected references**

 Ménager J, Gorin J-B, Maurel C, Drujont L, Gouard S, Louvet C, Chérel M, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, et al. Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction. *PLoS One* (2015) 10:e0130249. doi:10.1371/journal.pone.0130249

## O18 - RIBE induction using human ex vivo explants causes alterations in mitochondrial metabolism in bystander cells

### Aisling Heeran<sup>1</sup>

Helen Berrigan<sup>1</sup>, Croí Buckley<sup>1</sup>, Heleena Bottu<sup>2</sup>, Amy Buckley<sup>1</sup>, Niamh Clarke<sup>1</sup>, Noel Donlon<sup>1</sup>, Timothy Nugent<sup>1</sup>, Michael Durand<sup>3</sup>, Cara Dunne<sup>3</sup>, John Larkin<sup>3</sup>, Brian Mehigan<sup>3</sup>, Paul McCormick<sup>3</sup>, Lorraine Brennan<sup>2</sup>, Niamh Lynam-Lennon<sup>1</sup>, Jacintha O'Sullivan<sup>1</sup>

**Introduction:** Locally advanced rectal cancer is treated with neoadjuvant-chemoradiotherapy, however only 22% of patients achieve a complete response. Resistance mechanisms are poorly understood. Radiation-induced bystander effect (RIBE) describes the effect of radiation on neighbouring unirradiated cells. We investigated effects of *ex vivo* RIBE-induction from normal and rectal cancer tissue on bystander cell metabolism, mitochondrial function and metabolomic profiling. We correlated bystander events to patient clinical characteristics.

**Methods:** Human normal and rectal cancer tissue were cultured as *ex vivo* explants and either mockirradiated or received 1.8Gy radiation. Following 24hours, the tissue conditioned media was harvested and the effect of RIBE on bystander rectal cancer cell metabolism was investigated using Seahorse. Metabolomic profiling was conducted using NMR. The effect of RIBE induction on reactive oxygen species and mitochondrial membrane potential was investigated using fluorescent probes.

**Results:** Ex vivo RIBE-induction caused metabolic alterations in bystander cells, specifically reductions in OXPHOS following RIBE-induction in normal (p=0.01) and cancer tissue (p=0.03) and reduced glycolysis in cancer (p=0.01). Visceral fat area correlated with glycolysis (p=0.02) and ATP production (p=0.03) following exposure of cells to TCM from irradiated cancer biopsies. Leucine levels were higher in the irradiated normal compared to the irradiated cancer secretome (p=0.04). ROS levels were higher in cells exposed to the cancer compared to the normal secretome (p=0.04).

**Conclusion:** RIBE-induction *ex vivo* causes alterations in the metabolome in normal and malignant rectal tissue along with alterations in bystander cellular metabolism. This may offer greater understanding of the effects of RIBE on metabolism, mitochondrial function and the secreted metabolome.

<sup>&</sup>lt;sup>1</sup> Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin 8, Ireland

<sup>&</sup>lt;sup>2</sup> Institute of Food and Health and Conway Institute, UCD School of Agriculture and Food Science, UCD, Belfield, Dublin 4, Ireland

<sup>&</sup>lt;sup>3</sup> GEMS, St. James's Hospital, Dublin 8, Ireland.

# O19 - First pre-clinical study for lung carcinoma employing Synchrotron Microbeam Radiotherapy at the Australian Synchrotron

### Verdiana Trappetti<sup>1</sup>

Cristian Fernandez-Palomo<sup>1</sup>, Lloyd Smyth<sup>2</sup>, Mitzi Klein<sup>3</sup>, Duncan Buttler<sup>3</sup>, David Haberthür<sup>1</sup>, Micah Barnes<sup>3</sup>, Daniel Hausermann<sup>3</sup>, Michael de Veer<sup>4</sup>, Jean Laissue<sup>1</sup>, Valentin Djonov<sup>1</sup>

- <sup>1</sup> Institute of Anatomy, University of Bern, Switzerland
- <sup>2</sup> Obstetrics And Gynaecology Royal Women'S Hospital/Mercy, Melbourne, Australia
- <sup>3</sup> Australian Synchrotron ANSTO, Clayton, Australia

**Introduction:** Synchrotron Microbeam Radiation Therapy (S-MRT) spatially fractionates Synchrotron X-rays into an array of micro-planar beamlets. This spatial fractionation together with a FLASH mode delivery of the radiation allows for minimal normal tissue toxicity while delaying tumour growth or even ablating malignancies. Here, we wanted to use S-MRT to treat lung carcinoma in mice for the first time.

**Methods:** Lewis lung carcinoma-bearing mice were irradiated with crossfired arrays of either S-MRT or Synchrotron Broad Beam (S-BB) 11 days after tumour cell injection in their right lung. The S-MRT field size was 7x7 mm (50  $\mu$ m beam width spaced by 400  $\mu$ m) with a peak-dose of 400 Gy delivered in 418 ms. While S-BB delivered a homogeneus dose of 5.16 Gy in 5.4 ms (does rate 957Gy/sec). Mice were sacrificed when human endpoints were reached.

**Results:** Both treatments significantly increased the survival of the animals relative to the control group, however there was no difference between S-BB and S-MRT. Pleural effusion was observed after S-MRT in tumor-bearing mice but not in sham-implanted mice. This suggests that the presence of a tumour changes the response of the lung to S-MRT.

**Conclusion:** We made a first step towards the use of S-MRT for lung cancer, targeting precisely a localized lung carcinoma. This study suggests that the S-MRT parameters (beam configuration, peak dose, and dose rate for a full FLASH effect) need to adapt in relation to the sensitivity of the organ bearing the malignancy, in order to reduce collateral effects and increase survival.

<sup>&</sup>lt;sup>4</sup> Monash Biomedical Imaging Facility, Monash University, Clayton, Australia

# O20 - Proteomic expression analysis of rat thyroid tissue 12 months after low-intermediate 1311 exposure

#### Malin Larsson<sup>1</sup>

Emman Shubbar<sup>1</sup>, Johan Spetz<sup>1</sup>, Britta Langen<sup>1</sup>, Toshima Parris<sup>2</sup>, Khalil Helou<sup>2</sup>, Eva Forssell-Aronsson<sup>1</sup>

**Introduction:** <sup>131</sup>I is released during nuclear accidents, with the thyroid being an organ at risk. Thyroid cancer incidence increased in children but not adults after the Chernobyl accident, possibly due to higher absorbed dose to the thyroid and higher radiosensitivity.

The aim of this study was to identify potential age-dependent biomarkers for <sup>131</sup>I exposure, thyroid function and cancer induction by evaluating the long-term effects of <sup>131</sup>I irradiation in thyroid tissue in young and adult rats.

**Methods:** Male Sprague Dawley rats were divided into three groups (n=12/group): young (irradiated at 5 weeks), adult (irradiated at 17 weeks), and controls (mock treated). Six individuals from each age group (young and adult) were i.v. injected with 50 kBq or 500 kBq  $^{131}$ I, with six controls per age group. The rats were killed twelve months after study start. LC-MS/MS analysis was performed on thyroid protein extracts. Statistical analysis and functional enrichment were performed using the Preseus software with a fold change cut-off set to  $\pm 1$ .

**Results:** In this study, age-related proteins that were identified only in young or adult rats, independent of absorbed dose were found. Dose-related proteins that were common for exposure to 50 or 500 kBq regardless of age were identified. Furthermore, unique proteins that were present only in one group were detected. These proteins were mainly related to RNA processing, protein cleavage and energy metabolism.

**Conclusion:** We have identified several age- and dose-related biomarker candidates. However, further validation is necessary.

<sup>&</sup>lt;sup>1</sup> Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, SE-413 45 Gothenburg, Sweden

<sup>&</sup>lt;sup>2</sup> Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, SE-413 45 Gothenburg, Sweden

### 021 - Normal tissue reaction following proton irradiation of the mouse brain

### Elke Beyreuther<sup>1, 2, 3</sup>

T Suckert<sup>1,3</sup>, J Müller<sup>1,3,4</sup>, B Azadegan<sup>1</sup>, E Bodenstein<sup>1</sup>, R Haase<sup>5</sup>, M Schürer<sup>1,6</sup>, M Krause<sup>1,3,4,6,7</sup>, A Lühr<sup>1,3,8</sup>, C von Neubeck<sup>1,3,9</sup>, A Dietrich<sup>1,3</sup>

- <sup>1</sup> OncoRay National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden Rossendorf, Dresden, Germany
- <sup>2</sup> Helmholtz-Zentrum Dresden Rossendorf, Institute of Radiation Physics, Dresden, Germany
- <sup>3</sup> German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany
- <sup>4</sup> Helmholtz-Zentrum Dresden Rossendorf, Dresden, Institute of Radiooncology OncoRay, Germany
- <sup>5</sup> Myers Lab, Max Planck Institute CBG, Dresden, Germany
- <sup>6</sup> National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and; Helmholtz Association / Helmholtz-Zentrum Dresden Rossendorf (HZDR), Dresden, Germany
- <sup>7</sup> Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- <sup>8</sup> Medical Physics and Radiotherapy, Faculty of Physics, TU Dortmund University, Germany
- <sup>9</sup> Department of Particle Therapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

**Introduction:** Due to the beneficial inverse physical depth-dose profile, proton radiotherapy (PT) offers the potential to reduce normal tissue toxicity by depositing the maximum dose within the tumor volume while sparing the surrounding tissue. However, range uncertainties and necessary clinical safety margins in combination with varying relative biological effectiveness (RBE) may result in a critical dose in the normal tissue. Dedicated preclinical studies are needed to assess and better understand potential adverse effects of PT and to develop potential biomarkers and countermeasures for backtranslation into clinics.

**Methods:** For this purpose, a high-precision image-guided proton irradiation setup for small animals was established at the University Proton Therapy Dresden that mimics the clinical workflow, including pre-treatment imaging, treatment planning and image-guided brain irradiation.

**Results:** The right hippocampus of C57BL/6 and C3H/HeN mice was irradiated to study the dose-and time-dependent radiation response of mouse brain tissue after short or long-term follow-up analyses. A Monte Carlo model of the proton irradiation field was designed in the simulation toolkit TOPAS to calculate the dose distributions *in vivo*. The observed radiation response was spatially correlated with the proton dose and linear energy transfer distributions.

**Conclusion:** The combination of geometric accuracy of proton irradiation, detailed dose simulations on mouse CT and cell-based assessment enable a biologically and spatially resolved analysis of short-term radiation response and RBE. In addition, the long-term follow up over six months provides insights into the formation of normal tissue damage in mouse brain after PT.

### O22 - Differential neurocognitive response after partial brain proton irradiation

### Daniëlle Voshart<sup>1, 2</sup>

Fleur van Buuren-Broek<sup>1,2</sup>, Peter van Luijk<sup>1,2</sup>, Rob Coppes<sup>1,2</sup>, Lara Barazzuol<sup>1,2</sup>

**Introduction:** Modern radiotherapy technologies, such as proton therapy, enable the potential sparing of brain regions that contribute most to radiotherapy-associated neurocognitive decline. However, current knowledge is largely limited to the role of the hippocampus. This study aims to identify regional contribution to the development of radiotherapy-induced neurocognitive decline. **Methods:** High-precision brain irradiation with 14 Gy protons was delivered to the 100%, the 50% anterior and the 50% posterior sub-volumes of the rat brain. Cognitive function was measured at different time points using several behavioral tests, including the Novel Object Recognition test, the Barnes maze test and the Rotarod test.

**Results:** Preliminary results indicate that irradiation of the 50% anterior brain sub-volume leads to a greater loss in memory function and learning than the 50% posterior brain sub-volume, as measured by the Novel Object Recognition and Barnes Maze tests. Although this difference was evident at 12 weeks post irradiation, it largely resolved at 48 weeks post irradiation. Rotarod performance was similarly impaired in all treatment groups at 12 weeks post irradiation. However, at 48 weeks post irradiation, 50% anterior irradiated animals showed a significant improvement.

**Conclusion:** Our data indicate that irradiation of the 50% anterior brain sub-volume leads to a greater decline in memory and spatial learning. In contrast, the 50% posterior brain sub-volume seems to be more important for locomotor function and skill learning. This suggests a differential contribution of the anterior and posterior part of the brain to the development of neurocognitive dysfunction after radiotherapy.

<sup>&</sup>lt;sup>1</sup> Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

<sup>&</sup>lt;sup>2</sup> Department of Biomedical Sciences of Cells and Systems, Section of Molecular Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

# O23 - The new experimental beam line and research facility at CNAO for radiobiological studies with charged particles

### Angelica Facoetti<sup>1</sup>


Marco Donetti<sup>1</sup>, Marco Pullia<sup>1</sup>, Simone Savazzi<sup>1</sup>, Sandro Rossi<sup>1</sup>

**Introduction:** CNAO is one of the four centers in Europe, and six worldwide, offering treatment of tumours with both protons and carbon ions. Although the Center is mainly dedicated to clinical irradiation, it also provides great opportunities to perform research related to radiobiology, biophysics, space, dosimetry, radiation detections. Besides three treatment rooms, a fourth room dedicated to experimental activities is now available.

**Methods:** The maximum energies available are up to 400 MeV/u (corresponding to a Bragg peak depth of up to 27 cm in water) for carbon ions and up to 230 MeV for protons (Bragg peak depth of up to 32 cm in water), minimum extraction energies are 60 MeV and 120 MeV/u for protons and carbon ions respectively. All the intermediate energies are possible and are distributed in steps of 1 mm range rather than in fixed energy steps.

**Results:** The experimental beamline can be arranged in different configurations according to the needs in term of space downstream the target or in terms of field size dimensions (figure). Within 2023, a third source will be installed and additional ions will be made available in the experimental room. For external researchers, the access to the cell laboratory is available.

**Conclusion:** In the next 2 years the research area will be expanded and the radiobiology laboratories foresee new premises for a total area of about 250 square meters. Thanks to a strong collaboration with the University of Pavia, it is possible to carry out *in vivo* irradiations, after approval by the local ethical committee.



<sup>&</sup>lt;sup>1</sup> CNAO National Center for Oncological Hadrontherapy, Pavia, Italy

## O24 - RBE-dependence on LET and fractionation in the rat cervical spinal cord after helium ion irradiation

### Lisa Hintz<sup>1, 2, 3</sup>

Christin Glowa<sup>1,3,4</sup>, Maria Saager<sup>1,3</sup>, Rosemarie Euler-Lange<sup>5</sup>, Peter Peschke<sup>1,3</sup>, Stephan Brons<sup>3,6</sup>, Jürgen Debus<sup>1,3,4</sup>, Christian Karger<sup>1,3</sup>

- <sup>1</sup> Department of Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- <sup>2</sup> Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
- <sup>3</sup> National Center for Radiation Research in Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany
- <sup>4</sup> Department of Radiation Oncology and Radiotherapy, University Hospital Heidelberg, Germany
- <sup>5</sup> Division of Radiooncology/Radiobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- <sup>6</sup> Heidelberg Ion Beam Therapy Center (HIT), Heidelberg, Germany

**Introduction:** Helium (<sup>4</sup>He) ions show less lateral scattering compared to protons and a lower variability of the relative biologoical effectiveness (RBE) than carbon ion and therefore pose a promising alternative in ion beam radiotherapy. For patient treatments, the relative biological effectiveness (RBE) needs to be predicted with biophysical models and uncertainties in these predictions may lead to under- or over-dosages. Therefore, models have to be validated by experimental data. This study uses the rat cervical spinal cord (CSC) to investigate the RBE of late effects *in vivo* in dependence of the linear energy transfer (LET) and the fractionation.

**Methods:** The CSC of female Sprague Dawley (SD) rats was irradiated with increasing doses of <sup>4</sup>He-ions in 1 or 2 fractions (fx) at 4 different positions within a 6 cm Spread-out Bragg-peak (SOBP). Dose-response curves were measured for the endpoint paresis grade II (palsy of the forelimbs) within 300 days after irradiation. RBEs were calculated based on the TD<sub>50</sub>-values (dose at 50% complication probability) and using previously measured values for photons [1].

**Results:** With increasing LET, the RBE increased from 1.1 to 1.5. No significant difference was observed between 1 and 2 fx.

**Conclusion:** We found a clear LET-dependence of the RBE for <sup>4</sup>He-ions, which is larger than for protons [2]. Similar to protons, no fractionation effect was observed for the applied high doses, however, the RBE might increase at higher fraction numbers. This study established the LET- and dose-dependence of the RBE in late-responding tissue after for <sup>4</sup>He-irradiation, which can be used to benchmark RBE-models.

#### Selected references

[1] Radiat Res. 2003 Nov;160(5):536-42 [2] Radiother Oncol. 2018 Mar 21. pii: S0167-8140(18)30134-8

### O25 - Proton-FLASH - Radiation effects of ultrahigh dose-rate irradiation

### Sarah Rudigkeit<sup>1</sup>

Nicole Matejka<sup>1</sup>, Ce-Belle Chen<sup>2</sup>, Parisa Hosseinpour<sup>1</sup>, Annique Hunger<sup>3</sup>, Matthias Sammer<sup>1</sup>, Thomas Schmid<sup>3, 4</sup>, Günther Dollinger<sup>1</sup>, Judith Reindl<sup>1</sup>

**Introduction:** Tissue sparing by irradiation with ultra-high dose-rates – the so-called FLASH-effect - is investigated since several years using electrons or x-rays. Since protons already show advantageous effects compared to conventional therapy, we designed a study to test the FLASH-effect with protons in-vivo and in-vitro.

**Methods:** We performed irradiation with 20 MeV protons at the ion microprobe SNAKE at the 14 MV tandem accelerator in Garching near Munich using three different dose-rates (2 Gy/min, 10 Gy/s and 1000 Gy/s). In the in-vitro experiments we compared genetic damage measured by micronuclei induction to cell survival using colony forming assay and cell death using a caspase 3/7-sytox assay on a flowcytometer. For the in-vivo study we irradiated the right ears of 63 Balb/c mice and measured the ear thickness, desquamation and erythema over 180 days.

**Results:** No difference in cell survival was visible. Whereas, early apoptotic and late apoptotic cells were reduced after irradiation with 1000 Gy/s to base level of sham irradiated controls. In the in-vivo study we obtained a 16 % reduction of the earthickness after 32 Gy irradiation with 1000 Gy/s and a 22 % reduction for 10 Gy/s compared to the conventional dose-rate of 2 Gy/min. Desquamation and erythema was reduced by half for both higher dose-rates.

**Conclusion:** By using FLASH dose-rates for low-LET proton irradiation a tissue sparing effect can be achieved. But especially the in-vitro experiments showed more diverse results than expected. Therefore, further investigations are necessary to understand the underlying mechanisms and interactions in the tissue after FLASH-irradiation.

<sup>&</sup>lt;sup>1</sup> Universität der Bundeswehr München, Institut für Angewandte Physik und Messtechnik, Neubiberg, Germany

<sup>&</sup>lt;sup>2</sup> Centre for Ion Beam Applications, Department of Physics, National University of Singapore, 2 Science Drive 3, Singapore 117542, Singapore

<sup>&</sup>lt;sup>3</sup> Helmholtz Zentrum München, Institute of innovative Radiotherapy, Neuherberg, Germany

<sup>&</sup>lt;sup>4</sup> Klinikum rechts der Isar, Technische Universität München, Radiooncology, München, Germany

## O26 - Investigating FLASH irradiation on acute normal tissue toxicity in the murine gastrointestinal system

### Jia-Ling Ruan<sup>1</sup>

Iain DC Tullis<sup>1</sup>, Sean C Smart<sup>1</sup>, James Thompson<sup>1</sup>, Mark A Hill<sup>1</sup>, Anderson J Ryan<sup>1</sup>, Ruth J Muschel<sup>1</sup>, Borivoj Vojnovic<sup>1</sup>, Anne E Kiltie<sup>1</sup>, Kristoffer Petersson<sup>1</sup>

**Introduction:** Gastrointestinal damage caused by ionising radiation of abdominal tissues is a dose-limiting factor in radiotherapy treatment. Recently, preclinical and clinical studies using ultra-high dose rate (FLASH) irradiation have shown reduced normal tissue toxicity in multiple organs compared to conventional dose rate radiotherapy.

**Methods:** In this study, we investigated acute normal tissue effects in C3H mice where the whole abdomen was irradiated with either single pulse 6 MeV electron FLASH irradiation (dose rate = 2- $6*10^6$  Gy/s) or conventional dose rate irradiation (15 Gy/min), delivered by a modified experimental linear electron accelerator. Mice were irradiated using either irradiation technique at various radiation doses and culled after 3.75 days. The small intestines were made into "Swiss rolls" for histological assessment. Normal tissue damage was quantified using a modified crypt assay. **Results:** We found statistically significant differences in crypt survival between mice irradiated with doses between 7.5 and 12.5 Gy. Nonlinear regression analysis of the dose-response curves for both irradiation techniques showed a dose modifying factor of  $\approx 1.1$ , i.e. a 10% higher dose was needed for FLASH compared conventional dose rate irradiation to achieve the same level of toxicity. Mice irradiated with FLASH also showed reduced weight loss compared to those groups that received conventional irradiation, but the effect was not statistically significant.

**Conclusion:** This study demonstrates that FLASH irradiation is a promising radiotherapy technique, capable of sparing gastrointestinal normal tissue. Further research will focus on identifying the optimal pulse structure for maximising the FLASH sparing effect.

<sup>&</sup>lt;sup>1</sup> Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom

# O27 - First veterinary patient treated with electron FLASH radiotherapy at a clinical linear accelerator

#### Elise Konradsson<sup>1</sup>

Maja L. Arendt<sup>2</sup>, Kristine Bastholm Jensen<sup>3</sup>, Betina Børresen<sup>2</sup>, Crister Ceberg<sup>1</sup>, Anders E. Hansen<sup>4</sup>, Annemarie T. Kristensen<sup>2</sup>, Per Munck af Rosenschöld<sup>5</sup>, Kristoffer Petersson<sup>5, 6</sup>

- <sup>1</sup> Medical Radiation Physics, Department of Clinical Sciences, Lund University, Lund, Sweden
- <sup>2</sup> Department of Veterinary Clinical Sciences, University of Copenhagen, Frederiksberg, Denmark
- <sup>3</sup> Veterinärhuset Öresund, Limhamn, Sweden
- <sup>4</sup> Department of Biotherapeutic Engineering and Drug Targeting, DTU Health Tech, Kgs, Technical University of Denmark, Lyngby, Denmark
- <sup>5</sup> Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
- <sup>6</sup> Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

**Introduction:** There is a growing interest in advancing ultra-high dose rate radiotherapy (FLASH-RT) towards clinical studies. However, the availability of accelerators capable of delivering ultra-high dose rates in a clinical setting is still limited. We have initiated a veterinary clinical study of FLASH-RT for clinical canine cancer patients with superficial tumors using the electron beam of our modified clinical linear accelerator. Here we present the treatment of the first patient.

**Methods:** A clinical canine cancer patient diagnosed with a grade 1 soft tissue sarcoma at the right forelimb, with incomplete excision after surgery, was treated with 15 Gy FLASH-RT using a field size of 8x4 cm<sup>2</sup> (Figure 1). The irradiation was delivered with a source-to-surface distance of 70 cm. Dosimetric equipment consisted of radiochromic film, an ionization chamber (for relative measurements) and phantom material mimicking the experimental setup for irradiation. *In vivo* dose measurements were performed with film to verify the delivered dose.

**Results:** For the canine patient, the prescribed dose was accurately delivered ( $14.8 \pm 0.5$  Gy) using 7 pulses in 0.03 s, i.e. with an average dose rate of 500 Gy/s. Only grade 1 cutaneous side effects were observed at 7 and 30 days post treatment.

**Conclusion:** We present irradiation parameters and toxicity data for the first clinical veterinary patient receiving electron FLASH-RT using a clinical linear accelerator. The treatment was feasible, safe, delivered with good dosimetric accuracy and successful in terms of the observed treatment toxicity.



Figure 1: Treatment setup for the first patient receiving FLASH-RT at our clinical linear accelerator.

# O28 - Immunomodulatory effects of external and targeted radiotherapy depend on radiation type

#### Julie Constanzo<sup>1</sup>

Jihad Karam<sup>1</sup>, Julien Faget<sup>1</sup>, Frank Bruchertseifer<sup>2</sup>, Alfred Morgenstern<sup>2</sup>, Isabelle Vila<sup>3</sup>, Nadine Laguette<sup>3</sup>, Nathalie Bonnefoy<sup>1</sup>, Jean-Pierre Pouget<sup>1</sup>

**Introduction:** Beside conventional radiotherapy, TRT consists in the administration of radiopharmaceuticals made of monoclonal antibodies or peptides coupled to a radionuclide-emitting alpha, beta and Auger particles, specifically irradiating disseminated tumor cells. Here, we investigate the role of X-rays, alpha and Auger in triggering systemic effects through the cGAS-STING pathway.

**Methods:** B16F10 melanoma cells were subcutaneously injected in C57BL/6J and Athymic mice. Mice received intraperitoneal injections of anti-TA99 mAb targeting TYRP-1/gp75 tumor antigen radiolabeled either with <sup>225</sup>Ac (1× 9.25 kBq; 74MBq/mg, alpha-TRT) or <sup>125</sup>I (2× 27 MBq; 37MBq/mg, Auger-TRT), or with extracellular vesicles (EVs) purified from cells exposed either to 0.5 Gy X-rays or to 4 MBq/mL <sup>125</sup>I-anti-TA99.

**Results:** *In vivo*, T-cells contribute to both alpha- and Auger-TRT efficacy. Despite its short penetration range ( $\approx 1 \mu m$ ), Auger-TRT demonstrated significant tumor growth delay and survival (controls: 15 days versus  $^{125}$ I-anti-TA99 : 29 days, \*\*p = 0.0035) in immunocompetent mice, while no difference was observed in Athymic mice. *In vitro*, B16F10 cells exposed to  $^{125}$ I-anti-TA99, demonstrated a weak accumulation of cytosolic dsDNA compared to X-rays (Fig.1). However, an early and persistent activation of the cGAS-STING pathway (up-regulation of cGAS, p-STING, p-IRF3 and p-TBK1 expression) was observed, from 1h-48h following the beginning of Auger-TRT incubation. Finally, we showed that EVs purified from Auger TRT do not contribute to proimmunogenic response *in vivo*, which was associated with absence of dsDNA in their content, while EVs purified from X-rays do carry dsDNA and induce tumor growth delay in immunocompetent mice.

**Conclusion:** Cytosolic dsDNA and dsDNA-containing EVs mediate radiation-induced systemic response *in vivo*.

<sup>&</sup>lt;sup>1</sup> IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, F-34298, France

<sup>&</sup>lt;sup>2</sup> Directorate for Nuclear Safety and Security, European Commission - Joint Research Centre, Karlsruhe, Germany

<sup>&</sup>lt;sup>3</sup> IGH, Institut de Génétique Humaine, CNRS, Université de Montpellier, Molecular Basis of Inflammation Laboratory, Montpellier, France




Fig. 1. Detection of cytosolic dsDNA by immunostaining, using a Zeiss Apotome.2 (40x magnification).

## O29 - Examining the effect of radiation on the secretome of normal and rectal cancer tissue and how this secretome interacts with the innate immune system

### Aisling Heeran<sup>1</sup>

Margaret Dunne<sup>1</sup>, Maria Morrissey<sup>1</sup>, Croí Buckley<sup>1</sup>, Niamh Clarke<sup>1</sup>, Aoife Cannon<sup>1</sup>, Noel Donlon<sup>1</sup>, Timothy Nugent<sup>1</sup>, Michael Durand<sup>2</sup>, Cara Dunne<sup>2</sup>, John Larkin<sup>2</sup>, Brian Mehigan<sup>2</sup>, Paul McCormick<sup>2</sup>, Niamh Lynam-Lennon<sup>1</sup>, Jacintha O'Sullivan<sup>1</sup>

<sup>1</sup>Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin 8, Ireland

**Introduction:** Locally advanced rectal cancer is treated with neoadjuvant-chemoradiotherapy, however only 22% of patients achieve a complete response. Resistance mechanisms are poorly understood. We profiled the inflammatory secretome of normal rectal and rectal cancer tissue preand post-radiation and investigated the effect of this secretome on immune cell function. We correlated findings with patient clinical characteristics.

**Methods:** Human normal and rectal cancer tissue were cultured as *ex vivo* explants and either mockirradiated or received 1.8Gy radiation. Following 24hours, the tissue conditioned media was harvested and the *ex vivo* secretomes were profiled. The effect of these secretomes on innate immune cell function, specifically dendritic cell (DC) maturation was assessed by flow cytometry measuring CD86, CD80, CD83, PD-L1 and CD11c.

**Results:** Radiation increases the secretion of MDC, GM-CSF, IL-15 and IL-17A (p<0.05) in normal rectal tissue and IL-15 and TNF- $\beta$  (p=0.05) in rectal cancer tissue. The secretome from the irradiated *ex vivo* rectal cancer tissue significantly enhanced DC maturation markers, specifically CD86, PD-L1 and CD11c compared to the secretome of irradiated normal tissue. Secreted levels of MIP3 $\alpha$ , IL-7 and IL1RA following radiation correlated with patient's visceral fat area while secreted levels MIP3 $\alpha$ , VEGF and IL1RA correlated with intermuscular fat.

**Conclusion:** Radiation causes significant alterations in the *ex vivo* inflammatory secretome of normal and rectal cancer tissue. The *ex vivo* secretome of rectal cancer tissue enhances DC maturation. This may offer greater understanding of the effects of radiation on inflammation and immunity and the connection with treatment response in rectal cancer patients.

<sup>&</sup>lt;sup>2</sup>GEMS, St. James's Hospital, Dublin 8, Ireland

# O30 - Clinical Trial Evaluating the Efficacy of Mesenchymal Stromal Cell Injections for the Treatment of Radiation Induced Chronic Pelvic Complications

### Alain Chapel<sup>1</sup>

Alexandra Sémont<sup>1</sup>, Christine Linard<sup>1</sup>, Noëlle Mathieu<sup>1</sup>, Christelle Demarquay<sup>1</sup>, Claire Squiban<sup>1</sup>, Fabien Milliat<sup>1</sup>, Marc Benderitter<sup>1</sup>, Hélène Rouard<sup>2</sup>, Christophe Martinaud<sup>3</sup>, Norbert-Claude Gorin<sup>4</sup>, Mohamad Mohamad Mohty<sup>4</sup>, Jean-Marc Simmon<sup>5</sup>

- <sup>1</sup> Service de recherche en radiobiologie et en médecine régénérative (SERAMED), Laboratoire de Radiobiologie des expositions médicales (LRMED), Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Fontenay, FRANCE
- <sup>2</sup> Unité Bioingénierie Cellulaire, Tissulaire et Sanguine à Usage Thérapeutique (BCTSVT) EA 3952, Hôpital Henry Mondor, Etablissement Français du Sang (EFS), Créteil, FRANCE
- <sup>3</sup> Département des activités cliniques, Hôpital militaire de Percy, Centre de transfusion sanguine des armées (CTSA), Clamart, FRANCE
- <sup>4</sup> Service : Hématologie clinique et thérapie cellulaire, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, FRANCE
- <sup>5</sup> Service d'Oncologie Radiothérapie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, FRANCE

**Introduction:** Radiation cystitis or proctitis are pathologies resulting from pelvic radiotherapy that may be refractory to standard therapy. Our group has demonstrated that cell therapy can provide therapeutic benefit when other treatments have failed.


Methods: A phase 2 clinical trial is being enrolled in patients with post-radiotherapy abdominal and pelvic complications who did not improve their symptoms after conventional treatments (NCT02814864, Trial evaluating the efficacy of systemic mesenchymal stromal cells (MSC) injections for the treatment of radiation-induced abdominal and pelvic complications that are severe and chronic and refractory to standard therapy (PRISME). It involves the participation of 6 radiotherapy departments for the recruitment of 12 patients. They will all be treated and followed up in the haematology department of Saint Anthony's Hospital. The cells will be prepared in two centres (EFS Mondor and CTSA Clamart) belonging to the EcellFrance national network of regenerative medicine and MSC-based cell therapy. Treatment is a suspension of allogeneic stromal mesenchymal stromal stem cells from an intra-familial donor.

**Results:** Eligible patients must have a grade higher than 2 for rectorrhagia or hematuria at the inclusion. Each patient will receive 3 MSC injections, 7 days apart. Patients will be followed up over a period of 12 months. The main objective is decrease of one grade on the SOMA LENT scale for rectorrhagia or hematuria. The secondary goal is to reduce the frequency of diarrhea, analgesic consumption, pain and improve quality of life.

**Conclusion:** This clinical trial open new treatment for sequelae from radiotherapy for breast, prostate, bladder and uterus cancers.

#### **Selected references**

Clin Rev Allergy Immunol 2013 Oct;45(2):180-92. doi: 10.1007/s12016-012-8347-6. Use of Mesenchymal Stem Cells (MSC) in Chronic Inflammatory Fistulizing and Fibrotic Diseases: A Comprehensive Review Jan Voswinkel, Sabine François, Jean-Marc Simon, Marc Benderitter, Norbert-Claude Gorin, Mohamad Mohty, Loïc Fouillard, Alain Chapel



## O31 - Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up

#### Anna Sundlöv<sup>1</sup>

Katarina Sjögreen Gleisner<sup>2</sup>, Jan Tennvall<sup>1</sup>, Ludvig Dahl<sup>3</sup>, Johanna Svensson<sup>4</sup>, Anna Åkesson<sup>5</sup>, Peter Bernhardt<sup>6</sup>, Ola Lindgren<sup>1,7</sup>

- <sup>1</sup> Department of Clinical Sciences, Oncology, and Pathology, Skåne University Hospital, Lund University, Lund, Sweden
- <sup>2</sup> Medical Radiation Physics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
- <sup>3</sup> Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden
- <sup>4</sup> Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
- <sup>5</sup> Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden
- <sup>6</sup> Department of Radiation Physics, University of Gothenburg, Gothenburg, Sweden
- <sup>7</sup> Department of Endocrinology, Skåne University Hospital, Lund University, Lund, Sweden

**Introduction:** The pituitary gland has a high expression of somatostatin receptors and is therefore a potential organ at risk for radiation-induced toxicity after 177Lu-DOTATATE treatment. Objective: To study changes in pituitary function in O31patients with neuroendocrine tumors (NETs) treated with dosimetry-based 177Lu-DOTATATE to detect possible late toxicity.

**Methods:** 68 patients from a phase II clinical trial of dosimetry-based, individualized 177Lu-DOTATATE therapy were included in this analysis. Patients had received a median of 5 (range 3–9) treatment cycles of 7.4 GBq/cycle. Median follow-up was 30 months (range 11–89). The GH/IGF-1 axis, gonadotropins, and adrenal and thyroid axes were analyzed at baseline and on a yearly basis thereafter. Percent changes in hormonal levels over time were analyzed statistically using a linear mixed model and described graphically using box plots. The absorbed radiation dose to the pituitary was estimated based on post-therapeutic imaging, and the results analyzed versus percent change in IGF-1 levels over time.

**Results:** A statistically significant decrease in IGF-1 levels was found (p < 0.005), which correlated with number of treatment cycles (p = 0.008) and absorbed radiation dose (p = 0.03). A similar decrease, although non-significant, was seen in gonadotropins in postmenopausal women, while in men there was an increase during the first years after therapy, after which the levels returned to baseline. No change was observed in the adrenal or thyroid axes.

**Conclusion:** No signs of severe endocrine disorders were detected, although a significant decrease in the GH/IGF-1 axis was found, where dosimetric analyses indicated radiation-induced damage to the pituitary gland as a probable cause.

### 032 - Decision tool for radiotherapy compliance in elderly cancer patients

### Biche Osong<sup>1</sup>

Inigo Bermejo<sup>1</sup>, Andre Dekker<sup>1</sup>, Seok Ho Lee<sup>2</sup>, Johan van Soest<sup>1</sup>

- <sup>1</sup> Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands
- <sup>2</sup> Department of Radiation Oncology, Gachon University, College of Medicine, Gil Medical Center, Incheon, Korea

**Introduction:** Radiotherapy is one of the most common treatment modality for cancer. However, treatment is often affected by unwanted interruptions (non-compliance), which ultimately affects the local control and overall survival of the patient.

**Methods:** Among the patients who received radiation therapy between 2005 to 2017 at our institution, 789 patients over 75 years of age were retrospectively analyzed. Radiotherapy compliance was determined by whether the scheduled radiotherapy plan was completed. Chi-square tests and 5-fold cross-validation repeated ten times was used to establish the decision tree model after a 70 - 30 split percentage of the original data to train and test the model, respectively. The discriminative performance of the developed tree distinguishing compliant and non-compliant patients was assessed measuring the area under the receiver operating characteristic curve (AUROC).

**Results:** The decision tree uses four predictors (Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS), treatment aim, age, and gender) to make a decision, as shown in Figure 1. The mean AUROCs of the trees discriminating ability on the training, and test datasets are 0.71 (0.65 - 0.77), and 0.65 (0.55 - 0.76) respectively

**Conclusion:** We developed and internally validated a novel decision tree that could discriminate between patients who will or will not comply with radiotherapy treatment. This model could be used to guide caregivers and physicians to opt for alternative therapies, such as short-course radiotherapy, for patients who are predicted to be non-compliant. Alternatively, it could help target these patients with strategies to help them comply with radiotherapy treatment.

#### **Selected references**

- Repetto, L. et al. Geriatric oncology: A clinical approach to the older patient with cancer. Eur. J. Cancer 39,870–880,http://doi:10.1016/S0959-8049(03)00062-5 (2003).
- Davies, J. et al. Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. World J. Surg 22,1048–1055 (1998).
- Vironen, J.H., Sainio, P., Husa, A.I. & Kellokumpu, I.H. Complications and survival after surgery for rectal cancer in patients younger than and aged 75 years or older. Dis. Colon Rectum 47,1225–1231, http://doi:10.1007/s10350-004-0557-4 (2004).
- Yoon, W.S., Yang, D.S.&Kim, C.Y. The evaluation of radiation therapy and combined-modality therapy for non-small-cell lung cancer in elderly. J Korean Soc Ther Radio Oncol25, 101-108,http://doi:10.3857/jkstro (2007).




Figure 1: Decision tree for predicting radiotherapy compliance in elderly cancer patients.

### O33 - Characterization of monocytes-endothelium interactions after radiotherapy

### Ségolène Ladaigue<sup>1</sup>

Anne-Charlotte Lefranc<sup>1</sup>, Khadidiatou Baldé<sup>1</sup>, Monica Quitoco<sup>1</sup>, Valérie Buard<sup>1</sup>, Fabien Milliat<sup>1</sup>, Olivier Guipaud<sup>1</sup>


<sup>1</sup> Radiobiology of medical exposure laboratory, LRMED. French institute for radiological protection and nuclear safety, IRSN. Fontenay-aux-roses, France.

**Introduction:** Normal tissue damages associated with chronic innate immune cell infiltration is thought to drive late normal tissue injury induced by radiotherapy (RT). While macrophages may play a major role in these adverse effects, little is known about how their precursors, the monocytes (Mo), are recruited in irradiated tissues through the endothelium. This study aims to clarify the role of the different endothelial cell (EC)'s actors: high-mannose N-glycosylations (HMNG), CCR2/CCL2 and CX3CR1/CX3CL1 in Mo recruitment after irradiation.

**Methods:** *In vitro* interactions of Mo with irradiated ECs, i.e. firm arrests on ECs under flow and trans-endothelial migration, were evaluated by real-time imaging techniques (video-microscopy and IncuCyte live cell analysis system) using a human Mo cell line (THP-1) and human primary ECs (HUVECs). The roles of endothelial HMNG, MAN1C1, involved in the trimming of HMNG, CCR2/CCL2 and CX3CR1/CX3CL1 were evaluated using siRNA, lentiviral particles and molecular competitors.

**Results:** siRNA against *man1c1* in ECs increased Mo adhesion and the level of HMNG on ECs, suggesting a role of MAN1C1 in the recruitment of Mo. In addition, we developed a reliable transmigration test allowing us to show that irradiation of ECs stimulates Mo transmigration in a dose-dependent manner. We also showed that Mo transmigration and adhesion are regulated by CX3CL1 signaling in ECs using competitors and siRNA.

**Conclusion:** Our results suggest that CX3CR1 and MAN1C1 may regulate Mo recruitment at different steps following irradiation. Mo adhesion after endothelial MAN1C1 overexpression, as well as *in vivo* studies of leukocytes-endothelium interactions in specific murine models are now under investigation.



# O34 - Colonic and microbial alterations in a colorectal cancer mouse model provoked by pelvic fractionated X-ray treatment

### Shari Wouters<sup>1, 2</sup>

Mieke Neefs<sup>1</sup>, Sarah Baatout<sup>1</sup>, Natalie Leys<sup>1</sup>, Surbhi Malhotra-Kumar<sup>2</sup>, Samir Kumar-Singh<sup>2</sup>, Mieke Verslegers<sup>1</sup>, Mohamed Mysara<sup>1</sup>

**Introduction:** Radiotherapy plays an adjunctive role in colorectal cancer (CRC) treatment. However, (hypo)fractionated pelvic x-ray irradiation involves exposure to high cumulated doses (25-55 Gy), which leads to collateral damage of the surrounding intestinal tissue and drives substantial changes in the gut microbiome, termed dysbiosis. Consecutively, dysbiosis leads to epithelial destruction and mucosal ulceration which might require premature treatment interruption or additional symptomatic treatment. Hence, to reduce radiation-induced side effects, maintaining a healthy gut microbiome could be key.

**Methods:** Therefore, a reproducible CRC mouse model (AOM/DSS) receiving farctionated pelvic radiation (6x3 Gy) was established to represent clinical radiation-induced pathology. Upon dissection, tumour development was assessed and tissues were harvested to assess temporal radiation-induced damage and bacterial translocation. Fresh faeces were collected for microbial analysis.

**Results:** Mice showed consistent weight loss (<10%) following each session of radiation but quickly recovered three days post final irradiation. As anticipated, a significant decrease (19-33%) in number of macroscopically identifiable tumours was observed in irradiated animals as compared to sham-irradiated controls. Additionally, a significant overall decrease in spleen size was observed following irradiation, which might be indicative of radiation-induced atrophy. Finally, observed temporal changes in lymph node bacterial count are believed to be associated with increasing bacterial translocation and colon permeability post irradiation.

**Conclusion:** Altogether, our results support the successful development of a reproducible CRC mouse model receiving fractionated pelvic radiation. The analysis of the histological, inflammatory and dysbiotic status is ongoing to further validate the developed model. In future, our model can be employed to test potential prophylactic therapies.

<sup>&</sup>lt;sup>1</sup> Belgian Nuclear Research Centre, SCK•CEN, Interdisciplinary Biosciences group, Mol, Belgium

<sup>&</sup>lt;sup>2</sup> University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium

# O35 - p53 drives premature neuronal differentiation in response to radiation-induced DNA damage during early neurogenesis

### Roel Quintens1

André-Claude Mbouombouo Mfossa<sup>1, 2</sup>, Mieke Verslegers<sup>1</sup>, Tine Verreet<sup>1, 3</sup>, Haris Bin Fida<sup>1</sup>, Mohamed Mysara<sup>1</sup>, Wilfred FJ Van Ijcken<sup>4, 5</sup>, Winnok H De Vos<sup>6</sup>, Lieve Moons<sup>3</sup>, Sarah Baatout<sup>1</sup>, Mohammed A Benotmane<sup>1</sup>, Danny Huylebroeck<sup>4, 5</sup>

**Introduction:** p53 regulates the cellular DNA damage response (DDR). Hyperactivation of p53 during embryonic development, however, can lead to a range of developmental defects including microcephaly.

**Methods:** Here, we induce microcephaly by acute irradiation (1 Gy of X-rays) of mouse fetuses at the onset of neurogenesis (embryonic day 11). We used fluorescence microscopy and RNA sequencing to investigate radiation effects mostly at early time points after irradiation. Dorsal forebrain-specific *Trp53* knock-out (cKO) mice were generated by crossing *Trp53*fl/fl mice to *Emx1*-Cre mice.

**Results:** Besides a classical DDR culminating in massive apoptosis, we observe ectopic neurons in the subventricular zone in the brains of irradiated mice, indicative of premature neuronal differentiation. A transcriptomic study indicates that p53 activates both DDR genes and differentiation-associated genes. In line with this, *Trp53* cKO mice do not show this ectopic phenotype and partially restore brain size after irradiation. Irradiation furthermore induces an epithelial-to-mesenchymal transition-like process resembling the radiation-induced proneural-mesenchymal transition in glioma and glioma stem-like cells.

**Conclusion:** Our results demonstrate a critical role for p53 beyond the DDR as a regulator of neural progenitor cell fate in response to DNA damage.

<sup>&</sup>lt;sup>1</sup> Radiobiology Unit, Institute of Environment, Health and Safety, Belgian Nuclear Resreach Centre, SCK CEN, Mol, Belgium

<sup>&</sup>lt;sup>2</sup> Laboratory of Molecular Biology (Celgen), Department Development and Regeneration, KU Leuven, Leuven, Belgium

<sup>&</sup>lt;sup>3</sup> Laboratory of Neural Circuit Development and Regeneration, Department of Biology, Faculty of Science, KU Leuven, Leuven, Belgium

<sup>&</sup>lt;sup>4</sup> Center for Biomics, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>&</sup>lt;sup>5</sup> Department of Cell Biology, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>&</sup>lt;sup>6</sup> Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, University of Antwerp, Antwerp, Belgium

# O36 - NOTCH inhibition promotes bronchial stem cell renewal and epithelial barrier integrity after irradiation

#### Lorena Giuranno<sup>1</sup>

Eloy Moreno Roig<sup>1</sup>, Carolien Wansleeben<sup>1</sup>, Annette Van Den Berg<sup>1</sup>, Arjan Groot<sup>1</sup>, Ludwig Dubois<sup>1</sup>, Marc Vooijs<sup>1</sup>

**Introduction:** Tumor control by radiotherapy is limited by dose-limiting adverse effects, which negatively affect patients quality of life. NOTCH signaling pathway plays a key role in the regeneration of the airway epithelium. Deregulated NOTCH activity is associated with tumor growth and radiotherapy resistance and therefore is a potential therapeutic target. However, the mechanism through which NOTCH inhibition integrates with airway repair and treatment response is unknown. We therefore aimed to characterize the effect of inhibiting NOTCH signaling in the normal lung to investigate whether extra normal tissue toxicity derives from the use of NOTCH inhibitors. **Methods:** We used an air-liquid interface pseudo-stratified culture derived from primary human bronchial epithelial cells (PBECs), and we blocked the NOTCH signaling pathway using the pan-NOTCH γ-secretase inhibitor DBZ alone and in combination with irradiation (2, 4 Gy). **Results:** We found that stem cells (TP63+) proliferation decreases overtime but inhibiting NOTCH alone and in combination with radiotherapy increases TP63+cells proliferation and stemness capability. In irradiated cultures, we observed reduced 53BP1 foci 24 hours and 3days postirradiation when NOTCH signaling was inhibited. The increased stem cells proliferation together with reduced damage contributed to a more intact epithelium, as shown by the upregulation of ZO1,

increased stem cell proliferation.

Conclusion: These data support the use of normal patient tissue for predictive toxicity screening of combination treatments and disclose novel interactions between NOTCH inhibition and radiotherapy.

AFADIN, CD2AP when NOTCH was inhibited and combined with irradiation. Comparable results were obtained after *in vivo* irradiation, where the combination of NOTCH inhibition and irradiation

<sup>&</sup>lt;sup>1</sup> Maastricht University

### 037 - Preclinical study of Chronic radiocystitis and cell therapy treatment

### Clément BROSSARD<sup>1, 2, 3</sup>

Anne-Charlotte Lefranc<sup>1, 2, 3</sup>, Morgane Dos Santos<sup>1, 3, 4</sup>, Mohamedamine Benadjaoud<sup>1, 3</sup>, Christelle Demarquay<sup>1, 2, 3</sup>, Valérie Buard<sup>1, 2, 3</sup>, Georges Tarlet<sup>1, 2, 3</sup>, Claire Squiban<sup>1, 2, 3</sup>, Christine Linard<sup>1, 2, 3</sup>, Noëlle Mathieu<sup>1, 2, 3</sup>, Romain Granger<sup>3, 5</sup>, Amandine Sache<sup>3, 5</sup>, Delphine Denais Lalieve<sup>3, 5</sup>, Jean-Marc Simon<sup>6</sup>, Marc Benderitter<sup>1, 3</sup>, Fabien Milliat<sup>1, 2, 3</sup>, Alain Chapel<sup>1, 2, 3</sup>

**Introduction:** Chronic radiocystitis (CRC) is a pathology resulting from irradiation of pelvic area without effective treatment. CRC is characterized by chronic inflammation leads to fibrosis. We investigated whether Mesenchymal Stromal Cells (MSC) treatment could reverse CRC damages. **Methods:** Our study is divided into two parts, the modelling of CRC and the effect of treatment with MSCs. Preclinical CRC modelling in rats was performed by CT-guided localized irradiation of the bladder from 20 up to 80 Gy with a follow-up of 3 to 15 months after irradiation. Concerning MSCs treatment, bladder was irradiated at 40 Gy. Four month later, three intravenous injections, every two weeks, of 5.10<sup>6</sup> of MSCs was performed. A physiological, histological and molecular follow-up was done until 12 months post- irradiation.

**Results:** The transient haematuria increasing with time and irradiation dose. Transcriptomic analysis indicates an acute inflammation at 3 months (CCL2, CCL5, TNF $\alpha$  and IL1 $\beta$  upregulation). Results are in favour of tissue and vascular regeneration (EGF and VEGF upregulation) coupled with Extra Cellular Matrix (ECM) remodelling with overexpression of metalloprotease MMP2 and inhibitors, TIMP1/2/4, collagens Col1 $\alpha$ 2, Col3 $\alpha$ 1 and proteoglycan Cspg4.

At 6 months, a second wave of inflammation (CCL5, IL1 $\beta$ , IL6 and HIF1 $\alpha$  upregulation) is observed, correlated with urothelium disorganization but without tissue and vascular regeneration or remodelling of the ECM.

**Conclusion:** Results have shown an initiation of CRC at 6 months, with chronic inflammation, hematuria, disorganization of the urothelium and fibrosis. Study is in progress to evaluate the efficacy of MSC treatment.

<sup>&</sup>lt;sup>1</sup> Service de recherche en radiobiologie et en médecine régénérative (SERAMED)


<sup>&</sup>lt;sup>2</sup> Laboratoire de Radiobiologie des expositions médicales (LRMED)

<sup>&</sup>lt;sup>3</sup> Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-roses

<sup>&</sup>lt;sup>4</sup> Laboratoire de radiobiologie des expositions accidentelles (LRAcc)

<sup>&</sup>lt;sup>5</sup> Service de recherche sur les effets biologiques et sanitaires des rayonnements ionisants (SESANE), Groupe de support à la recherche et à l'éthique animale (GSEA)

<sup>&</sup>lt;sup>6</sup> Département de radio-oncologie, Hôpital universitaire de la Pitié-Salpêtrière, Paris, France



# O38 - Can rosiglitazone protect endothelial cells from irradiation-induced mitochondiral dysfunction?

### Bjorn Baselet1

An Aerts<sup>1</sup>, Sarah Baatout<sup>1</sup>

<sup>1</sup> Radiobiology unit, Interdisciplinary biosciences, Institute for environment, health and safety, SCK CEN, Mol, Belgium

**Introduction:** Up to 50–60% of all cancer patients receive radiotherapy as part of their treatment strategy. However, the mechanisms accounting for increased vascular risks after irradiation are not completely understood. MitochondrOial dysfunction has been identified as a potential cause of radiation-induced atherosclerosis.

**Methods:** Assays for apoptosis, cellular metabolism, mitochondrial DNA content, functionality and morphology were used to compare the response of endothelial cells to a single 2 Gy dose of X-rays under basal conditions or after pharmacological treatments that either reduced (EtBr) or increased (rosiglitazone) mitochondrial content.

**Results:** Exposure to ionizing radiation caused a persistent reduction in mitochondrial content of endothelial cells. Pharmacological reduction of mitochondrial DNA content rendered endothelial cells more vulnerable to radiation-induced apoptosis, whereas rosiglitazone treatment increased **Conclusion:** Pre-existing mitochondrial damage sensitizes endothelial cells to ionizing radiation-induced mitochondrial dysfunction. Rosiglitazone protects endothelial cells from the detrimental effects of radiation exposure on mitochondrial metabolism and oxidative stress. Thus, our findings indicate that rosiglitazone may have potential value as prophylactic for radiation-induced atherosclerosis.

### O39 - Evaluation of the radioprotective potential of a PTEN inhibitor bpV(HOpic)

#### Ankit Chauhan<sup>1</sup>

Dhananjay Kumar Sah<sup>1</sup>, Neeraj Kumari<sup>1</sup>, Yogesh Rai<sup>1</sup>, Namita Kalra<sup>1</sup>, Ravi Soni<sup>1</sup>, Anant Narayan Bhatt<sup>1</sup>

**Introduction:** Ionizing radiation (IR) exposures during the events of medical or nuclear accidents pose a critical threat to human health. Hence, there is an urgent need for the development of potent and safe radioprotective agents for the management of radio-nuclear emergencies. This study was undertaken to investigate the radioprotective potential of a Phosphatase and tensin homolog (PTEN) inhibitor, bpV(HOpic).

**Methods:** The cell cytotoxicity, proliferation index, and clonogenic survival assays were performed for assessing the safe dose and radioprotective potential of bpV(HOpic). The IR-induced apoptosis, the kinetics of DNA repair, cytogenetic damage, and IR-induced oxidative stress were studied as the indices of modification of radiation response. Furthermore, the in-vitro observation was verified invivo.

**Results:** A safe dose of bpV(HOpic) was shown to be radioprotective in the cells of three radiosensitive tissue origin. Further, bpV(HOpic) significantly reduced the IR-induced apoptosis and associated pro-death signaling. A faster and better DNA repair kinetics and reduced cytogenetic damage was also observed in bpV(HOpic) pretreated cells exposed to IR. Additionally, bpV(HOpic) decreased the IR-induced oxidative stress and significantly enhanced the anti-oxidant defense mechanisms in cells. The radioprotective effect of bpV(HOpic) was found to be AKT dependant and primarily regulated by the enhanced glycolysis and associated signaling. Intraperitoneal administration of bpV(HOpic) in C57BL/6 mice resulted in AKT activation and conferred survival advantage against IR-induced mortality.

**Conclusion:** These results imply that bpV(HOpic) diminishes IR-induced oxidative stress and cell death by inducing AKT signaling mediated anti-oxidant defense system and DNA repair pathways, thus strengthening its potential to be used as a radiation countermeasure.

### **Selected references**

Lai, J.-P., Bao, S., Davis, I. C. & Knoell, D. L. Inhibition of the phosphatase PTEN protects mice against oleic acid-induced acute lung injury. Br. J. Pharmacol. **156**, 189–200 (2009).

Guo, J.-Y. et al. Dose-Dependent Protective Effect of Bisperoxovanadium against Acute Cerebral Ischemia in a Rat Model of Ischemia/Reperfusion Injury. Int. J. Mol. Sci. **14**, 12013–12022 (2013). Sakurai, H., Yasui, H. & Adachi, Y. The therapeutic potential of insulin-mimetic vanadium complexes. Expert Opin Investig Drugs **12**, 1189–1203 (2003).

Bevan, A. P., Drake, P. G., Yale, J. F., Shaver, A. & Posner, B. I. Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Mol. Cell. Biochem. **153**, 49–58 (1995).

<sup>&</sup>lt;sup>1</sup> Institute of Nuclear Medicine and Allied Sciences, Delhi, India.

### O40 - Cardiomyocyte dysfunction upon radiation

#### Timo Smit<sup>1</sup>

E. Schickel<sup>1</sup>, S. Ritter<sup>1</sup>, M. Durante<sup>1</sup>, I. S. Schroeder<sup>1</sup>
<sup>1</sup> GSI Helmholtz Center for Heavy Ion Research, Darmstadt, Germany

**Introduction:** The risk of developing cardiovascular disease (CVD) increases with the received radiation dose, even at doses as low as 0.5 Gy. Therefore, radiotherapy patients and astronauts on space missions are considered groups with increased CVD risk [1]. However, the underlying mechanisms are poorly understood.

**Methods:** We used cardiomyocytes (CM) generated from human embryonic stem cells as a 3D model, which mirrors key features of the myocardium such as contraction automaticity and a functional syncytium. Physiology was investigated by patch clamp technique and cardiac pharmaceutical response. Matured clusters (100 days after differentiation initiation) were irradiated with 0.5 or 2 Gy X-rays. Functional parameters such as beat rate and rhythmicity were assessed up to one week after irradiation using a video-based analysis developed at GSI [2].

**Results:** At the time of exposure, CM showed highly organized sarcomeric structures and responded physiologically to pharmaceuticals. The video analysis of irradiated clusters with 0.5 Gy X-rays (n=77) did not result in strong effects on the function compared to the controls (n=70). In contrast, clusters irradiated with 2 Gy X-rays (n=48) revealed an increase in the beat rate compared to the controls (n=49). Additionally, cardiac abnormalities such as arrhythmias were observed. To expand the model to space-relevant radiation quality an experiment with <sup>56</sup>Fe radiation (1 GeV/n) has been recently performed.

**Conclusion:** In summary, the effects/changes observed after X-ray irradiation reflect a broad range of cardiac dysfunctions. Thereby mechanisms of the CVD development and the role of cardiomyocytes upon radiation can be studied in detail.

#### Selected references

- 1. Hughson, R., Helm, A. & Durante, M. Heart in space: effect of the extraterrestrial environment on the cardiovascular system. Nat Rev Cardiol 15, 167–180 (2018). https://doi.org/10.1038/nrcardio.2017.157
- 2. Nitsch, S., et al., Functional video-based analysis of 3D cardiac structures generated from human embryonic stem cells. Stem Cell Res. 29: p. 115-124. (2018). https://doi.org/10.1016/j.scr.2018.03.013

### O41 - Early-life X-ray exposure accelerates brain aging in a 3xTg-AD mouse model

Emma Coninx<sup>1</sup>

Amelie Coolkens<sup>1</sup>, Sarah Baatout<sup>1</sup>, Winnok De Vos<sup>2</sup>, Lieve Moons<sup>3</sup>, Roel Quintens<sup>1</sup>, **Mieke Verslegers**<sup>1</sup>

- <sup>1</sup> Radiobiology Unit, Institute for Environment, Health and Safety, SCK CEN, Mol, Belgium
- <sup>2</sup> Laboratory of Cell Biology and Histology, University of Antwerp, Belgium

**Introduction:** Cranial radiotherapy is inevitable to treat pediatric brain tumors, the second most common childhood cancer. Due to therapeutic advances, survival rates of pediatric brain cancer patients have increased, leading to a higher risk for developing long-term cognitive defects. As irradiation is speculated to accelerate cellular and tissue aging and given that the developing brain is particularly radiosensitive, we hypothesize that pediatric cranial radiotherapy patients are at risk for accelerated brain aging. Further, we want to elucidate whether this predisposes the irradiated brain to develop Alzheimer's disease (AD).

**Methods:** Ten-day-old female C57BL/6J and triple transgenic (3xTg) AD mice were exposed to 1.8 Gy X-rays. Acute as well as persistent radiation-induced defects that could potentially induce brain aging were investigated in the hippocampus and correlated to cognitive outcome. Additionally, a potential exacerbation of AD pathology was examined using 3xTg-AD mice.

**Results:** An acute radiation-induced increase in DNA damage and oxidative stress confirmed the radiosensitivity of the developing brain. Furthermore, a persistent reduction in the number of neuronal progenitors in the dentate gyrus and an impaired hippocampal long-term potentiation was found in irradiated 3xTg-AD mice, accompanied by changes in fear response and sociability. Yet, with a newly developed brain epigenetic clock, no change in hippocampal aging rate was observed following irradiation. Finally, tissue-clearing experiments revealed radiation-induced changes in AD pathology.

**Conclusion:** Our study showed that early-life radiation exposure directly damages the hippocampus, resembling impairments in neurogenesis and plasticity in the aging brain. This increased aging is potentially contributing to AD pathology.

<sup>&</sup>lt;sup>3</sup> Neural Circuit Development and Regeneration Research Group, University of Leuven, Belgium

# O42 - The time-dependence of radiological benefit of decontamination of residential areas after a nuclear fallout for newborn and adults

### Christopher Rääf<sup>1</sup>

Johan Martinsson<sup>1</sup>, Yvonne Hinrichsen<sup>1</sup>, Robert Finck<sup>1</sup>, Mats Isaksson<sup>2</sup>

**Introduction:** Experience from Japan after the Fukushima fallout shows that decontamination measures of residential areas may take up to several years to achieve. The averted cumulative lifetime attributable risk (CUMLAR) as a function of implementation time of decontaminating residential areas has been theoretically evaluated for a number of scenarios involving unfiltered releases of fission products (such as <sup>137</sup>Cs) by applying an existing exposure model designed to compute age and gender dependent time integrated cancer risk.

**Methods:** The scenarios are partly based on data from the Chernobyl and Fukushima releases and from theoretical source terms from Swedish Nuclear Power Plants.


**Results:** Our models predict that compliance with existing reference level of 20 mSv y<sup>-1</sup> can be possible for <sup>137</sup>Cs deposition levels up to ca 3 MBq m<sup>-2</sup>, resulting in averted CUMLAR of up to 20% for the most sensitive population group (newborn girls). It is, however, found that the averted CUMLAR per unit fallout of <sup>137</sup>Cs decreases rapidly with a half-time of 2-3 y, depending on initial <sup>134</sup>Cs to <sup>137</sup>Cs activity ratio and the ecological half-time of the external dose rate (<5 y). If the decontamination time is 5 y before evacuate residents can return, the averted CUMLAR for newborn girls will be about 10% of that obtained by evacuation alone during the same time.

**Conclusion:** We conclude that although decontamination may have societal benefits in terms of restored trust of the public, decision makers need to consider the short time-window of the radiological benefits of this protective action compared with just evacuation before return.

### **Selected references**

Rääf et al., 2020. Averting cumulative lifetime attributable risk (LAR) of cancer by decontamination of residential areas affected by a large-scale nuclear power plant fallout: Time aspects of radiological benefits for newborns and adults. Accepted for publication in J. Radiol. Protection

DOI: 10.1088/1361-6498/ab993a



<sup>&</sup>lt;sup>1</sup> Medical Radiation Physics, ITM, Lund University

<sup>&</sup>lt;sup>2</sup> Department of Radiation physics, Institute of Clinical Sciences, Sahlgrenska Academy. University of Gothenburg

# O43 - Improved patient dosimetry at radioiodine therapy by combining the ICRP iodide compartment model and the EANM pre-therapeutic standard procedure

#### Martin Andersson<sup>1</sup>

Sören Mattsson<sup>1</sup>

**Introduction:** Radioactive iodine is commonly used for the treatment of different thyroid conditions since the 1940s. The EANM has developed a standard pre-therapeutic procedure to estimate patient specific thyroid uptake. The procedure which models the time dependent fractional thyroid uptake is a two compartment fitting system, one representing the thyroid and the other the blood. The absorbed dose is however only estimated for the thyroid and not for any other organ in the body. A more detailed biokinetic model for iodine is given by the ICRP and includes a systemic iodide transport in the whole body. The ICRP model has however fixed transfer coefficients and is only presented with three different thyroid uptake values (low, normal and high).

**Methods:** Combining the EANM method and the ICRP model gives both patient specific uptake estimation and include also most organs in the body. The ICRP model has 30 different compartments and 48 transfer coefficients to model the biokinetics of iodide and to model different transfer for inorganic iodide and organic iodine. However, as the ICRP model is a recirculation iodine model, the optimization is therefore performed on the whole model and not exclusively on the thyroid as in the EANM procedure.

**Results:** Fitted to data for a specific patient, the transfer coefficient from blood to thyroid was 16/day insted of the 7/day giving a 2.5 times higher thyroid uptake than with the ICRP normal uptake model.

**Conclusion:** Combining the ICRP and EANM methodologies gives a improve thyroid dosimetry and information on absorbed dose to radiosensitive organs.

### **Selected references**

Hänscheid H. et al. EANM Dosimetry Committee Series on Standard Operational Procedures for Pre-Therapeutic Dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging 40(7), 1126–34, 2013

ICRP. Radiation Dose to Patients fromRadiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. ICRP Publication 128. Ann. ICRP 44(2S) 2015. Leggett R. An age-specific biokinetic model for iodine.J.Radiol.Prot.37(4), 864-882, 2017



Figure: The iodine software. To the left image shows the patient specific activity measurements (circles), and the results of the ICRP model for normal (red) and high (black) thyroid uptake. The blue line is the software generated comparmental fit according to the whole biokinetic model presented in the middle image for oral administration. The table in right image shows sex specific absorbed doses for both the thyroid and all 48 other organs.

<sup>&</sup>lt;sup>1</sup> Medical Radiation Physics Malmö, Department of Translational Medicine, Lund University

# O44 - Coadministration of three antioxidants did not influence the tumour response to radiotherapy in GOT1 neuroendocrine tumour model

#### Charlotte Andersson<sup>1</sup>

Emman Shubbar<sup>1</sup>, Lukas Lundholm<sup>1</sup>, Bo Åkerström<sup>2</sup>, Magnus Gram<sup>3</sup>, Khalil Helou<sup>4</sup>, Eva Forssell-Aronsson<sup>1</sup>

**Introduction:** It is a common view that antioxidants can be used to protect against cancer, although there're studies that contradict this view and even show that antioxidants can increase cancer progression. These conflicting results should be considered when exploring combination treatment with radiotherapy together with an antioxidant that could be used to improve the cancer treatment. We previously demonstrated that the antioxidant rA1M, a potential kidney protector during treatment with <sup>177</sup>Lu-octreotate, did not negatively affect the therapeutic response of <sup>177</sup>Lu-octreotate in neuroendocrine tumour (NET) mouse model.

In this study we further investigated if rA1M interferes with the radiation induced response in NET. We also studied effects of two other antioxidants that previously showed to increase tumour burden and promote metastastatic growth in other tumour types.

**Methods:** Female BALB/c nude mice with GOT1 NET tumours were divided into 4 groups and treated with external beam radiotherapy (EBRT), 6 Gy to the tumour. Three of the groups also received antioxidant supplements: N-acetylcysteine, rA1M or vitamin E. The tumour response was monitored over time by measuring the tumour volume.

**Results:** During the first days after EBRT the mean tumour volume decreased to less than 10 % of the initial volume, and about a week later the mean tumour volume increased again. Statistical analysis of the area under the curves showed no difference between the EBRT only group and the antioxidant groups.

**Conclusion:** In conclusion, supplements of the antioxidants rA1M, N-acetylcysteine or vitamin E did not negatively affect the tumour response of EBRT in GOT1 NET mouse model.

<sup>&</sup>lt;sup>1</sup> Dept. of Radiation Physics, Inst. of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

<sup>&</sup>lt;sup>2</sup> Lund University, Dept. of Clinical Sciences, Infection Medicine, Lund, Sweden

<sup>&</sup>lt;sup>3</sup> Lund University, Dept. of Clinical Sciences, Pediatrics, Lund, Sweden

<sup>&</sup>lt;sup>4</sup> Dept. of Oncology, Inst. of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

## O45 - Effects of $\alpha$ -particles and X-rays on human lung epithelium

### Kim Carola Roeder<sup>1</sup>

David Eilenstein<sup>1</sup>, Michael Scholz<sup>1</sup>, Marco Durante<sup>1, 2</sup>, Sylvia Ritter<sup>1</sup>

**Introduction:** Radon is the second most common cause of lung cancer. To gain a deeper insight into the effects of  $\alpha$ -particles and X-rays on lung epithelium, human bronchial epithelium cells (NHBE) were used. NHBE function as stem cells, ensure tissue homeostasis and repair. In vitro they form a functional epithelium consisting of basal, goblet, club and ciliated cells.

Methods: NHBE were irradiated with α-particles (0.25–1.5 Gy) from <sup>241</sup>Am or X-rays (0.5-5 Gy). Cell survival and stem cell identity of surviving cells (RT-qPCR analysis) were examined. Differentiation capacity of irradiated NHBE was analyzed via epithelium formation. Gene expression of cell type specific markers was quantified by RT-qPCR over 5 weeks. Additionally, for functional analysis (i.e. mucociliary clearance, MCC), micro-beads were placed onto the cells. Efficiency of MCC was assessed by an in-house designed video-based software.

**Results:** For NHBE  $\alpha$ -particles were more effective in cell inactivation than X-rays. Both radiation types did not affect the expression of selected markers in surviving cells. Their capability to generate a functional epithelium was impaired. Most selected markers were dysregulated. First video-based analyses showed a disturbed ciliary beat (CB) pattern after X-ray irradiation;  $\alpha$ -particle experiments are currently being carried out.

Conclusion: Per unit dose  $\alpha$ -particles are more effective in killing NHBE than X-rays. Surviving progeny are able to form an epithelium. Yet, RT-qPCR and CB analyses suggest that the functionality of the epithelium is compromised. In the case of inhaled radon, MCC impairment can exacerbate the radiation damage, as the transport of  $\alpha$ -decay products out of the lung is impeded.

<sup>&</sup>lt;sup>1</sup> GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany

<sup>&</sup>lt;sup>2</sup> Technische Universität Darmstadt, Germany

# O46 - G2/M checkpoint abrogation with selective inhibitors results in chromosome break repair defects in RPE and 82-6 hTERT cells

#### Aggeliki Nikolakopoulou

Aashish Soni<sup>1</sup>, Gabriel Pantelias<sup>2</sup>, Martha Habibi<sup>2</sup>, Pantelis Karaiskos<sup>3</sup>, Georgia Terzoudi<sup>2</sup>, George Iliakis<sup>1</sup>

**Introduction:** While technological advances in radiation oncology have led to a more precise delivery of radiation dose, there is a significant need to decrease risk of side effects and to overcome tumor resistance in radiation. Hence, there is a strong interest in combining radiotherapy treatment with new agents such as G2-M checkpoint inhibitors, which differentiate tumor's radiosensitivity. It is necessary, therefore, to investigate the role of ATM, ATR and chk1 inhibitors in G2 regulation and to evaluate their radiosensitizing effect.

**Methods:** The contribution of ATR, ATM and chk1 inhibition in human cell lines by using G2-M checkpoint potent inhibitors was examined. RPE and 82-6 hTERT human cell lines were irradiated during G2- to M-phase transition. G2-checkpoint was inactivated by means of caffeine, VE-821 and UCN-1, the inhibitors were added 1h before irradiation, and the number of chromatid breaks was obtained using a modified G2-chromosomal radiosensitivity assay.

**Results:** The results obtained showed a substantial increase in the number of chromatid breaks after treatment with all three inhibitors, however, the ATRi inhibitor VE-821 showed the maximum effect with an increase of 60%.

**Conclusion:** The treatment of 82-6 hTERT and RPE cells with all three inhibitors led to abrogated G2 checkpoint after irradiation and the ATR appears potentially to play a bigger role in G2 regulation compared to ATM. The results are promising, since a defective regulation of the G2 checkpoint may contribute to the phenotype of radiosensitivity.

- 1) Maréchal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5(9):a012716. Published 2013 Sep 1. doi:10.11016
- 2) Prevo R, Fokas E, Reaper PM, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012;13(11):1072-1081. doi:10.4161
- 2) Chen HHW, Kuo MT. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 2017;8(37):62742-62758. Published 2017 Jun 8. doi:10.18632
- 3) Yang SH, Kuo TC, Wu H, et al. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J Gastroenterol. 2016;22(32):7275-7288. doi:10.3748/wjg.v22.i32.7275
- 4) Mladenov E, Fan X, Dueva R, Soni A, Iliakis G. Radiation-dose-dependent functional synergisms between ATM, ATR and DNA-PKcs in checkpoint control and resection in G<sub>2</sub>-phase. Sci Rep. 2019;9(1):8255. Published 2019 Jun 4. doi:10.1038

<sup>&</sup>lt;sup>1</sup> Institute of Medical Radiation Biology, University of Duisburg-Essen, Germany

<sup>&</sup>lt;sup>2</sup> Laboratory of Health Physics, Radiobiology & Cytogenetics, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety (INRASTES), National Centre for Scientific Research "Demokritos"

<sup>&</sup>lt;sup>3</sup> Medical Physics Laboratory, Medical School, National & Kapodistrian University of Athens

# O47 - Detection of DNA damage and chromosomal aberrations after exposure to low ionizing radiation doses in interventional cardiology

#### Martha Habibi<sup>1</sup>

Panagiotis Karyofyllis<sup>2</sup>, Aggeliki Nikolakopoulou<sup>1</sup>, Panagiotis Papagiannis<sup>3</sup>, Pantelis Karaiskos<sup>3</sup>, Nikolaos Kollaros<sup>4</sup>, Irene Mastorakou<sup>4</sup>, Vasilis Voudris<sup>2</sup>, Georgia Terzoudi<sup>1</sup>

- <sup>1</sup> Laboratory of Health Physics, Radiobiology & Cytogenetics, INRASTES, National Centre for Scientific Research "Demokritos", Athens, Greece
- <sup>2</sup> Department of Interventional Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
- <sup>3</sup> Medical Physics Laboratory, Medical School, National & Kapodistrian University of Athens

**Introduction:** Little information is available about the effect of reportedly low ionizing radiation doses, such as those very often delivered to patients in interventional cardiology. As interventional cardiac procedures are a major contribution to total collective effective dose, there is a growing concern about the safety of physicians and patients regarding radiation protection issues and the late health effects. The purpose of this study was to investigate the use of potential biomarkers for low ionizing radiation dose from exposure during interventional cardiac procedures, based on different molecular and cytogenetic endpoints.

**Methods:** Lymphocytes from whole blood samples were collected from 25 patients before and after interventional cardiac examination. Biomarkers based on DNA and cytogenetic damage and repair such as γH2AX foci, dicentric chromosomes and micronuclei were studied.

**Results:** The results obtained indicated that all three endpoints studied showed increased yields relative to the baseline (p<0.001) for all patients after their medical exposure. Furthermore, 24 hours after exposure, residual  $\gamma$ H2AX foci were still detectable in irradiated lymphocytes with their decline found to vary significantly among the different individuals and their repair found to range from 20% to 97.2% of the initial  $\gamma$ H2AX foci.

Conclusion: The three different endpoints examined can function as biomarkers of exposure after interventional cardiac procedures. However, the results illustrate a clear advantage of the use of  $\gamma$ H2AX foci over the conventional dicentric and micronuclei assays after low dose exposure, as well as variability in the kinetics of the  $\gamma$ H2AX foci among the different individuals.

- 1. Abe Y, Miura T, Yoshida MA, Ujiie R, Kurosu Y, Kato N, Katafuchi A, Tsuyama N, Ohba T, Inamasu T, Shishido F, Noji H, Ogawa K, Yokouchi H, Kanazawa K, Ishida T, Muto S, Ohsugi J, Suzuki H, Ishikawa T, Kamiva K, Sakai. Analysis of chromosome translocation frequency after a single CT scan in adults. J Radiat Res. 2016 Jun;57(3):220-6
- 2. Won Hee Lee, Patricia K. Nguyen, Dominik Fleischmann, Joseph Wu. DNA damage-associated biomarkers in studying individual sensitivity to low-dose radiation from cardiovascular imaging. Eur Heart J. 2016 Oct 21; 37(40): 3075-3080.
- 3. Yanti Lusiyanti, Iin Kurnia, Viria Agesti Suvifan, Sardini Sardini, Sofiati Purnami, Nastiti Rahajeng. Evaluation of Chromosomal Aberrations and Micronuclei in Medical Workers Chronically Exposed to Low Dose Ionizing Radiation. Biosaintifika 9 (3) (2017) 585-591
- 4. Igor Piotrowski, Dr. Katarzyna Kulcenty, Wiktoria Maria Suchorska, Agnieszka Skrobała, Małgorzata Skorska, Marta Kruszyna-Mochalska, Anna Kowalik, Weronika Jackowiak and Julian Malicki. Carcinogenesis Induced by Low-dose Radiation. Radiol Oncol. 2017 Dec; 51(4): 369–377.

<sup>&</sup>lt;sup>4</sup> Imaging Department, Onassis Cardiac Surgery Center, Athens, Greece

5.	Fang, Lianying et al. "Assessment of Genomic Instability in Medical Workers Exposed to Chronic Low-Dose X-Rays in Northern China." Dose-response: a publication of International Hormesis Society vol. 17,4 1559325819891378. 28 Nov. 2019, doi:10.1177/1559325819891378
	446

## O48 - Mathematical modelling of radiation-induced acute myeloid leukaemia incidence

## Sjors Stouten<sup>1, 2</sup>

Sjoerd Verduyn Lunel<sup>2</sup>, Rosemary Finnon<sup>3</sup>, Christophe Badie<sup>3</sup>, Fieke Dekkers<sup>1,2</sup>

- <sup>1</sup> The Dutch National Institute for Public Health and the Environment
- <sup>2</sup> Utrecht University
- <sup>3</sup> Public Health England

Introduction: Atomic bomb survivor studies have shown that the low-dose acute myeloid leukaemia (AML) response curve is probably nonlinear. Although different nonlinear curves can be used to adequately describe high-dose risk, they provide distinct low-dose risk estimates after extrapolation. Animal models are widely used to elucidate various pathways of leukaemogenesis. Murine radiation-induced AML can largely be explained by two mutations: an exposure-related deletion with Sfpi1/PU1 loss; and the occurrence of a specific point mutation in the remaining allele. This major pathway of leukaemogenesis is translated into a mathematical model in order to study the possible form of the low-dose response curve in CBA/H mice.

**Methods:** We have developed a stochastic model in which each simulation corresponds to a photon-irradiated *in silico* male CBA/H mouse capable of developing AML in a time-dependent manner. Besides quantifying AML incidence, the model also describes dose-dependent cell death, formation of Sfpi1 deletions and animal death due to non-AML causes.

**Results:** Model predictions are in accordance with experimental data on cell/animal survival, time of AML onset and high-dose AML incidence. Low-dose AML incidence was found to be proportional to the number of cells with Sfpi1 deletions, which is approximately linear-quadratic. A linear-quadratic function could be used to accurately predict modelled low-dose incidence when only high-dose model estimates were made available in a fitting procedure.

**Conclusion:** By translating the main pathway of leukaemogenesis into a mathematical model we have found a linear-quadratic low-dose response curve for AML incidence in photon-irradiated male CBA/H mice.

# O49 - Modeling early radiation damage occurring during [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy with the Geant4-DNA toolkit

### Giulia Tamborino<sup>1, 2</sup>

Marijke De Saint-Hubert<sup>1</sup>, Lara Struelens<sup>1</sup>, Julie Nonnekens<sup>2, 3</sup>, Mark W. Konijnenberg<sup>2</sup>, Marion De Jong<sup>2</sup>, Yann Perrot<sup>4</sup>, Carmen Villagrasa<sup>4</sup>

- <sup>1</sup> Research in Dosimetric Applications, Belgian Nuclear Research Centre (SCK•CEN), Mol, Belgium
- <sup>2</sup> Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands
- <sup>3</sup> Department of Molecular Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

**Introduction:** The aim is to build a simulation framework for the number of DNA double strand breaks (DSBs) induced during *in vitro* targeted radionuclide therapy (TRNT).

**Methods:** A multiscale approach is implemented to simulate the number of DSBs produced by the cumulated decays of <sup>177</sup>Lu-DOTATATE, preliminary assumed as purely beta emitter, without including any repair. The approach involves 2 sequential simulations performed with Geant4/Geant4-DNA and accounts for a realistic geometry of the cell population and detailed sampling of the activity distribution within it.

To reproduce the exposure conditions of cells incubated 4h with <sup>177</sup>Lu-DOTATATE (2.5MBq/ml), a phase space is scored by recording particles that enter the nucleus of a cell belonging to a population modelled by polygonal mesh structures. The radioactive source is sampled according to dedicated uptake experiments evaluating the distribution of activities within medium and cells, thereby assuming instant and permanent internalization. The particles recorded in the phase space file are released within an ellipsoidal nucleus geometry, including a multi-scale description of the DNA. DnaFabric software is used to model the entire human genome with a continuous chromatin fiber per chromosome. This geometry is used to simulate the physical, physicochemical and chemical stages in Geant4-DNA and score the number of DSB/decay.

**Results:** Our results reveal induction of 6-10 DSBs/cell, depending on the cell confluence, compared to 11±2 DSBs/cell experimentally measured. The impact of physical/chemical parameters is currently under investigation.

**Conclusion:** This work represents the first step towards modeling DSBs during TRNT allowing a better understanding of underlying mechanisms for improved response prediction.

<sup>&</sup>lt;sup>4</sup> IRSN, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux Roses, France.

# O50 - RBE prediction by the BIANCA model for in vitro and in vivo irradiation by different hadron therapy ion-beams

#### Mario P. Carante<sup>1</sup>

Giulia Aricò<sup>2</sup>, Alessia Embriaco<sup>1</sup>, Alfredo Ferrari<sup>2</sup>, Christian P. Karger<sup>3</sup>, Wioletta Kozlowska<sup>2, 4</sup>, Andrea Mairani<sup>5</sup>, Paola Sala<sup>6</sup>, Francesca Ballarini<sup>1, 7</sup>

- <sup>1</sup> INFN (Italian National Institute for Nuclear Physics), Sezione di Pavia, via Bassi 6, I-27100 Pavia, Italy
- <sup>2</sup> CERN—European Organization for Nuclear Research, 1211 Geneva, Switzerland
- <sup>3</sup> Department of Medical Physics in Radiation Oncology, German Cancer Research (DKFZ), 69120 Heidelberg, Germany
- <sup>4</sup> Medical University of Vienna, 1090 Vienna, Austria
- <sup>5</sup> HIT (Heidelberg Ion-Beam Therapy Center), 69120 Heidelberg, Germany
- <sup>6</sup> INFN (Italian National Institute for Nuclear Physics), Sezione di Milano, via Celoria 16, I-20133 Milano, Italy


**Introduction:** BIANCA (*BIophysical Analysis of Cell death and chromosome Aberrations*) is a two-parameter biophysical model assuming that radiation induces DNA "critical lesions" that produce chromosome aberrations, some of which lead to cell death.

**Methods:** In view of RBE prediction for hadron therapy, first we tuned the model parameters to produce a radiobiological database (cell survival alpha and beta coefficients as a function of ion type and energy) for V79 cells, chosen as a reference. Afterwards, we developed an approach to produce analogous databases for other cell lines, for which the photon response is known. This approach does not require any further parameter adjustment, thus providing full predictions for, in principle, any cell line of interest; these databases can be read by a radiation transport code and/or a treatment planning system (TPS).

**Results:** In this work BIANCA was interfaced to the FLUKA transport code, and was applied to predict cell survival and RBE in typical hadron therapy scenarios. More specifically, very good agreement was found with experimental data on the survival of CHO cells exposed *in vitro* at different positions along Spread Out Bragg Peaks of protons, C-ions (Figure) and He-ions [1]. Furthermore, good agreement was obtained with proton and carbon RBE data on late effects in the rat spinal cord, which represent a model for CNS effects in head-and-neck tumor treatment [2]. **Conclusion:** This work suggests that BIANCA, interfaced to a transport code and/or TPS, can be used to predict RBE for hadron therapy treatments, and poses the bases for applications to patient cases.

- 1. M.P. Carante, G. Aricò, A. Ferrari, W. Kozlowska, A. Mairani and F. Ballarini, First benchmarking of the BIANCA model for cell survival predictions in a clinical hadron therapy scenario, *Physics in Medicine and Biology*, 64:215008 (2019)
- 2. M.P. Carante, G. Aricò, A. Ferrari, C.P. Karger, W. Kozlowska, A. Mairani and F. Ballarini, *In vivo* validation of the BIANCA biophysical model: benchmarking against rat spinal cord RBE data, *Int. J. Mol. Sci.*, 21(11), 3973 (2020

<sup>&</sup>lt;sup>7</sup> Physics Department, University of Pavia, via Bassi 6, I-27100 Pavia, Italy



# O51 - Development of a new microdosimetric biological weighting function for the RBE assessment in case of the V79 cell line exposed to ions from 1H to 238U

#### Alessio Parisi1

**Introduction:** With the increasing use of ions for cancer-radiotherapy it is of primary importance to model radiation-induced effects for treatment planning, quality control and research purposes. In this work, a new biological weighting function (IBWF) is proposed to correlate microdosimetric<sup>[1]</sup> spectra with the RBE<sub>10</sub> for the cell survival of the V79 cell line.

**Methods:** The IBWF was determined through an iterative deconvolution process between 592 PHITS-simulated<sup>[2]</sup> microdosimetric spectra and 267 *in vitro* survival-curves for V79 cells exposed to ions from <sup>1</sup>H to <sup>238</sup>U<sup>[3]</sup>.

The IBWF results were compared with corresponding calculations performed using the modified MKM<sup>[4]</sup>. Furthermore, RBE values computed with the reference biological weighting function (BWF)<sup>[5]</sup> for the *in vivo* early intestine tolerance in mice were also included to investigate potential correlations between the two biological endpoints.

Finally, the IBWF was unchangingly applied to microdosimetric spectra experimentally measured with 8 different microdosimeters in 17 different <sup>1</sup>H and <sup>12</sup>C beams at 8 clinical facilities.

**Results:** The average deviation between IBWF-derived RBE values and the *in vitro* data was ~14%. Using the MKM, it was not possible to successfully reproduce the RBE<sub>10</sub> data for ions heavier than  $^{20}$ Ne.


The RBE values assessed by the IBWF using as input the measured microdosimetric spectra were found to be in agreement with the ones calculated in combination with computer-simulated spectra, with an average relative deviation of 0.8% and 5.7% for <sup>1</sup>H and <sup>12</sup>C ions respectively.

#### **Conclusion:**

The IBWF can be used as a fast and easy tool for intercomparing clinical beams or the results acquired with different microdosimeters.

- [1] International Commission on Radiation Units and Measurements, 1983. ICRU Report 36 Microdosimetry. Bethesda, International Commission on Radiation Units and Measurements.
- [2] Sato, T., Iwamoto, Y., Hashimoto, S., Ogawa, T., Furuta, T., Abe, S.I., Kai, T., Tsai, P.E., Matsuda, N., Iwase, H. and Shigyo, N., 2018. Features of particle and heavy ion transport code system (PHITS) version 3.02. *Journal of Nuclear Science and Technology*, 55(6), pp.684-690.
- [3] Friedrich, T., Scholz, U., ElsäSser, T., Durante, M. and Scholz, M., 2013. Systematic analysis of RBE and related quantities using a database of cell survival experiments with ion beam irradiation. *Journal of radiation research*, *54*(3), pp.494-514.
- [4] Kase, Y., Kanai, T., Matsumoto, Y., Furusawa, Y., Okamoto, H., Asaba, T., Sakama, M. and Shinoda, H., 2006. Microdosimetric measurements and estimation of human cell survival for heavyion beams. *Radiation research*, *166*(4), pp.629-638.
- [5] Loncol, T., Cosgrove, V., Denis, J.M., Gueulette, J., Mazal, A., Menzel, H.G., Pihet, P. and Sabattier, R., 1994. Radiobiological effectiveness of radiation beams with broad LET spectra: microdosimetric analysis using biological weighting functions. *Radiation Protection Dosimetry*, 52(1-4), pp.347-352.

<sup>&</sup>lt;sup>1</sup> Belgian Nuclear Research Centre (SCK CEN)



Overview of the RBE<sub>10</sub> calculated by the IBWF (lines) for selected ions in comparison to *in vitro* data (dots) for the V79 cell line.

# O52 - EURADOS WG10 and RENEB WG2 exercise on retrospective dosimetry methods in a simulated small scale incident involving ionising radiation.

### Lovisa Waldner<sup>1</sup>

Christian Bernhardsson<sup>1</sup>, Céline Bassinet<sup>2</sup>, François Trompier<sup>2</sup>, Eric Gregoire<sup>2</sup>, Olivier van Hoey<sup>3</sup>, Clemens Woda<sup>4</sup>, Ursula Oestreicher<sup>5</sup>, Ulrike Kulka<sup>5</sup>, David Endesfelder<sup>5</sup>, Andrzej Wojcik<sup>6</sup>, Jonathan Ekins<sup>7</sup>, Elizabeth Ainsbury<sup>7</sup>

- <sup>1</sup> Lund University, Department of Translational Medicine, Medical Radiation Physics, Sweden
- <sup>2</sup> Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, France
- <sup>3</sup> Environment, Health and Safety Institute, Belgian Nuclear Research Center (SCK•CEN), Belgium
- <sup>4</sup> Helmholtz Zentrum München, Institute of Radiation Medicine, Neuherberg, Germany
- <sup>5</sup> Bundesamt für Strahlenschutz, BfS, Department of Radiation Protection and Health, Oberschleissheim, Germany
- <sup>6</sup> Stockholm University, Department of Molecular Biosciences, The Wenner-Gren Institute, Sweden
- <sup>7</sup> Public Health England, CRCE, Chilton, Didcot, Oxon, UK

**Introduction:** With the risk of accidents or malevolent use of ionising radiation, a number of methods have been developed to retrospectively reconstruct involuntary individual radiation exposures. Physical retrospective dosimetry is mainly done by EPR or luminescence (TL/OSL) methods and biological dosimetry methods include analysis of aberrations and damage of chromosomes and DNA. To ensure the quality and dependability of these methods and to study their compatibility, inter-laboratory comparisons (ILCs) are an important tool. The aim of this ILC was to estimate whole body, partial body, and organ doses to exposed anthropomorphic phantoms using the blood samples and physical materials placed on the phantoms.

**Methods:** Within the EURADOS network, Working Group 10 and RENEB Working Group 2 organised an ILC with the intention to simulate a small-scale incident involving ionising radiation. A 1.3 TBq <sup>192</sup>Ir source was used in an outdoor open-air geometry, to expose 4 phantoms in different geometrical configurations to absorbed doses up to several gray. Positioned on the phantoms were materials intended for accident dosimetry (e.g mobile phones, blood), and for reference dosimetry (LiF, NaCl, Glass rods).

**Results:** Absorbed doses from different materials were estimated at participating laboratories and will be put together for further analysis. The results were compared to Monte Carlo simulations and reference dosimeters.

**Conclusion:** Because of their value, many more ILCs will follow and the recent exercise provided useful experience in terms of planning and execution of future ILCs, with respect to radiation protection, time management, and reference dosimetry to be considered to obtain relevant data for analysis.

### **Selected references**

Ainsbury EA, Bakhanova E, Barquinero JF, et al (2011) Review of retrospective dosimetry techniques for external ionising radiation exposures. Radiat Prot Dosimetry 147:573–592. https://doi.org/10.1093/rpd/ncq499

Bassinet C, Woda C, Bortolin E, et al (2014) Retrospective radiation dosimetry using OSL of electronic components: Results of an inter-laboratory comparison. Radiat Meas 71:475–479. https://doi.org/10.1016/j.radmeas.2014.03.016

# O53 - About the Absence of Reactive Oxygen Species Overproduction in the Presence of Gold Nanoparticles

### Viacheslav Shcherbakov<sup>1</sup>

**Introduction:** Gold nanoparticles (AuNPs) attract attention as a promising radiosensitizing agent for cancer treatment. Many *in vivo* and *in vitro* studies show that AuNPs increase the damage caused by ionizing radiation. However, the mechanism remains unknown. Now it is clear, that initially proposed a concept of high-Z materials, consisting of higher absorbed dose due to their larger cross-sections to ionizing radiation, cannot explain observed biological responses. Therefore, the last two decades many different biological and chemical explanations were proposed.<sup>1</sup>

Reactive oxygen species (ROS) overproduction in the presence of AuNPs were reported in many studies of both cell and molecular systems.<sup>2</sup> Usually, ROS are measured indirectly by fluorescent dyes.<sup>3</sup> The change in luminescence properties is assumed to be proportional to the concentration of 'OH radical or O<sub>2</sub>'. However, AuNPs catalytic effect on chemical reactions occurring in the transformation of initial dye molecule to final product with another fluorescent property is never considered.


**Methods:** Pulse radiolysis with time-resolved spectroscopy, Gamma radiolysis, HPLC, UV-vis spectroscopy. AuNPs were synthesized by reduction with NaBH<sub>4</sub> and Turkevich method.

**Results:** AuNPs do not cause primary radical overproduction at the concentration used *in vivo* or *in vitro* studies. Instead, drastic change in radical chemistry is observed by affecting the ratio and yields of the products. In addition, even without radiation in the presence of oxygen, the AuNPs can stimulate the degradation of stable molecules such as Vitamin C.

**Conclusion:** The catalytic activity of AuNPs must be taken into account in both ROS detection and explanation of radiosensitization.

- (1) Her, S.; Jaffray, D. A.; Allen, C. Gold Nanoparticles for Applications in Cancer Radiotherapy: Mechanisms and Recent Advancements. *Adv. Drug Deliv. Rev.* **2017**, *109*, 84–101.
- (2) Howard, D.; Sebastian, S.; Le, Q. V. C.; Thierry, B.; Kempson, I. Chemical Mechanisms of Nanoparticle Radiosensitization and Radioprotection: A Review of Structure-Function Relationships Influencing Reactive Oxygen Species. *Int. J. Mol. Sci.* **2020**, *21*.
- (3) Gomes, A.; Fernandes, E.; Lima, J. L. F. C. Fluorescence Probes Used for Detection of Reactive Oxygen Species. *J. Biochem. Biophys. Methods* **2005**, *65*, 45–80.

<sup>&</sup>lt;sup>1</sup> Institute de Chimie Physique (ICP), CNRS/Université Paris-Saclay, 91405 Orsay, France



# O54 - Azide and hydroxyl radicals induce several di-tyrosine bridge isomers from the amino acid to the protein scale

#### Anouchka GATIN<sup>1</sup>

Isabelle BILLAULT<sup>1</sup>, Patricia DUCHAMBON<sup>2</sup>, Guillaume VAN DER REST<sup>1</sup>, Cécile SICARD-ROSELLI<sup>1</sup>

- <sup>1</sup> Université Paris-Saclay, CNRS, Institut de Chimie Physique UMR 8000, 91405 Orsay Cedex, France
- <sup>2</sup> CNRS UMR9187, INSERM U1196, Institut Curie, Université Paris Saclay, 91405 Orsay Cedex, France


**Introduction:** In neurodegenerative diseases, di-tyrosine bridge formation has been evidenced and is used as a biomarker<sup>1,2</sup> of oxidative pathologies. Herein, we bring into light new observations about the dimerization process.

**Methods:** Hydroxyl and azide radicals were produced by gamma radiolysis, then the induced biological oxidative damages were analysed by a specifically optimized chromatographic separation coupled to mass spectrometry, electrophoresis gels and fluorometry.

**Results:** We chose to focus our study on human centrin 2 which was shown to dimerize *via* its unique tyrosyl residue. With hydroxyl radicals, centrin dimerization appeared highly significant among other oxidative damages. Surprisingly, we highlighted that for human centrin 2 and a five amino acid peptide, up to five different dimers were highlighted. Though for free tyrosine, oxidation only leads to three different dimers. New dimers' structures were characterized coupling complementary approaches: isotopic labelling, mass spectrometry fragmentation and ionic mobility spectrometry.

**Conclusion:** Their evidence raises some questions: what is their respective role *in vivo* and hence their relative toxicity? Why do more complex and so more sterically hindered systems generate a higher number of di-tyrosine bridge isomers?

- [1] Grune, T., Oxidized protein aggregates: Formation and biological effects. *Free Radic Biol Med* **2020,** *150*, 120-124.
- [2] Davies, M. J.; Fu, S.; Wang, H.; Dean, R. T., Stable markers of oxidant damage to proteins and their application in the study of human disease. *Free Radical Biology and Medicine* **1999**, *27* (11), 1151-1163.



## O55 - Presolvated electron attachement towards nucleotides in liquids: pulsed radiolysis studies

## Sergey DENISOV<sup>1</sup>

Jun MA<sup>2</sup>, Amitava ADHIKARY<sup>3</sup>, Mehran MOSTAFAVI<sup>1</sup>

**Introduction:** In the works of Leon Sanche it was shown that DNA radicals anions formed on electron attachment with certain kinetic energies in the gas phase lead to the formation of resonant DNA structures and rupture of the helix. Thus, such dissociative electron attachment (DEA) could be an unaccounted mechanism of DNA damage under ionizing radiation in cells. The DEA studies were limited to the gas and solid-state phases. After 10 years it is still under debate if it occurs in the liquid phase.

**Methods:** Herein we investigated non-equilibrium  $e_{pre}^-$  scavenging by nucleobases/sides/tides in water and such viscous solvent as diethylene glycol, allowing to slow down electron solvation using 5 ps electron (7 MeV) pulse radiolysis coupled with broadband transient absorption spectroscopy. **Results:** The  $e_{pre}^-$  is more reactive with pyrimidine than purine bases/nucleotides with a reactivity order T > C > A > G. The signal due to the formation of the resulting anion radical directly correlates with the loss of the initial  $e_{hyd}^-$  signal.[2] In the case of uridine monophosphate (UMP), the hole formed by either direct-ionization or via reaction of UMP with the radiation-mediated water cation radical ( $H_2O^{*+}$ ) facilely localize on the ribose site, despite the fact that a part of them was initially created either on the phosphate or uracil.[3]


**Conclusion:** Our results indicate that DEA for nucleotides in water is not active (within 5% experimental error), while in more viscous solvent DEG case pieces of evidence are present for C-N bond cleavage between nucleobase and sugar moities.[4]

- 1. B. Boudaïffa, P. Cloutier et al. Resonant formation of DNA strand breaks by low-energy (3–20 eV) electrons. *Science*, *2000*, **287**, 1658-1660
- 2. J. Ma, S. Denisov et al. Reactivity of prehydrated electrons toward nucleobases and nucleotides in aqueous solution *Science Adv.*, 2017, **3**, e1701669
- 3. J. Ma, S.Denisov et al. Ultrafast Electron Attachment and Hole Transfer Following Ionizing Radiation of Aqueous Uridine Monophosphate *J. Phys. Chem. Lett.*, 2018, **9**, 5105–5109
- 4. J.Ma, A. Kumar et al. Observation of dissociative quasi-free electron attachment to a nucleoside via excited anion radical in solution *Nat. Commun.*, 2019, **10**, 102

<sup>&</sup>lt;sup>1</sup> Institute de Chimie Physique, UMR8000 CNRS/Université Paris-Saclay, Bâtiment 349, 91405 Orsay, France

<sup>&</sup>lt;sup>2</sup> Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China

<sup>&</sup>lt;sup>3</sup> Department of Chemistry, Oakland University, 146 Library Drive, Rochester, MI, 48309, USA



# O56 - UrMAX - the light from Lund. Preservation of epoch-making scientific equipment illustrated by the evolution from UrMAX to MAX IV.

Bengt Forkman<sup>1, 2</sup>


Bertil R Persson<sup>1, 3</sup>, Lotta Elmros<sup>4</sup>, **Sverker Werin**<sup>1, 5</sup>


- <sup>1</sup> Lund University, Lund Sweden
- <sup>2</sup> Nuclear Physics
- <sup>3</sup> Medical Radiation Physica
- <sup>4</sup> Exhibition producer, Sweden
- <sup>5</sup> MAX IV, Lund

Introduction: This digital exhibition is a collaboration between Malmö Museum, the Conservation Group at Lund University\*), and the Lund University of Technology, with funding from the Thora Olsson Foundation. The exhibition depicts the development of UrMAX, a small but 1.3-ton heavy electron accelerator that has become a historic goldmine, as well as the development that followed. Methods: With UrMAX as a basis, researchers have paved the way for MAX IV, Sweden's largest research infrastructure, and the world's brightest synchrotron system, through groundbreaking experiments and theories. The exhibition also illuminates the UrMAX accelerator as an example of the value of preserving experimental equipment.

**Results:** There is a great interest in educationally described experiments and their importance for modern theories and modern technology. Luckily, the first electron accelerator in Lund was donated to Malmö Museum, when it was discarded in the 1960s, instead of ending up as rubbish. One could not then believe that it was the seed of a series of accelerators that led to the explosive development of the synchrotron light research in Lund and the MAX IV plant at Brunnshög. With this example, the exhibition also shows the importance of preserving objects to increase the possibility of future research and education to have a broader context and a historical scientific connection.

**Conclusion:** Through this virtual exhibition, you are able to see UrMAX, texts, and sample images. Click on each image and text to read more about the development of UrMAX from 1960 until today with MAX IV, as a chronological story.





# P1 - Development of a low-energy proton beamline for studies on the biological effectiveness of Proton-Boron Capture Therapy

### Valerio Ricciardi<sup>1, 2</sup>

Giuseppe Porzio<sup>1, 2</sup>, Raffaele Buompane<sup>1, 2</sup>, Lucio Gialanella<sup>1, 2</sup>, Lorenzo Manti<sup>2, 3</sup>

- <sup>1</sup> Dipartimento di Matematica e Fisica, Università degli Studi della Campania Luigi Vanvitelli, 81100, Caserta (CE), Italy
- <sup>2</sup> Istituto Nazionale di Fisica Nucleare Sezione di Napoli, 80126, Naples (NA), Italy
- <sup>3</sup> Dipartimento di Fisica E. Pancini, Università degli Studi di Napoli Federico II, 80126, Naples (NA), Italy

**Introduction:** Charged particle inverted dose-depth profile represents the physical pillar of protontherapy [1]. In the NEPTUNE project [2], new approaches to improve protontherapy effectiveness using nuclear reactions able to generate short-range high-LET alpha particles, are investigated. Significant enhancement of proton biological effectiveness has been demonstrated by exploiting the  $p^{+11}B\rightarrow 3\alpha$  (pB) reaction [3], an approach termed Proton-Boron Capture Therapy (PBCT). The maximum of the cross section for the pB reaction occurs for proton energy of about 700 keV. The present work describes the implementation of an irradiation facility at the 3MV tandem accelerator of the CIRCE laboratory (Univ. Vanvitelli, Caserta), for the study of the pB radiobiological effects near cross section maximum.

**Methods:** The system mainly consists of a scattering chamber in whose centre it is possible to mount a target-holder, provided with beam collimators and a beam scatterer Au foil; proton irradiation occurs through Rutherford scattering. Live beam dosimetry is performed measuring protons energy by Silicon Surface-Barrier detectors placed at different angles [4]. Particle fluence and beam uniformity are measured and monitored by means of CR-39 detectors.

**Results:** The tests of the facility performance are discussed. With the scattering system, proton count rates corresponding to possible dose rates selectable in a range from 0.5-2 Gy/min were consistently obtained. Uniformity in energy and fluence was achieved with uncertainties of 2 and 5%, respectively.

**Conclusion:** The scattering chamber assembly and tests were completed. Proton beams with characteristics suitable for cellular irradiation at energies required by PBCT studies were obtained: first radiobiological experiments are in progress.

- [1] Newhauser, W. D. & Zhang, R. The physics of proton therapy. *Physics in Medicine & Biology*; **2015**; 60.8: R155. doi: 10.1088/0031-9155/60/8/r155
- [2] INFN (Istituto Nazionale di Fisica Nucleare) **2019**. NEPTUNE Call. Available online: https://agenda.infn.it/event/16042/contributions/32412/attachments/22891/26030/NEPTUNE\_FB.pd f
- [3] Cirrone G.A.P. et al. First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness. *Sci. Rep;* **2010**. 8(1):1141. doi: 10.1038/s41598-018-19258-5 [4] Belli M. et al. Proton irradiation facility for radiobiological studies at a 7 MV Van de Graaff accelerator. *Nuclear Instruments and Methods in Physics Research;* **1987**, A256 576-580. doi: 10.1016/0168-9002(87)90304-4

# P2 - Establishing a method for commissioning and validation of the micro-RayStation beam model of a 220 kV XenX small animal irradiator

#### Elise Konradsson<sup>1</sup>

Kristoffer Petersson<sup>2, 3</sup>, Crister Ceberg<sup>1</sup>

- <sup>1</sup> Medical Radiation Physics, Department of Clinical Sciences, Lund University, Lund, Sweden
- <sup>2</sup> Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK
- <sup>3</sup> Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden

**Introduction:** To ensure high quality in the translation from pre-clinical radiotherapy research into clinical radiotherapy, a treatment planning system adapted for pre-clinical studies is of great value. The aim of this work was to establish a method for commissioning and validation of a beam model of the small animal irradiator XenX created in micro-RayStation, a new pre-clinical treatment planning system.

**Methods:** A method for commissioning and validation of the micro-RayStation beam model of a XenX 220 kV irradiator was established. The validation method is based on dose measurements in a 3D printed mouse phantom.

**Results:** Commissioning of the beam model involves import of profiles and depth dose curves for six collimator sizes  $(3x3 \text{ mm}^2, 5x5 \text{ mm}^2, 10x10 \text{ mm}^2, 9x3 \text{ mm}^2, \emptyset=5 \text{ mm}^2 \text{ and } \emptyset=10 \text{ mm}^2)$  and a variable collimator, measured with EBT3 film at a source-to-surface distance of 33 cm in a solid water phantom. The beam model is manually tuned to achieve good agreement with the measurements. Reference dosimetry is performed using an ionization chamber at 2 cm depth in solid water. Validation of the beam model is done by comparing measured and calculated beam profiles and depth dose curves, as well as with different treatment plans delivered to a 3D printed mouse phantom based on a segmented CT image of a mouse.

**Conclusion:** We have established a method for commissioning and validating a new treatment planning system for pre-clinical radiotherapy using measurements in a solid water phantom as well as in a 3D-printed mouse phantom created using a CT image.

# P3 - Evaluating the impact of gamma sterilization on calcium phosphates composites with different TiO2 nanomaterials

Ina Erceg<sup>1</sup>

Suzana Šegota<sup>1</sup>, **Nadica Maltar-Strmečki**<sup>1</sup>, Maja Dutour Sikirić<sup>1</sup>


**Introduction:** Calcium phosphates (CaPs) composites with different TiO<sub>2</sub> nanomaterials (TiNMs) have recently attracted attention as promising implant materials for hard tissue regeneration. In this study, influence of TiO<sub>2</sub> nanoparticles (TiNPs) and titanate nanotubes (TiNTs) on CaPs spontaneous precipitation was investigated by AFM, SEM, FTIR, XRD and EPR.

**Methods:** EPR analyses were performed to monitor the possible difference in local structure after the formation of CaP in the presence of TiNPs and TiNTs. All results were compared with the control system. Before irradiation, no EPR signal was detected for any samples supporting the quality of synthesis. To monitor changes in the microenvironment, the radiation-induced centers were used. The samples were irradiated at 25 kGy, in order to simultaneously validate the suitability of the gold standard for gamma sterilization.

**Results:** In the presence of both TiNMs, at different concentrations, after one hour of reaction time CaDHA was the only formed crystalline phase. Experimental spectra of CaP formed in the presence of TiNPs and TiNTs and theoretical results show the same features and simulation parameters as control, indicating contributions of same type of paramagnetic center.

**Conclusion:** Therefore, it can be can concluded that the addition of the TiNPs and TiNTs does not induce changes in local structure of CaDHA. These findings are of importance for biomimetic preparation of CaP/TiNMs composites since they indicate that CaDHA composites with desired properties, could be prepared on different TiNMs without the need for a change of the experimental conditions.

The study was supported by Croatian Science Foundation, Grant HRZZ-IP-2018-01-1493.



<sup>&</sup>lt;sup>1</sup> Ruđer Bošković Institute, Bijenička c. 54, 10000 Zagreb, Croatia

# P4 - Machine learning for automated assessment of in vitro T-47D colonies using principal component based watershed segmentation

#### Delmon Arous<sup>1</sup>

Stefan Schrunner<sup>1</sup>, Ingunn Hanson<sup>2</sup>, Nina J. Edin<sup>2</sup>, Eirik Malinen<sup>2</sup>

**Introduction:** For in vitro cell culture assays, manual identification of viable colonies is time-consuming with potentially large inter-observer variations. However, by optical imaging, dishes with stained colonies can be assessed digitally. Image processing of such pictured/scanned assays depends upon several factors like background noise, clustering of cells/colonies, variable staining and cell line specific characteristics.

**Methods:** A robust machine learning procedure is presented that circumvents these issues by characterizing, extracting and segmenting inquired colonies through implementation of three pillar techniques: principal component analysis, k-means clustering and a modified watershed segmentation algorithm, respectively. For this purpose, an imageset consisting of 16 cell culture flasks used for clonogenic assay of the T-47D (breast) cancer cell line was deployed. To validate the segmentation quality, automated colony count (ACC) delivered by the algorithm was compared to manual colony count (MCC) facilitated by 3 independent human observers. Additionally, an extra independent observer established a ground truth - manual counting during a microscopic analysis of the culture dishes.

**Results:** There was a high correspondence between the automated and manual count as the ACC obtained slightly lower F1 scores relative to the MCC, but the absolute ranges for both procedures were on a very high level (F1 score > 0.9) which underlines the ability of the algorithm to align with manual observers. Also, the algorithm produced a low relative error (< 10%) with a small tendency to underestimate the ground truth.

**Conclusion:** By agreement with ground truth data, the proposed method accurately maps cell colonies and produces a precise quantitative estimate of number and localization.




Fig. 1: Example image from the T-47D cell line. The segmentation suggested by our algorithm is outlined in red.

<sup>&</sup>lt;sup>1</sup> Department of medical physics, Oslo University Hospital, Oslo, Norway

<sup>&</sup>lt;sup>2</sup> Department of physics, University of Oslo, Oslo, Norway

# P5 - Modeling of the radiation situation in the rooms at BNCT research post using the MCNP code.

## Martyna Araszkiewicz<sup>1, 2</sup>

Agnieszka Korgul<sup>1</sup>, Kamila Maliszewska-Olejniczak<sup>2</sup>, Katarzyna Tymińska<sup>2</sup>, Grzegorz Wojtania<sup>2</sup>

particle flux and the dose of ionizing radiation were calculated.

**Introduction:** Boron Neutron Capture Therapy (BNCT) consists of administering to the patient boron agents with a stable isotope  $^{10}$ B that selectively accumulate in cancerous tissues. Then the tumor is irradiated with a beam of neutrons with epithermal or thermal energy. The capture of thermal neutrons by the  $^{10}$ B nuclei results in the production of the high-energy  $\alpha$  particle and  $^{7}$ Li nucleus. The range of these particles is comparable with the size of a single cell. Thanks to this, only cancer cells are destroyed. In the National Centre for Nuclear Research in Świerk a research post for BNCT is created. The source of neutrons is the MARIA research reactor.

**Methods:** Before starting the research, it is necessary to assess the radiation situation in the rooms in the planned laboratory and to design radiation shielding to ensure safe working conditions. For this purpose, a three-dimensional model of rooms was created in the MCNP (Monte Carlo N-Particle Transport Code System) program which is used to analyze the transport of neutrons and photons. **Results:** The calculations allows to determine the spatial distribution of neutron and photon flux in all research rooms. Additionally, thirteen cubic cells with an edge of 20 centimeters were defined in the most important spots in the laboratory. The cells played the role of ideal detectors in which the

**Conclusion:** The calculated values will be compared with the results of planned measurements.

<sup>&</sup>lt;sup>1</sup> University of Warsaw, Faculty of Physics, Warsaw, Poland

<sup>&</sup>lt;sup>2</sup> National Centre for Nuclear Research, Świerk, Poland

### P6 - Up to speed – Real-time dosimetry for FLASH radiotherapy

### Alessia Gasparini<sup>1</sup>

Piet Stevens<sup>1</sup>, Giuseppe Felici<sup>2</sup>, Emiliano D'Agostino<sup>3</sup>, Dirk Verellen<sup>1</sup>

- <sup>1</sup> GasthuisZusters Antwerpen/Iridium network, Antwerp, Belgium
- <sup>2</sup> Sordina IORT Technologies, R&D Department, Aprilia, Italy
- <sup>3</sup> DoseVue, Diepenbeek, Belgium

**Introduction:** FLASH Radiation Therapy (RT) is a recently introduced modality that could potentially modify radiation treatments. It uses ultra-high dose over very short time (above 40 Gy/s). Unexpectedly, FLASH RT increases the therapeutic window between tumour and healthy tissue, allowing the use of higher radiation doses to the tumour with the same normal tissue response. Dosimetry for high dose-rates is not standard and highly challenging. Studies using an adapted LINAC for dose-rates up to 1050 Gy/s, compared alanine, Gafchromic films and thermoluminescent dosimeters<sup>1</sup>. The detection methods agreed within 3%, showing no dose-rate dependency. The most commonly used real-time detectors (ion chamber and semiconductors) fail to accurately measure dose at high dose-rates, due to saturation issues.

**Methods:** Scintillator detectors are possibly independent from saturation issues and have the potential to be used as real-time detectors for high dose-rate systems, calibrated against films or alanine. We tested the system DoseWire, a multi-channel scintillating optical fiber system from DoseVue. Current measurements have been performed on a LINAC dedicated for Intra-Operative electron RT (LIAC HWL, SIT), which employs high dose per pulse with low pulse frequency (PRF), corrisponding to dose-rates higher than 15 Gy/s at PRF of 400 Hz.

**Results:** DoseWire showed an agreement with the advanced Markus chamber up to 4.5 cGy/pulse at 12 MeV, with an accuracy of 5%.

**Conclusion:** Scintillation dosimeters, and specifically DoseWire, are promising candidates for real-time dosimetry with high dose per pulse. In the next step, the DoseWire system will be tested on the ELECTRONFLASH4000, the dedicated Flash electron unit SIT developed.

#### **Selected references**

1 Jorge, P. G. et al. Radiotherapy and Oncology, 2019

## P7 - A lineage tracing tool to map the fate of hypoxic tumour cells

#### Jonathan Ient<sup>1</sup>

Jenny Vermeer<sup>2</sup>, Bostjan Markelc<sup>2, 3</sup>, Jakob Kaeppler<sup>2</sup>, Lydie Barbeau<sup>1</sup>, Arjan Groot<sup>1</sup>, Ruth Muschel<sup>2</sup>, Marc Vooijs<sup>1</sup>

**Introduction:** Hypoxia is known to play a role in many types of cancer, and is linked to metastasis, genetic instability, resistance to therapy and poor prognosis. Hypoxic modification has been tested in clinical trials but results have been inconclusive. This is in part due to a knowledge gap into the characterization and behaviour of hypoxic tumour cells. In this study, hypoxic cells are lineage traced and they are analysed both *in vivo* by intravital imaging as well as by IHC to investigate their behaviour.

**Methods:** To explore this issue in a spatial and temporally-controlled manner we developed a genetically encoded sensor by fusing the  $O_2$ -labile Hypoxia-Inducible Factor  $1\alpha$  to eGFP and tamoxifen-regulated Cre recombinase. Under normoxic conditions HIF- $1\alpha$  is degraded but under hypoxia, the HIF- $1\alpha$ -GFP-Cre-ER<sup>T2</sup> fusion protein is stabilised and in the presence of tamoxifen activates a tdTomato reporter gene that is constitutively expressed in hypoxic progeny.

**Results:** We visualise the random distribution of hypoxic tumour cells from hypoxic or necrotic regions and vascularised areas using immunofluorescence and intravital microscopy. Using this system, we could show that the post-hypoxic cells were more proliferative *in vivo* than non-labelled cells.

**Conclusion:** Our results demonstrate that single-cell lineage tracing of hypoxic tumour cells can allow visualisation of their behaviour in living tumours using intravital microscopy. Furthermore we are developing a model that allows selective ablation of labelled hypoxic cells; to investigate their role in treatment resistance further. These tools should prove valuable to study dissemination and treatment response of post-hypoxic tumour cells *in vivo* at single-cell resolution.

<sup>&</sup>lt;sup>1</sup> Department of Department of Radiation Oncology (MAASTRO)/GROW - School for Oncology, Maastricht University Medical Center + , Maastricht, The Netherlands

<sup>&</sup>lt;sup>2</sup> CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford

<sup>&</sup>lt;sup>3</sup> Department of Experimental Oncology, Institute of Oncology Ljubljana, Slovenia

# P8 - A novel EdU-based protocol for the investigation of cell cycle kinetics of irradiated human lymphocytes

## Evi Duthoo<sup>1, 2</sup>

Anne Vral<sup>1, 2</sup>, Ans Baeyens<sup>1, 2</sup>

**Introduction:** In radiation biology, gaining insights into the effects of irradiation on the proliferation and kinetics of cells is imperative. A powerful tool to accurately quantify cell cycle kinetics is the use of nucleoside analogues, such as 5-ethynyl-2'-deoxyuridine (EdU). EdU is a thymidine analogue that can be incorporated into DNA during replication. Via bivariate analysis of cellular DNA content and EdU incorporation, a distinction between cell cycle phases can be made. By performing a time-lapse analysis of EdU pulse-labeled cells, kinetics of the cell cycle can be investigated. Lymphocytes are widely used in radiation research. However, knowledge of the effects of radiation on their cell cycle kinetics is still limited. In this study, we optimized an EdU-labeling protocol on whole blood cultures to study the cell cycle progression of irradiated human lymphocytes.

**Methods:** Whole blood was cultured and cell division was stimulated by the addition of phytohaemagglutinin (PHA). After 4 days of culture, the cells were pulse-labeled with EdU and irradiated *in vitro* with 1, 2 and 4 Gy of 220 kV X-rays. Time-lapse analysis was performed from 0 up to 25 hours of incubation, with one-hour intervals. After counterstaining with DAPI to measure DNA content, the cells were analyzed by flow cytometry.

**Results:** G2-arrest after irradiation of the lymphocytes could be detected with our EdU-based cell cycle analysis protocol. The length of the G2 arrest depends on the irradiation dose.

**Conclusion:** We propose a novel protocol of EdU-based cell cycle analysis to determine the proliferation kinetics of human lymphocytes in whole blood cultures.

<sup>&</sup>lt;sup>1</sup> Radiobiology group, Department of Human Structure and Repair, Ghent University, Ghent, Belgium

<sup>&</sup>lt;sup>2</sup> Cancer Research Institute Ghent, Ghent, Belgium

# P9 - A Raman spectroscopy-based alternative approach for the analysis of X-ray irradiated SH-SY5Y human neuroblastoma cells

### Valerio Ricciardi<sup>1, 2</sup>

Ines Delfino<sup>3</sup>, Lorenzo Manti<sup>2, 4</sup>, Giuseppe Perna<sup>5, 6</sup>, Maria Lasalvia<sup>5, 6</sup>, Vito Capozzi<sup>5, 6</sup>, Maria Lepore<sup>7</sup>

- <sup>1</sup> Dipartimento di Matematica e Fisica, Università degli Studi della Campania Luigi Vanvitelli, 81100, Caserta (CE), Italy
- <sup>2</sup> Istituto Nazionale di Fisica Nucleare Sezione di Napoli, 80126, Naples (NA), Italy
- <sup>3</sup> Dipartimento di Scienze Ecologiche e Biologiche, Università degli Studi della Tuscia, 01100, Viterbo (VT), Italy
- <sup>4</sup> Dipartimento di Fisica E. Pancini, Università degli Studi di Napoli Federico II, 80126, Napoli (NA), Italy
- <sup>5</sup> Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia,71122, Foggia (FG), Italy
- <sup>6</sup> Istituto Nazionale di Fisica Nucleare Sezione di Bari, 70126 Bari (BA), Italy
- Dipartimento di Medicina Sperimentale, Università degli Studi della Campania Luigi Vanvitelli, 80138 Napoli (NA), Italy

**Introduction:** Raman spectra of cytoplasm and nucleus region of single cells indicate differential changes induced by X-rays as for DNA/RNA, lipid, and protein contributions [1,2]. The present work aims to introduce a new approach to deepen radiobiological investigation on single SH-SY5Y human neuroblastoma cells. To this end, the difference spectra obtained by subtracting each cytoplasm-related Raman spectrum from the corresponding one acquired for the nucleus were examined using multivariate analysis.

**Methods:** Raman micro-spectroscopy was performed on in-vitro single cells after irradiation by graded X-ray doses (2, 4, 6, 8 Gy). Spectra from nucleus and cytoplasm regions were acquired and the difference spectra were examined by interval Principal Component Analysis (i-PCA).

**Results:** The analysis by i-PCA of the nucleus-cytoplasm difference spectra allowed us to shed light on the modifications, due to X-ray irradiation, of Raman features due to components with different relative contents in the two regions or modes with a low intensity that are not appreciable in the simple spectra [3]. In particular, the effects on DNA/RNA backbone and single nucleobases and those occurring on lipids and proteins are discussed.

**Conclusion:** The proposed approach allowed us to highlight newly identified specific characteristics not previously reported.

- [1] S.J. Van Nest, et al., Raman spectroscopic signatures reveal distinct biochemical and temporal changes in irradiated human breast adenocarcinoma xenografts, Radiat. Res. 189 (2018) 497–504.
- [2] I. Delfino, et al., Visible micro-Raman spectroscopy of single human mammary epithelial cells exposed to X-ray radiation, J. Biomed. Opt. 20 (3)(2015), 035003
- [3] A.D. Meade, et al., Prediction of DNA damage and G2 chromosomal radio-sensitivity ex vivo in peripheral blood mononuclear cells with label-free Raman microspectroscopy, Int. J. Radiat. Biol. (2018), http://dx.doi.org/10.1080/09553002.2018.1451006
- [4] Delfino I., Perna G., Ricciardi V., Lasalvia M., Manti L., Capozzi, V., Lepore M. X-ray irradiation effects on nuclear and membrane regions of single SH-SY5Y human neuroblastoma cells investigated by Raman micro-spectroscopy. J. Pharm. Biomed. Anal. 2019, 164, 557–573

# P10 - Bi-modal treatment using radiation therapy and drug delivery nano-systems for enhanced cytotoxicity in radio-resistant tumor models

## Roxana-Cristina Popescu<sup>1, 2, 3</sup>

Mihai Straticiuc<sup>4</sup>, Cosmin Catalin Mustaciosu<sup>1, 2</sup>, Roxana Trusca<sup>2</sup>, Hiltraud Hosser<sup>5</sup>, Carsten Herskind<sup>3</sup>, Mihai Radu<sup>1</sup>, Marlon R. Veldwijk<sup>3</sup>, Diana Iulia Savu<sup>1</sup>

- <sup>1</sup> "Horia Hulubei" National Institute for Research and Development in Physics and Nuclear Engineering, Department of Life and Environmental Physics
- <sup>2</sup> University Politehnica of Bucharest, Department of Science and Engineering of Oxide Materials and Nanomaterials
- <sup>3</sup> University of Heidelberg, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Department of Radiation Oncology
- <sup>4</sup> "Horia Hulubei" National Institute for Research and Development in Physics and Nuclear Engineering, Department of Applied Nuclear Physics
- <sup>5</sup> University of Heidelberg, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Center for Biomedicine and Medical Technology, Department of Anatomy and Developmental Biology

**Introduction:** This study aims to investigate whether ionizing radiation combined with doxorubiciniron oxide nano-systems (DOX-NP) improves the cytotoxic effects of the nano-carrier-mediated drug delivery in radio-resistant tumor models (MG-63, human osteosarcoma and respectively HeLa, human cervical adenocarcinoma).

**Methods:** For this, two approaches have been investigated: the application of nanoparticles (NP) before irradiation and respectively after.

**Results:** The nanoparticle internalization was evaluated qualitatively through fluorescence and electron microscopy emphasizing efficient loading through macro-pinocytosis and localization in the peri-nuclear area. Quantitative measurements were performed using Particle Induced X-Ray Emission showing that previous exposure to ionizing radiation significantly improved the internalization of the nanoparticles. Cells that underwent irradiation and NP treatment proved a statistically significant reduction in their clonogenic survival. 100 μg/mL DOX- free NP enhanced the radio-sensitivity of 50 kV X-Rays with a DMF<sub>SF0.1</sub>= 1.13±0.06, but no additional effect to 6 MV X-Rays, while DOX-NP resulted in a DMF<sub>SF0.1</sub>=1.3±0.1 at 6 MV X-Ray. Genotoxicity evaluation showed that DNA breaks increased with NP concentration and irradiation at 48h in the case of radiation treatment followed by NP exposure. Initial NP incubation followed by radiation showed that the enhanced radio-modulatory effect of the NP was not linked to the induction of DNA double strand breaks in tumor cells.

**Conclusion:** These results conclude that DOX-NP are good candidates for the controlled delivery of DOX to enhance the cytotoxic effects of ionizing radiation.

### P11 - Causes and Consequences of telomere instability

Cecile Herate<sup>1</sup>

### Laure Sabatier<sup>1</sup>

<sup>1</sup> PROCyTox, French Alternative Energies and Atomic Energy Commission (CEA), Paris-Saclay University, Fontenay-aux-Roses, France.

**Introduction:** Telomeres control chromosomal integrity and stability by forming a protective structure that avoids the signaling of DNA damage. By shortening with each cell division, they act as a lifeguard, driving aged and damaged cells towards death. Telomeres are composed of DNA repeat sequences at the ends of chromosomes that recruit a multitude of proteins to form a complex loop structure at each extremity. The integrity of this structure is critical and correct conformation of the loop is essential for the protection of chromosome ends from DDR signaling. Many external factors, such as irradiation, cellular stress, trigger cell-cycle dysfunction and, in some cases, enable the survival of cells with threateningly short telomeres.

**Methods:** The genome instability generated by telomere dysfunction mostly promotes cell death. Destabilized loops at chromosome ends can then lead to dramatic consequences, by a butterfly effect such as multiple chromosomal fusions and rearrangements causing large chromosomal deletions, XXL-LOH, the expression of recessive mutations, and potential cell transformation.

**Results:** Carcinogenesis due to multiple Telo-LOH is still an exceptional event, with dramatic consequences although telomere insults are frequent. A recent study from our lab showed telomeres to be hypersensitive to DNA damage, which is over-signaled as DSBs by  $\gamma$ -H2AX foci, even after DNA repair [Ricoul et al, 2019]. Moreover, subtelomeric regions also show elevated sensitivity to DNA DSBs.

**Conclusion:** These observations support the hypothesis that IR causes irreversible damage and stress, specifically at the telomere regions, that can still be detected long after IR.

### **Selected references**

Ricoul M, Gnana Sekaran TS, Brochard P, Herate C, **Sabatier L**. γ-H2AX Foci Persistence at Chromosome Break Suggests Slow and Faithful Repair Phases Restoring Chromosome Integrity. *Cancers (Basel). 2019* Sep 19;11(9).

# P12 - Cell-cycle perturbation, atypical mitosis and micronuclei in Caco-2 cells as indicator of radiation-induced genomic instability

## Isabella Guardamagna<sup>1</sup>

Leonardo Lonati<sup>1</sup>, Andrea Ottolenghi<sup>1</sup>, Monica Savio<sup>2</sup>, Lucia Anna Stivala<sup>2</sup>, Giorgio Baiocco<sup>1</sup>
<sup>1</sup> Radiation Biophysics and Radiobiology Group (RadBioPhys), Physics Department, University of Pavia, Pavia, Italy

**Introduction:** We have started an extensive experimental characterization of the response to X-rays of Caco-2: this cell line is derived from human colorectal adenocarcinoma, usually adopted as intestinal barrier model and recently characterized as radioresistant (1, 2). Colorectal cancer is the fourth most common cancer worldwide, commonly treated with radiotherapy and chemotherapy before surgery or as adjuvant therapy following surgery.


**Methods:** Studied endpoints include: cell survival, cell cycle distribution, necrosis and apoptosis, micronuclei and atypical mitosis. Combined techniques of flow-cytometry and immunofluorescence microscopy were used.

**Results:** The clonogenic assay confirmed a radioresistant behaviour of Caco-2 up to 5 Gy. Cells exposed to 10 Gy showed an initial ability to proliferate, creating small colonies that can be observed only for a period of about a week. Flow-cytometry analysis showed dose- and time-dependent modulation of cell-cycle distribution and activation of death mechanisms. Cells showed an increase in atypical mitosis (**Figure**) with increasing dose, at 48 hours after irradiation. Micronuclei formation was found to increase up to 5 Gy, while at 10 Gy we were not able to distinguish micronuclei from early necrosis events (coherently with results from the clonogenic assay and flow-cytometry measurements).

Conclusion: The integration of results from different endpoints allows to achieve a more detailed picture of radiation effects to Caco-2 cells, both in terms of survival and consequences leading to genomic instability as suggested by induction of atypical mitosis and micronuclei (3). Knowledge acquired in this experimental campaign can be exploited in perspective to address the effectiveness of different therapeutic strategies.

- (1) Morini J, Babini G, Barbieri S, Baiocco G, Ottolenghi A. The Interplay between Radioresistant Caco-2 Cells and the Immune System Increases Epithelial Layer Permeability and Alters Signaling Protein Spectrum. *Front Immunol*. 2017;8:223.
- (2) Borsci G, Barbieri S, Guardamagna I, Lonati L, Ottolenghi A, Ivaldi G B, Liotta M, Tabarelli de Fatis P, Baiocco G, Savio M. Immunophenotyping Reveals No Significant Perturbation to PBMC Subsets When Co-cultured With Colorectal Adenocarcinoma Caco-2 Cells Exposed to X-Rays. Front Immunol. 2020;11:1077.
- (3) Yoko Matsuda, Junko Aida, Naoshi Ishikawa, Kaiyo Takubo, Toshiyuki Ishiwata and Tomio Arai. Morphological Markers of Chromosomal Instability. Chromosomal Abnormalities A Hallmark Manifestation of Genomic Instability (Chapter 2).

<sup>&</sup>lt;sup>2</sup> Immunology and General Pathology Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy



Representative images of atypical mitotic figures of Caco-2 cells. DNA is marked with Hoechst dye (blue fluorescence) and phospho-H3 (Ser 10) is a marker of mitosis (red fluorescence). Scale bar 10  $\mu$ m.

# P13 - Cytotoxicity study of peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours

### Lorain Geenen<sup>1, 2</sup>

Sarah Baatout<sup>1,3</sup>, Julie Nonnekens<sup>4</sup>, Marion De Jong<sup>2</sup>, An Aerts<sup>1</sup>

- <sup>1</sup> Radiobiology Unit, Interdisciplinary Biosciences (BIO), Institute for Environment, Health and Safety, SCK CEN | Belgian Nuclear Research Centre, Mol, Belgium
- <sup>2</sup> Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- <sup>3</sup> Department of Molecular Biotechnology, Ghent University, Ghent, Belgium
- <sup>4</sup> Department of Molecular Genetics, Department of Radiology and Nuclear Medicine, Oncode Institute, Erasmus MC, Rotterdam, The Netherlands

**Introduction:** Radiopharmaceuticals for peptide receptor radionuclide therapy (PRRT) consist of a cancer-seeking molecule labeled with a radionuclide to deliver therapeutic doses of ionizing radiation directly to the cancer sites, both the primary tumour and metastatic lesions. This cancer treatment modality holds promise to be more effective and to reduce the detrimental effects on the healthy tissues compared to external beam radiotherapy. However, much of the radiobiology is not fully investigated for radionuclide therapy and (long term) cytotoxic effects are yet not well understood. Therefore, in this project we aim to obtain a better understanding of the cellular and molecular mechanisms underlying the cytotoxic responses of PRRT. We will focus on the radionuclide [177]Lu]lutetium coupled to the somatostatin analogue DOTA-TATE ([177]Lu]Lu-DOTA-TATE) for the treatment of neuroendocrine tumours, which have overexpression of the somatostatin receptor.

**Methods:** Currently we are conducting in vitro studies in neuroendocrine tumour cell models (AR42J and CA20948) as well as normal human kidney (HK-2), liver (THLE-2) and microvascular endothelial (TIME) cells. The expression of somatostatin receptor type 2 (SSTR2) is being investigated by western blot analysis. Furthermore radiolabeling studies have been performed and the binding capacity of the radiopeptide will be evaluated for the different cell lines, followed by the comparison of the membrane-bound fractions and internalized fractions. In complement we are optimizing different models for the determination of cell viability, clonogenic survival and apoptosis after incubation with [177Lu]Lu-DOTA-TATE.

#### **Results:**

**Conclusion:** This way we hope to contribute to the optimization of PRRT by further reducing side effects while maintaining efficient tumour targeting.

### P14 - Deep learning-based approach for the segmentation of human carcinoma cells

### Bahareh Omidali<sup>1</sup>

Alexey Sofiev<sup>1</sup>, **Tuomas Kaseva**<sup>2</sup>, Eero Hippeläinen<sup>3</sup>, Vappu Reijonen<sup>4</sup>, Ulla Wilppu<sup>2</sup>, Marjo Yliperttula<sup>5</sup>, Sauli Savolainen<sup>1</sup>, Eero Salli<sup>2</sup>

- <sup>1</sup> Department of Physics, University of Helsinki, POB 64, FI-00014 Helsinki, Finland.
- <sup>2</sup> HUS Diagnostic center, Radiology, University of Helsinki and Helsinki University Hospital, POB 340, FI-00290 Helsinki, Finland.
- <sup>3</sup> HUS Diagnostic center, Clinical Physiology and Nuclear Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- <sup>4</sup> Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- <sup>5</sup> Centre for Drug Research, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Finland.

**Introduction:** Assessment of absorbed radiation dose at cellular level is believed to be a crucial part of optimizing molecular radionuclide therapy. In that process three-dimensional cell segmentation is a predominant step. The segmentation can also be utilized in analyzing morphological features of cells and tissues efficiently. Although a variety of different algorithms exists for the automated segmentation of the cells, they are often specialized to certain cell types and may fail in conditions that are more adverse.

**Methods:** In this study, we propose a novel deep learning-based method for three-dimensional cell segmentation. The method is trained and evaluated with 12 human hepatocellular carcinoma HepG2 spheroids, which consist of densely distributed and arbitrary shaped and sized cells. Each spheroid has been manually segmented to obtain ground truth labels. In the method, the neural network is first applied for the segmentation of axial slices of the chosen spheroid, and then these slices are combined to form a final 3D-segmentation

**Results:** The method is validated using SEG-score and compared with multiple different well-established cell segmentation algorithms. In the experiments, we split our dataset to 11 training spheroids and to one evaluation spheroid. In this preliminary setting, our method outperforms the reference algorithms and reaches 0.55 SEG-score

**Conclusion:** We developed and validated a promising deep-learning based method for advanced 3D cell segmentation


### **Selected references**

Chen, Hao, et al. "DCAN: Deep contour-aware networks for object instance segmentation from histology images." *Medical image analysis* 36 (2017): 135-146.

Reijonen, Vappu, et al. "Multicellular dosimetric chain for molecular radiotherapy exemplified with dose simulations on 3D cell spheroids." *Physica Medica* 40 (2017): 72-78.

Blin, Guillaume, et al. "Nessys: A new set of tools for the automated detection of nuclei within intact tissues and dense 3D cultures." *PLoS biology* 17.8 (2019): e3000388.

Lou, Xinghua, et al. "A rapid and efficient 2D/3D nuclear segmentation method for analysis of early mouse embryo and stem cell image data." *Stem cell reports* 2.3 (2014): 382-397



# P15 - Ephrin receptors take part in cellular DNA damage response after ionizing radiation and regulate cell viability of non-small lung cancer cells.

### Vitaliy Kaminskyy<sup>1</sup>

Petra Hååg<sup>1</sup>, Metka Novak<sup>1</sup>, Vasiliki Arapi<sup>1</sup>, Rolf Lewensohn<sup>1, 2</sup>, Kristina Viktorsson<sup>1</sup>

**Introduction:** Receptor tyrosine kinases (RTK) regulate various pro-survival pathways in tumor cells. Besides the conventional role of RTK in transduction of kinase signaling via ligand-receptor interactions, understanding of their other functions may help us to reveal novel targets to overcome therapy resistance. Thus, besides a well-known function of EGFR as a tyrosine kinase, this receptor has been reported to be engaged in DNA damage repair (DDR) upon cellular response to ionizing radiation (IR) via its interaction with DNA-PK<sup>1</sup>. Ephrin family receptors is the largest family of RTK that regulate cell proliferation, migration, invasion and angiogenesis in tumors. Recent reports have demonstrated the involvement of EphA5 receptor in DDR via its accumulation at DNA foci and interaction with ATM<sup>2</sup>.

**Methods:** Immunoprecipitation, cell fractionation, mass spectrometry, gene silencing, immunoblotting

**Results:** We demonstrate that some Ephrin family members correlate to some extent with IR sensitivity of non-small cell lung cancer cells (NSCLC). By gene silencing we show that targeting the EphA2 receptor sensitizes NSCLC to IR and reduces clonogenic potential. Furthermore, we demonstrate that the EphA2 receptor is partially localized in nuclei of NSCLC cells either prior or post IR. Using immunoprecipitation of EphA2 from nuclear extracts and mass spectrometry analysis, we identified components of DDR signaling that suggest EphA2 to be linked to the cellular DDR response.

**Conclusion:** Taking into account our data with responsiveness to IR and previous reports showing upregulation of some Ephrins in various tumor malignancies, understanding their role in DDR can help us to explore significance of targeting these receptors in cancer therapy.

- 1. Dittman paper. Dittman K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, Rodemann HP. Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase. *J Biol Chem.* 2005; 280(35):31182-9.
- 2. Staquicini FI, Qian MD, Salameh A, Dobroff AS, Edwards JK, Cimino DF, Moeller BJ, Kelly P, Nunez MI, Tang X, Liu DD, Lee JJ, Hong WK, Ferrara F, Bradbury AR, Lobb RR, Edelman MJ, Sidman RL, Wistuba II, Arap W, Pasqualini R. Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer. *J Biol Chem.* 2015;290(12):7345-59.
- 3. Ståhl S, **Kaminskyy VO**, Efazat G, Hyrslova Vaculova A, Rodriguez-Nieto S, Moshfegh A, Lewensohn R, Viktorsson K, Zhivotovsky B. Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. *Cell Death Dis.* 2013;4: e454.

<sup>&</sup>lt;sup>1</sup> Karolinska Institutet, Department of Oncology/Pathology, SE-171 76, Stockholm, Sweden.

<sup>&</sup>lt;sup>2</sup> Theme Cancer, Patient area head and neck, lung, and skin, Karolinska University Hospital, Stockholm, Sweden.

## P16 - Experimental database for research on low dose hyper-radiosensitivity and induced radioresistance

### Szabolcs Polgár<sup>1</sup>

Balázs Madas<sup>1</sup>

**Introduction:** One of the most frequently applied models describing low-dose hyper radiosensitivity (HRS) and induced radioresistance (IRR) is the induced repair (IR) model. While the model usually fits graphically well to experimental data, its parameters as well as the numerical values of experimental data are not given in many publications. The aim of this study was to set up a database of experimental data and compare it with the IR model.

**Methods:** From 38 articles, we collected 90 data sets i) showing low dose HRS, ii) containing readable data points, and iii) providing error bars. The publication date varied between 1993 and 2018. Besides the data points with the error bars, radiation parameters, the cell type, and parameters of the fitted IR or LQ model (if given) were also recorded in the database.

**Results:** We found that the IR model parameters were given for 53 datasets from 90. Fitting again the IR model to the collected datasets and comparing the results with the parameters given in the papers, we found a similarly good fit in 39 cases. In 14 cases, however, we could not reproduce the same results.

**Conclusion:** In the future, the database can be used for additional tests of the IR model or other mathematical models aiming to describe low dose HRS.

<sup>&</sup>lt;sup>1</sup> Radiation Biophysics Group, Centre for Energy Research, Budapest, Hungary

### P17 - Gene expression during radiation-induced differentiation of human fibroblasts in vitro

### Carsten Herskind<sup>1</sup>

Carsten Sticht<sup>2</sup>, Ahmad Sami<sup>1</sup>, Frank A. Giordano<sup>1,3</sup>, Frederik Wenz<sup>1,4</sup>

- <sup>1</sup> Dept. of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany
- <sup>2</sup> Centre for Medical Research, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany
- <sup>3</sup> Dept. of Radiation Oncology, University Medical Centre Bonn, Faculty of Medicine, University of Bonn, Germany

**Introduction:** Fibroblasts play a major role in radiation-induced fibrosis. However, most studies on radiation-induced gene expression in fibroblasts have focused on early time points (0-24h). The purpose was to study differential gene expression during radiation-induced fibroblast differentiation *in vitro*.

**Methods:** The fibroblast phenotype of three skin fibroblast strains (GS3-5) was determined in the colony formation assay, and the myofibroblast marker  $\alpha$ -smooth muscle actin was detected by immunofluorescence microscopy. Differential gene expression was analysed on microarrays and validated by real-time qRT-PCR. Pathway analysis was performed using Reactome. 6 MV X-rays were used for irradiation.

**Results:** 163 genes were up- and 253 down-regulated by >4-fold in GS4 at least once on day 2, 3 or 5 after irradiation with 4 Gy. The upregulated extracellular matrix (ECM) gene, *COL11A1*, showed maximum expression on day 5. Several of the down-regulated genes were related to cell division and cell-cycle progression. 216/268 downregulated pathways were common to all three time points with more than a third relating to the cell cycle. 45/106 upregulated pathways were common to all time points with ~60% relating to ECM proteins or glycosaminoglycans. Independent microarray experiments for day 3, showed 243/319 down-regulated and 59/133 up-regulated pathways common to all three strains. Up-regulated pathways were dominated by ECM synthesis and processing, and inflammatory responses. Independent real-time PCR on day 1-6 confirmed upregulation of several collagen genes, *ACTA2*, and signalling genes, and downregulation of a matrix metalloproteinase, *MMP12*.

**Conclusion:** Differential gene expression reflected premature differentiation of fibroblasts and represented aspects of inflammation, wound healing and fibrogenesis.

<sup>&</sup>lt;sup>4</sup> University Medical Centre, Freiburg, Germany

### P18 - Identifying the cellular response to complex DNA damage induced by high-LET protons

### Rachel Carter<sup>1</sup>

Catherine Nickson<sup>1</sup>, Andrzej Kacperek<sup>2</sup>, Mark Hill<sup>3</sup>, **Jason Parsons**<sup>1, 2</sup>

**Introduction:** Proton beam therapy (PBT) is a precise and effective cancer treatment that is increasingly being used worldwide. However, the radiobiology of PBT is not entirely understood due to increases in linear energy transfer (LET) at and around the Bragg peak where the radiation dose is deposited [1]. Here, there are increases in formation of complex DNA damage (CDD), containing multiple DNA lesions within close proximity, that can significantly contribute to cell death. The cellular response to CDD, however, is not entirely understood.

**Methods:** Utilising the 60 MeV cyclotron at the Clatterbridge Cancer Centre, we have analysed clonogenic survival of HeLa and head and neck cancer cells following low-LET (1 keV/ $\mu$ m) protons at beam entrance, versus high-LET (12 keV/ $\mu$ m) protons at the Bragg peak distal end. Data has been correlated with high-LET  $\alpha$ -particles and low-LET x-rays. CDD repair was monitored using an enzyme-modified neutral comet assay. siRNA screening has also been used to identify enzymes crucial for cell survival post-irradiation.

**Results:** We have demonstrated that high-LET protons generate increased amounts of CDD triggering a specific cellular DNA damage response [2]. siRNA screening has identified that USP6 is essential for maintaining cell survival and cell cycle progression following high-LET protons (and α-particles), mediated through stabilisation of PARP-1 required for efficient CDD repair [3]. Further preliminary screening experiments have also exposed other key DNA repair proteins and pathways important for cell survival following high-LET protons.

**Conclusion:** CDD induced by high-LET protons is repaired through a specific DNA damage response mechanism that promotes cell survival.

- 1. Vitti, E.T. and J.L. Parsons, *The Radiobiological Effects of Proton Beam Therapy: Impact on DNA Damage and Repair*. Cancers (Basel), 2019. **11**(7).
- 2. Carter, R.J., et al., Complex DNA Damage Induced by High Linear Energy Transfer Alpha-Particles and Protons Triggers a Specific Cellular DNA Damage Response. Int J Radiat Oncol Biol Phys, 2018. **100**(3): p. 776-784.
- 3. Carter, R.J., et al., *Characterisation of Deubiquitylating Enzymes in the Cellular Response to High-LET Ionizing Radiation and Complex DNA Damage.* Int J Radiat Oncol Biol Phys, 2019. **104**(3): p. 656-665.

<sup>&</sup>lt;sup>1</sup> Cancer Research Centre, University of Liverpool, UK

<sup>&</sup>lt;sup>2</sup> The National Eye Proton Therapy Centre, Clatterbridge Cancer Centre, Bebington, UK

<sup>&</sup>lt;sup>3</sup> CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, UK

## P19 - Increased immunogenic signaling in terms of calreticulin expression after x-ray irradiation

### Anne Marit Rykkelid<sup>1</sup>

Martine Ruud<sup>1</sup>, Adrian Eek Mariampillai<sup>2</sup>, Randi Syljuåsen<sup>2</sup>, Eirik Malinen<sup>1</sup>, Nina Jeppesen Edin<sup>1</sup> University of Oslo

Introduction: Immune checkpoint inhibitors have emerged as an efficient cancer treatment for some patients, but the effect appears to depend on a cancer specific immunogenic response. Such a response is associated with damage associated molecular patterns (DAMPs). One such DAMP is calreticulin, a protein that is translocated from the cytoplasm to the cell surface membrane as a response to cellular damage in a process called immunogenic cell death (ICD). Here, we investigate the effect of ICD induced by x-ray irradiation on calreticulin expression in lung cancer cells.

Methods: 220kV x-rays were used for irradiation of A549 lung cancer cells with different doses in one or two fractions. The cells were analyzed for calreticulin expression 48H post-irradiation using flow cytometry. Barcoded controls were added to irradiated samples. A fluorescence metric was calculated, taking unspecific binding of secondary antibody and background control levels into account.

**Results:** A significant increase in calreticulin expression was found for all doses tested (2-12 Gy). The increase seemed to stabilize at two levels with a single dose threshold between 4 and 6 Gy. For single doses of 4 Gy and lower a fold change of about 1.5 was found independent of number of fractions. For single doses above 4 Gy a fold change of about 2 was found, independent on number of fractions or further increase in dose.

**Conclusion:** This indicates that the eco-calreticulin may have a threshold dose for efficient activation, and that a further increase in dose does not influence the strength of the signal.




Fig. 1 Calreticulin expression in A549 cells 48H after x-ray irradiation. Signal was found as median fluorescence corrected for unspecific binding and normalized to control.

<sup>&</sup>lt;sup>2</sup> Oslo University Hospital

### P20 - Ionizing radiation, psychological stress, and microgravity in space: hind limb unloading animal model in mice

### Bjorn Baselet<sup>1</sup>

Mieke Neefs<sup>1</sup>, Sarah Baatout<sup>1</sup>

<sup>1</sup> Radiobiology unit, Interdisciplinary biosciences, Institute for environment, health and safety, SCK CEN, Mol, Belgium

**Introduction:** Space travel comprises a unique and complex stress model composed of physical (i.e. radiation and microgravity) and psychological stressors. These extreme conditions can induce specific responses in the human body that will ultimately affect several organ systems. The precise nature of these health effects is not completely understood, and multiple underlying causes might be involved. In view of future interplanetary travel, studies onboard the International Space station (ISS) will help to answer many critical questions. However, due to financial and technical restrictions of these flight experiments, ground-based analogues are required for researchers to test theories without launching experiments into space.

**Methods:** The Radiobiology Unit of SCK•CEN has implemented multiple ground-based *in vitro* and *in vivo* experiments using space flight analogues, like the hind limb unloading (HLU) model in mice. This rodent ground-based analog model was developed to study mechanisms, responses, and treatments for the adverse consequences of microgravity conditions during spaceflight.

**Results:** Currently, we are looking into the combined effects of psychological stress, ionizing radiation and microgravity on a multitude of organ systems, such as the eyes, the bones, the muscles and the immune organs.

**Conclusion:** The HLU model in mice as a rodent ground-based analog model has been optimized. It will serve it's use to gain insights into the mechanisms, responses, and treatments for the adverse consequences of microgravity conditions in combination with ionizing radiation exposure and psychologucal stress during spaceflight.

### P21 - Melanin production and radiobiological features of mucosal melanoma cells

### Angelica Facoetti<sup>1</sup>


Amelia Barcellini<sup>1</sup>, Federica Carnevale<sup>1</sup>, Alexandra Charalampopoulou<sup>1</sup>, Mario Ciocca<sup>1</sup>, Michele Ferrarini<sup>1</sup>, Giovanni Battista Ivaldi<sup>2</sup>, Marianna La Spada<sup>1</sup>, Marco Liotta<sup>2</sup>, Ester Orlandi<sup>1</sup>, Marco Pullia<sup>1</sup>, Paola Tabarelli de Fatis<sup>2</sup>, Francesca Valvo<sup>1</sup>

**Introduction:** Primary vaginal malignant mucosal melanoma is a rare and highly malignant disease intrinsically chemo- and radio-resistant.

**Methods:** In this study we evaluated morphology, melanin production and migration capacity of HMVII cells exposed to 6MV photons beams with doses between 0.5 and 10 Gy. Cells were observed under a phase contrast microscope and images captured at 2, 22 and 44 h.

**Results:** 22 hours after photon radiation the dendrite number and total dendrite length increased, particularly in samples irradiated with 8 or 10 Gy. Interestingly, we observed the appearance of brown cells from the second day after irradiation. The maximum number of brown cells was reached 12 days after 10 Gy-irradiation (Figure below). Subsequently the melanin enriched cells gradually decreased. These morphological observations were confirmed also by the pellets: higher doses corresponded to darker pellets. Then the influence of irradiation on the migration capability was evaluated by scratch assay: irradiation with either 2 or 4 Gy was able to increase the efficiency with which these cells restore the monolayer. This effect was dependent on the dose of radiation: the higher the dose, the greater the efficacy.

Conclusion: The formation of new dendrites together with the enhancement in melanin enriched cells are in agreement with the fact that melanocyte dendrites serve as the principal conduit for melanosome transfer. It is known that melanin protects normal melanocytes from ultraviolet radiation and oxidative stress, this is the first time that an induction of melanogenesis as protective mechanism after exposure to ionizing radiation was demonstrated in human cells.



Representative images of HMVII cells 12 days post exposure to 0 or 10 Gy of photons. Melanin enriched cells are clearly visible in irradiated samples (Magnification 200X).

<sup>&</sup>lt;sup>1</sup> National Center for Oncological Hadrontherapy, Fondazione CNAO, Pavia, Italy

<sup>&</sup>lt;sup>2</sup> I.C.S. Maugeri, Pavia, Italy

### P22 - Microbeam radiation therapy shows a sparing effect in normal tissue cells

### Sandra Bicher<sup>1, 2</sup>

Leo Schröpfer<sup>3</sup>, Stephanie E. Combs<sup>1, 2</sup>, Thomas E. Schmid<sup>1, 2</sup>, Stefan H. Bartzsch<sup>1, 2</sup>

- <sup>1</sup> Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
- <sup>2</sup> Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Ismaninger Str. 22, 81675 Munich, Germany
- <sup>3</sup> Department of Mechatronics and Medical Engineering, Ulm University of Applied Sciences, Albert-Einstein-Allee 55, 90091 Ulm, Germany

**Introduction:** Microbeam radiation therapy (MRT) is an innovative method in radiation oncology that delivers high doses in spatial fractions. This approach divides the radiation field into peakregions of 25-50  $\mu$ m width, receiving doses of up to several hundred Gy and valley-regions of 200-800  $\mu$ m width, receiving doses below the tissue tolerance. Up to date, the biological mechanism behind the differential response to MRT in tumor and normal tissue cells is poorly understood. It is hypothesized that bystander signaling or a faster DNA damage repair plays a critical role.

**Methods:** Human tumor and normal tissue cell lines, A549 and MRC5 were irradiated using broad beam radiation (BB) or MRT. Clonogenic cell survival and DNA repair were analyzed after MRT and BB irradiation in both cell lines.

**Results:** There was no significant difference in the cell survival after MRT for the lung adenocarcinoma cells A549 compared to BB. However, the lung fibroblasts MRC5 showed an increased survival of  $15.6\% \pm 0.9\%$  at 4 Gy MRT compared to  $2.2\% \pm 0.9\%$  at 4 Gy BB (p = 0.0137). These data correlate well with DNA double strand breaks in the yH2AX assay. In MRC5 MRT produced 42% less residual DNA damage than BB irradiation.

**Conclusion:** Our results evidence a normal tissue sparing after MRT *in-vitro*. MRT caused less DNA double strand breaks and increased the survival of normal tissue cells compared to BB, whilst achieving equal tumor cell killing at equivalent dose levels. The wider therapeutic window makes MRT a promising novel radiotherapy approach.

# P23 - Mitochondria nucleus communication is involved in DNA damage response following exposure to genotoxic stress

### Mihaela Temelie<sup>1</sup>

Rubab Talpur<sup>2</sup>, Nicoleta Moisoi<sup>2</sup>, Diana Savu<sup>1</sup>

Introduction: Cellular ageing is known as a process associated with persistent DNA damage, besides well-known mitochondrial damage and accumulation of dysfunctional proteins. Few very recent studies are focused on connection of mitochondrial pathways with DNA damage response (DDR) in neurodegeneration. Radiation effects on CNS are mainly studied in the context of space radiobiology, where the main component of radiation is represented by charged particles – protons or heavy ions. Proton radiation was found as a candidate for rapid aging/neurodegeneration induction. HtrA2 is a mitochondrial serine-protease that induces expression of transcription factor CHOP, specifically in the brain, leading to upregulation of components of the integrated stress response. Our aim was to evaluate how mitochondria-nucleus communication operates in mammalian cells in the context of mitochondrial / genotoxic stress.

**Methods:** We used Mouse Embrionary Fibroblasts (MEF) obtained from Wild-type (WT) mice and mitochondrial dysfunctional genetically modified mice – HtrA2 Knock Out (KO), CHOP KO, or double KO. Genotoxicity was induced by physical (X-rays, proton beam) and chemical factors (bleomycin - BLM).

**Results:** We proved exacerbated sensibility to all DNA-damaging factors in CHOP KO and HtrA2/CHOP KO cells. Protons exposure exhibited a slightly higher genotoxic effect in all cell lines. CHOP KO MEFs cells proved to be more sensitive to DNA damage, independently of HtrA2. Moreover, altered genotypes interfered with induction of molecular markers of compartmental stress responses.

**Conclusion:** Our study showed therefore that mitochondrial signaling pathways of HtrA2/CHOP are involved in DDR following exposure to physical and chemical genotoxic agents.

<sup>&</sup>lt;sup>1</sup> National Institute of Physics and Nuclear Engineering "Horia Hulubei", Magurele, Romania

<sup>&</sup>lt;sup>2</sup> Leicester School of Pharmacy, Faculty of Health Sciences, De Montfort University, Leicester, United Kingdom

# P24 - On to the molecular mechanisms of therapeutic and toxic responses of prostate cancer targeted radionuclide therapy

### Nathalie Heynickx<sup>1, 2</sup>

Sarah Baatout<sup>1, 2</sup>, An Aerts<sup>1</sup>

Introduction: Each year, worldwide, over 1 million men are diagnosed with prostate cancer, which is the second leading cause of cancer related death in men. Prostate specific membrane antigen (PSMA) is overexpressed in prostate cancer. Due to this overexpression, PSMA targeted radionuclide therapy is emerging as a treatment option for patients with advanced disease. In PSMA targeted radionuclide therapy, a PSMA-targeting molecule is labeled with a radionuclide to specifically target prostate cancer cells. Clinical trials using the beta-emitter <sup>177</sup>Lutetium (<sup>177</sup>Lu) showed promising results. However, approximately 30% of patients either showed no response or relapsed after treatment. Mechanisms underlying this radioresistance remain unclear and need to be investigated. Alpha-emitting particles are currently being investigated for targeted alpha therapy of prostate cancer. With their higher linear energy transfer, alpha particles are believed to induce more specific and efficient tumor cell killing, while sparing surrounding tissues. Clinical trials using <sup>225</sup>Actinium (<sup>225</sup>Ac) therapy showed good patient response, but some patients experienced severe, irreversible xerostomia (i.e. dry mouth), which is the dose-limiting side-effect. Xerostomia was also reported to a less severe extent with radionuclide therapy using beta emitters. Besides being extremely uncomfortable, xerostomia can also be dangerous due to the absence of protective saliva, making patients more susceptible for bacterial infections. Therefore, there is a high need to investigate the mechanisms underlying this salivary gland toxicity (xerostomia), as a basis to develop possible countermeasures.

With this project, we aim to gain a better understanding of PSMA-targeted radionuclide therapy to increase safety and to improve clinical efficacy.

### **Selected references**

**Acknowledgements.** This project is funded by ANMI SA – Advanced Nuclear Medicine Ingredients. NH is a recipient of a SCK CEN/UGhent doctoral grant.

<sup>&</sup>lt;sup>1</sup> Radiobiology Unit; Interdisciplinary Biosciences; Institute for Environment, Health and Safety; Belgian Nuclear Research Centre (SCK•CEN), Mol, Belgium

<sup>&</sup>lt;sup>2</sup> Department of Molecular Biotechnology; Ghent University, Ghent, Belgium

### P25 - Proteomic analysis of bystander effects in chondrosarcoma cells

Gilbert Antoine<sup>1, 2</sup>

Tudor Mihaela<sup>3, 4</sup>, Lepleux Charlotte<sup>1, 2</sup>, Rofidal Valérie<sup>5</sup>, Hem Sonia<sup>5</sup>, Almunia Christine<sup>6</sup>, Armengaud Jean<sup>6</sup>, Brotin Emilie<sup>7</sup>, Haghdoost Siamak<sup>1, 2</sup>, Savu Diana<sup>3</sup>, **François Chevalier**<sup>1, 2</sup>

- <sup>1</sup> LARIA, CEA-DRF-iRCM, François JACOB Institute, Caen, France
- <sup>2</sup> CIMAP UMR6252, Normandie Univ, ENSICAEN, UNICAEN, CEA, CNRS, Caen, France
- <sup>3</sup> Department of Life and Environmental Physics, Horia Hulubei National Institute of Physics and Nuclear Engineering, Magurele , Romania
- <sup>4</sup> University of Bucharest, Faculty of Biology, Splaiul Independentei 91-95, Bucharest R-050095, Romania
- <sup>5</sup> BPMP, Mass Spectrometry Proteomics Platform, Montpellier, France
- <sup>6</sup> Innovative technologies for Detection and Diagnostics, CEA-DRF-Li2D, Marcoule, France
- <sup>7</sup> ImpedanCELL Platform, Federative Structure 4206 ICORE, Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancers group (BioTICLA), Comprehensive Cancer Center F. Baclesse, 14000, Caen, France.

**Introduction:** Experimental evidences show that, in addition to direct and targeted effects of ionizing radiations, another effect is observed within the surrounding un-irradiated area; irradiated cells relay a stress signal in this close proximity, the bystander effect. Neighbouring un-irradiated cells react to this bystander signals with a specific response, characteristic of a biological context, but with a close relationship to the biological response typically associated with direct radiation exposure. Bystander responses and bystander factors secreted by irradiated cells were observed and studied in many physical and biological conditions, in vitro and in vivo [1].

**Methods:** In the present study, we investigated the capacity of chondrocytes in responding to bystander factors released by irradiated chondrosarcoma cells using a medium transfer protocol. The cells were irradiated with low doses X-rays and the bystander supernatant was transferred on non-irradiated cells. Survival and proliferation assays were performed to study the effects of this treatment on the bystander cells [2]. In order to study the impact of these treatments on the cellular proteome, we carried out proteomic analysis starting from the cellular protein lysates and the conditioned medium.

**Results:** The proteomic analysis showed the effect of irradiation on the secretome of chondrosarcoma cells as well as the bystander effect on the proteome of bystander chondrocytes. We then selected variant spots that were analysed by mass spectrometry.

**Conclusion:** An in-depth analysis of the identified proteins provides a better understanding of the mechanisms involved in cell irradiation as well as the radio-induced Bystander effect.

- 1. Chevalier F, et al. Proteomic overview and perspectives of the radiation-induced bystander effects. Mutation Research/Reviews in Mutation Research. 2014;763:280–93.
- 2. Lepleux C, et al. Bystander effectors of chondrosarcoma cells irradiated at different LET impair proliferation of chondrocytes. J Cell Commun Signal. 2019.

# P26 - Proton boron capture therapy (PBCT) approach to enhance radiobiological effectiveness of proton beams on cell culture models

### Gaia Pucci<sup>1</sup>

Luigi Minafra<sup>2, 3</sup>, Marco Calvaruso<sup>2, 3</sup>, Fransesco P. Cammarata<sup>2, 3</sup>, Gaetano Savoca<sup>2, 3</sup>, Valentina Bravatà<sup>2, 3</sup>, Guiseppe A.P. Cirrone<sup>3</sup>, Giada Petringa<sup>3</sup>, Vincenzo Cavalieri<sup>1</sup>, Lorenzo Manti<sup>4, 5</sup>, Giusi I. Forte<sup>2, 3</sup>, Ciacomo Cuttone<sup>3</sup>, Giorgio Russo<sup>2, 3</sup>

**Introduction:** Protontherapy (PT) represents an important radiation treatment modality used to treat cancer for several decades already, thanks to a better ballistic precision and a higher dose conformity than conventional radiotherapy (RT). A further improvement in the Relative Biological Effectiveness (RBE) of proton radiation, with a significant increase in tumor cell killing, may be obtained by exploiting the p + 11B  $\rightarrow$  3 $\alpha$  nuclear fusion reaction, to generate high-LET alpha particles through the use of the sodium borocaptate (NA2B12H11SH or "BSH"). This approach is known as the Proton Boron Capture Therapy (PBCT) and is expected to play a strategic role in medical applications, in particular to treat radioresistant tumors [Cirrone GAP et al, 2018]. **Methods:** To better investigate the radiobiological response at molecular level following PBCT in inducing a greater DNA Damage Response (DDR), we tested the enhancement effect of BSH in the human non-tumorigenic breast MCF10A cell line, commonly used as an healthy control epithelial cell line. After pretreatment with 80 ppm of BSH, cells were irradiated with 2 Gy dose at the middle position of the 62-MeV clinical Spread-Out Bragg Peak (SOBP) by using the proton beam at the superconducting cyclotron of the INFN-LNS facility (Catania, Italy). We evaluated the expression of the histone H2AX (γH2AX) as foci formation after irradiation, by immunofluorescence analysis, since it represents a well-known early marker of DNA break. We also studied by Western Blot analyses the expression of 5 proteins related to a DDR and involved in specific DNA repair pathways: the X-Ray Repair Cross Complementing 6 (XRCC6/KU70), the Xeroderma Pigmentosum Group A-Complementing Protein (XPA), the Polymerase Beta (POLB), the Ataxia Telangiectasia and Rad3-Related kinase (ATR) and, also, γH2AX to better quantify its expression levels. Results: Overall, the results obtained revealed a synergic effect of BSH in inducing a higher DNA damage repair response. In addition, we evaluated whether the BSH is able to induce an enhancement of cancer cell killing on a radioresistant cell type, the human pancreatic carcinoma cell line Panc-1, after irradiation with increasing doses of proton beam at the mid-SOBP position in the same condition described above. We observed through dose response curves as the BSH pretreatment plays a radiosensitizing effect, reducing significantly cell survival compared to proton irradiation alone.

**Conclusion:** Our data confirm the key role of BSH in increasing the radiobiological effectiveness of PT and highlight some molecular mechanisms involved in the cell response to PBCT.

<sup>&</sup>lt;sup>1</sup> Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STeBiCeF), University of Palermo

<sup>&</sup>lt;sup>2</sup> Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Cefalù

<sup>&</sup>lt;sup>3</sup> Laboratori Nazionali del Sud (LNS), INFN, Catania

<sup>&</sup>lt;sup>4</sup> Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Napoli, Naples

<sup>&</sup>lt;sup>5</sup> Radiation Biophysics Laboratory, Dipartimento di Fisica "E. Pancini", Università di Napoli Federico II, Naples

<b>Selected references</b> Funding: this work was support	ted by the National Institu	te for Nuclear Physics (	INFN)
Commissione Scientifica Nazionale 5 (CSN5) Call 'NEB	TUNE'.		

### P27 - Puzzling enhancement of proton-induced cellular damage by boron

Kateřina Pachnerová Brabcová<sup>1</sup>

Anna Michaelidesová<sup>1</sup>, Jana Vachelová<sup>1</sup>, Oldřich Zahradníček<sup>1</sup>, Irina Danilová<sup>1</sup>, Vladimír Vondráček<sup>2</sup>, **Marie Davídková**<sup>1</sup>

**Introduction:** For a long time, boron has been used as radiosensitizer in Boron Neutron Capture Therapy, producing high LET secondary particles by neutron nuclear reaction with <sup>10</sup>B isotope. Analogous idea has recently attracted attention in the proton therapy community, suggesting that the boron could amplify cell killing by producing low-energy alpha particles either via reaction with protons themselves or with capture of secondary thermal neutrons. Our goal is to elucidate the underlying mechanism of the observed enhanced biological effects of proton irradiation with the presence of boron.

**Methods:** Glioblastoma astrocytoma U87 MG and human prostate cancer cells DU145 were doped with 40 ppm of <sup>11</sup>B by cultivation with a delivery agent BSH (mercapto-undecahydro-dodecaborate, Na<sub>2</sub>B<sub>12</sub>H<sub>11</sub>SH). Cell monolayers were irradiated with monoenergetic pencil scanned beam of 200 MeV in a plateau and in a Bragg peak position. The possible boron-radiosenzitizing effect was monitored by clonogenic assay.

**Results:** The results were expressed as dose modifying factors (DMF), the ratio of radiation doses with and without the boron agent causing the same effect, in this case 50%-survival doses. Enhancing effect was observed for U87 MG in the Bragg peak (DMF 1.47±0.2), while no increase was observed in the plateau (DMF 0.94±0.1). No DMF changes were observed for DU145 under the similar experimental conditions (1.10±0.1 plateau, 1.05±0.09 Bragg peak).

**Conclusion:** Different results for the studied cellular lines might suggest that the underlying mechanism of the enhanced efficiency is likely caused by a biochemical or biological process rather than by a local enhancement of absorbed dose.

<sup>&</sup>lt;sup>1</sup> Dept. of Radiation Dosimetry, Nuclear Physics Institute of the CAS, Prague, Czech Republic

<sup>&</sup>lt;sup>2</sup> Proton Therapy Center Czech, Prague, Czech Republic

### P28 - Quantitative Modelling of Bystander Effects Within Spatially Fractionated Exposures

### Paul Cahoon<sup>1</sup>

Valentina Giacometti<sup>1,2</sup>, Conor McGarry<sup>1,2</sup>, Emily Russell<sup>1</sup>, Kevin Prise<sup>1</sup>, Stephen J. McMahon<sup>1</sup> Patrick G Johnson Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom;

**Introduction:** Radiation-induced bystander effects (RIBEs) damage cells located outside the directly irradiated field. This has led to increased interest in spatially fractionated radiotherapy, where through proper exploitation of RIBEs, non-uniform dose exposures could be used to enhance tumour control. However, this is challenging to optimise, as the mechanisms underlying RIBEs are not yet fully understood. We have created a mathematical model that captures the behaviour of RIBEs in *in vitro* experiments, simulating both direct damage as well as indirect damage mediated by signalling molecules. By supplementing experimental study with mathematical modelling techniques, it's possible to predict how different dose exposures influence cell survival, and identify optimal treatment approaches.

**Methods:** Using a clinical Linac, we delivered four plans to *in vitro* DU145 cells: a uniform plan and three heterogeneous exposures (Figure 1). In all plans the mean dose to the population was identical, with approximately 50% of the flask exposed in non-uniform plans.

**Results:** The clonogenic survival resulting from these exposures was well predicted by our mathematical model, and showed that all plans had similar effects at lower doses, while uniform exposure only proved most effective at higher doses.

**Conclusion:** This indicates that uniform exposures do not necessarily maximise cell kill at clinically relevant doses. With RIBEs considered it's possible that maximising the mean dose applied to the tumour would, in some cases, be a better use of resources than ensuring a fully uniform field. Future work will evaluate these effects in clinical treatment plans.




Figure 1: Example dose distributions for the (a) Uniform field and (b) 10 mm grid pattern exposures where the mean dose delivered to each T25 flask is 1 Gy. (c) The clonogenic survival resulting from each of the plans at the 1, 2, 4 and 8 Gy dose points is compared to the predictions made by the mathematical model.

<sup>&</sup>lt;sup>2</sup> Radiotherapy Physics, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Northern Ireland, United Kingdom

### P29 - Response of medulloblastoma cells to ionizing radiation

### Jana Klementová<sup>1, 2</sup>

Martina Zíková², Markéta Hurychová¹, Irina B. Danilová¹, Šárka Jarošová², Marie Davídková¹

**Introduction:** Brain and nervous system cancers in children represent the second most common neoplasia after leukemia. About 8-10 % of childhood brain tumors are medulloblastomas (MBs), embryonal tumors of the cerebellum (1). MB is not a single disease but is comprised of at least four subgroups, which are termed wingless (WNT), sonic hedgehog (SHH), group C, and group D (2). These subgroups differ in their molecular characteristics, clinical course, and are associated with different prognosis.

**Methods:** The established SHH MB cell lines DAOY (3) and ONS-76 (4) were cultured *in vitro* in standard adherent conditions or as neurospheres (medullospheres). The irradiation was performed by Co-60 gamma radiation and by X-ray beam, doses of 0 to 8 Gy. We determined tumorogenicity of cells by measuring their ability to proliferate, to form medullospheres, and to initiate colonies after irradiation.

**Results:** *TP53* gene mutations occur in a specific group of SHH MBs. We confirmed that DAOY cells express mutated *TP53* mRNA and ONS-76 cells express wild-type form of this gene. Both cell lines were able to grow as medullospheres in serum-free medium and moreover we verified the changes in the expression levels of stem cell markers in medullospheres compare to cells cultured as a monolayer. Additionally, we measured differences in colony formation after irradiation either in adherent or in attachment-independent conditions.

**Conclusion:** Because a significant part of cancer patients receive radiation as a critical part of the treatment regimen, the aim of our project is to characterize the functional impact of radiation on SHH MB cells.

- 1. T. C. Archer, E. L. Mahoney, S. L. Pomeroy, Medulloblastoma: Molecular Classification-Based Personal Therapeutics. *Neurotherapeutics* **14**, 265-273 (2017).
- 2. M. D. Taylor *et al.*, Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathol* **123**, 465-472 (2012).
- 3. Jacobsen *et al.*, Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. *Journal of Neuropathology and Experimental Neurology*, **44**, 472–485 (1985).
- 4. M. Yamada *et al.*, Establishment and biological characterization of human medulloblastoma cell lines. *No To Shinkei* **41**, 695-702 (1989).

<sup>&</sup>lt;sup>1</sup> Czech Academy of Sciences, Nuclear Physics Institute, Prague, Czech Republic

<sup>&</sup>lt;sup>2</sup> Czech Academy of Sciences, Institute of Molecular Genetics, Prague, Czech Republic

# P30 - Side effects of scattered versus scanned proton beams on normal tissues in total body irradiated mice: preliminary results

### Samia Chaouni<sup>1</sup>

Ludovic De Marzi<sup>2</sup>, Fréderic Pouzoulet<sup>3</sup>, Jean-Louis Habrand<sup>1, 4</sup>, François Sichel<sup>1, 4</sup>, Dinu Stefan<sup>1, 4</sup>, Delphine Lecomte<sup>4</sup>, Carine Laurent<sup>1, 5</sup>

- <sup>1</sup> ABTE(EA4651)-ToxEMAC, Caen University
- <sup>2</sup> Curie Institute, Protontherapy center, Orsay,France
- <sup>3</sup> Curie Institute, Translationnel Recherche Department, RadeXP plateform
- <sup>4</sup> CLCC François Baclesse, Caen, France
- <sup>5</sup> ARCHADE-SAPHYN, Caen, France

Introduction: Protons are now widely used instead of photons due to their ballistic properties which should allow to treat tumors localized near organs at risk (OAR) without leading to toxicities in these OAR. Nowadays, the state of knowledge is limited mainly to relative biological efficiency (RBE) on observables related to cell death. Moreover, difficulty of access to beam line facilities, initially dedicated to physics research, and their inadequacy with radiobiology experiments have limited the quantity and the quality of available and homogenous biological data. Therefore, only few studies have been performed on proton effects on normal tissues or cells in comparison with the large number of studies on conventional radiotherapy. In this way, there is a lack of data relative to biological effects of scattered versus scanned proton beams on normal tissues.

**Methods:** The present study aimed at evaluating the response of healthy tissues (skin, lung, heart and blood) after scattered or scanned proton beam irradiation. For this purpose, C57Bl6 mice were total body irradiated by DS (Double Scattering) or PBS (Pencil Beam Scanning) at different proton doses in the plateau phase of the Bragg peak. Blood and organs were collected 3 months after irradiation.

**Results:** First results showed differences between both types of proton delivery in terms of survival but also DNA damage, biomarkers of oxidative stress and inflammation

**Conclusion:** Experiments are in progress concerning other biomarkers of oxidative stress and inflammation on the collected blood and organs. Results will be then compared to normal tissues response after X-ray irradiation

# P31 - Small is beautiful: low activity alpha and gamma sources for small-scale radiation protection research experiments

Magdalena Plodowska<sup>1</sup>

Milagrosa Lopez-Riego<sup>2</sup>, Pamela Akuwudike<sup>2</sup>, Daniel Sobota<sup>3</sup>, Janusz Braziewicz<sup>3</sup>, Mateusz Filipek<sup>4</sup>, Urszula Kazmierczak<sup>5</sup>, Beata Brzozowska-Wardecka<sup>4</sup>, Halina Lisowska<sup>1</sup>, Lovisa Lundholm<sup>2</sup>, **Andrzej Wojcik**<sup>2</sup>

Introduction: Uncertainties regarding the magnitude of health effects following exposure to low doses of ionising radiation remain a matter of concern both for professionals and for the public. There is consensus within the international radiation research community that more research is required on biological effects of radiation doses below 100 mGy applied at low dose rates. Moreover, there is a demand for increasing education and training of future radiation researchers and regulators. Research, education and training is primarily carried out at universities but university-based radiation research is often hampered by limited access to radiation sources. The aim of the present report is to describe small and cost effective low activity gamma and alpha sources that can easily be installed and used in university laboratories.

**Methods:** A gamma radiation source was made from an euxenite-(Y) rock  $(Y,Ca,Ce,U,Th)(Nb,Ta,Ti)_2O_6)$  that was found in an abandoned mine in Sweden. It allows exposing cells grown in culture dishes to radiation at a dose rate of 50  $\mu$ Gy/h and lower. Three alpha sources were custom-made and yield a dose rate of 1 mGy/h each.

**Results:** The construction and dosimetry of the sources is described.

**Conclusion:** We hope that the report will stimulate research and training activities in the low dose field by facilitating access to radiation sources.

<sup>&</sup>lt;sup>1</sup> Institute of Biology, Jan Kochanowski University, Kielce, Poland

<sup>&</sup>lt;sup>2</sup> Centre for Radiation Protection Research, MBW Department, Stockholm University, Sweden

<sup>&</sup>lt;sup>3</sup> Institute of Physics, Jan Kochanowski University, Kielce, Poland

<sup>&</sup>lt;sup>4</sup> Institute of Experimental Physics, Warszawa University, Warszawa, Poland

<sup>&</sup>lt;sup>5</sup> Heavy Ion Laboratory, Warszawa University, Warszawa, Poland

## P32 - The cytokinesis-block micronucleus assay on isolated fresh and frozen peripheral blood mononuclear cells.

### Simon Sioen<sup>1</sup>

Karlien Cloet<sup>1</sup>, Anne Vral<sup>1</sup>, Ans Baeyens<sup>1</sup>

Introduction: The cytokinesis-block micronucleus (CBMN) assay is a standardized method used to evaluate genomic damage after exposure to various genotoxic agents such as ionizing radiation. Next to conventional whole blood cultures (WBC), also isolated peripheral blood mononuclear cells (PBMCs) cultures are used for the CBMN assay. However, there is no extensive investigation of a standardized protocol for the PBMCs CBMN assay. The aim of this study was to work out a reliable CBMN assay protocol for fresh and frozen isolated PBMC. Furthermore, we analyzed if PBMCs, isolated out of exposed whole blood, lead to representative MN data.

**Methods:** Blood samples of 10 donors were collected. Each donor's blood was used to set up a G<sub>0</sub> CBMN assay on whole blood, on isolated fresh and frozen PBMCs. In these assays isolation of PBMCs occurred before *in vitro* irradiation. Additionally, PBMCs were isolated from irradiated whole blood samples and MN were scored. Cells were exposed to *in vitro* doses ranging from 0,5 to 2 Gy of 220 kV X-rays.

**Results:** The CBMN assay on PBMCs, isolated both pre and post-irradiation, showed a high reproducibility, sensitivity and similarity with the conventional WBC CBMN assay. After freezing, cells showed no significant differences in MN counts until the time point of 2 weeks, where after significant elevated MN counts were assessed.

**Conclusion:** A reliable CBMN assay protocol for PBMCs, isolated both pre and post-irradiation, will be presented. Extra attention is needed when freezing isolated PBMCs for a longer period than 2 weeks.

<sup>&</sup>lt;sup>1</sup> Radiobiology Research Group, Department of Human Structure and Repair, Ghent University

# P33 - The influence of MGMT expression on radiation responses in human glioblastoma multiforme cell lines

### Anna Kirstein<sup>1, 2</sup>

Daniela Schilling<sup>1, 2</sup>, Stephanie E. Combs<sup>1, 2, 3</sup>, Thomas E. Schmid<sup>1, 2</sup>

**Introduction:** GBM exhibit high resistance to radiochemotherapy. MGMT counteracts the therapeutic efficacy of temozolomide and is therefore a biomarker for chemotherapy outcome. As the influence of MGMT in radiotherapy is unknown the aim is to identify the correlation between MGMT and radiation response.

**Methods:** Radiosensitivities were determined by colony forming assay (CFA), MGMT promoter methylation was quantified by MethyQESD. Western Blots showed MGMT expression while DNA repair capacities were investigated by 53BP1 foci and correlated to cell cycle analyses.

**Results:** U251 are more radioresistant, than LN18 and LN229 cells. MethyQESD revealed unmethylated promoter regions in LN18 (0.3%), hemi-methylated in U251 (29.7%) and methylated in LN229 (165.2%). MGMT expression levels vary between cell lines, which is in accordance to MethyQESD. Western Blots showed a successful MGMT knockdown in LN18 with a significant reduction in MGMT. 24 hours after irradiation residual damages are increased (LN18: 1.7-fold±0.2; LN229: 2.7-fold±0.4; U251: 1.1-fold±0.2), which corresponds with similar doubling times for LN18 (21h±1.7) and LN229 (19h±1) but increased doubling time in U251 (27h±0.6). Cell cycle analysis revealed 29%±0.04 LN18, 30%±6.6 LN229 and 47%±0.02 U251 cells in G<sub>2</sub>/M arrest 24 hours after irradiation.

Conclusion: Our results demonstrate increased repair capacity, slower growth and higher G<sub>2</sub>/M arrests in the radioresistant cell line. No correlation between MGMT status and radiosensitivity was found in parental cells. Further in vitro experiments to characterize MGMT knockdown cells are ongoing and in vivo experiments are planned. First CFA results indicate a radiosensitizing effect of MGMT in knockdown cells.

<sup>&</sup>lt;sup>1</sup> Institute of Radiation Medicine (IRM), Helmholtz Zentrum München, Neuherberg, Germany

<sup>&</sup>lt;sup>2</sup> Department of Radiation Oncology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany

<sup>&</sup>lt;sup>3</sup> Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany

### P34 - The specific role of DNA-PKcs in DNA-DSBs repair induced by the neutron-mixed beam

### Kamila Maliszewska-Olejniczak<sup>1</sup>

Agnieszka Dróżdż<sup>1</sup>, Martyna Waluś<sup>1</sup>, Michał Dorosz<sup>1</sup>, Maciej Wiliński<sup>1</sup>, Szymon Domański<sup>1</sup>, Martyna Araszkiewicz<sup>1, 2</sup>, Katarzyna Tymińska<sup>1</sup>, Agnieszka Korgul<sup>2</sup>, Maciej Maciak<sup>1</sup>, Michał A. Gryziński<sup>1</sup>

**Introduction:** The main goal of our research is to investigate the mechanisms of DNA-DSBs repair after exposure to the neutron-mixed beam used in boron neutron capture therapy (BNCT). The impact of a mixed beam on the activation of the DNA damage response is poorly understood. Our interest lies in neutron-gamma mixed beam which can induce another type of DNA damage, such as complex DNA damage, as indicated for high LET particles. The author assumes that after exposure to a neutron-mixed beam the reduced repair capacity will be observed, less efficient repair response will occur and may promote genome instability and cell death. Which repair pathway is involved and which proteins it is not clear in the case of the neutron-mixed beam.

**Methods:** We used *in vitro* model – colon cancer cell line and plan to introduce cell lines deficient in repair proteins and *C. elegans* which emerged recently as a suitable *in vivo* experimental model for studying the DNA damage response. Moreover, we have developed and introduced a reliable immunofluorescence staining protocol for the detection of radiation-induced DNA damage response with antibodies specific for repair factors from NHEJ and HRR pathways (Maliszewska-Olejniczak, *et al.*, 2020; *J. Vis. Exp.*).

**Results:** We observed the occurrence of the higher expression level of DNA-PKcs from NHEJ in the form of foci by immunofluorescence technique after neutron-mixed beam irradiation in comparison with other tested proteins from each repair pathway.

**Conclusion:** Our research will provide new knowledge about molecular mechanisms in the process of DNA damage formation and repair.

<sup>&</sup>lt;sup>1</sup> National Centre for Nuclear Research, Nuclear Facilities Operations Department, Otwock, Poland

<sup>&</sup>lt;sup>2</sup> University of Warsaw, Faculty of Physics, Warsaw, Poland

## P35 - The temperature effect at the level of DNA damage foci and micronucleus frequency in U2OS-53BP1 and U2OS-NBS1 cells.

### Magdalena Płódowska<sup>1</sup>

Wiktoria Krakowiak<sup>1</sup>, Aneta Węgierek-Ciuk<sup>1</sup>, Andrzej Wójcik<sup>1, 2</sup>, Anna Lankoff<sup>1</sup>, Karol Szary<sup>3</sup>, Krzysztof Lis<sup>4</sup>, Halina Lisowska<sup>1</sup>

- <sup>1</sup> Department of Medical Biology, Institute of Biology, Jan Kochanowski University, Kielce, Poland
- <sup>2</sup> Centre for Radiation Protection Research, MBW Department, Stockholm University, Sweden
- <sup>3</sup> Department of Atomic Physics and Nanophysics, Institute of Physics, Jan Kochanowski University, Kielce, Poland
- <sup>4</sup> Holy Cross Cancer Center, Artwińskiego 15, 25-406 Kielce, Poland

**Introduction:** The radioprotective effect of hypothermia, termed the temperature effect (TE), was mainly observed in human peripheral blood lymphocytes (PBL) as reduced levels of chromosomal aberrations and micronuclei. TE was not visible at the level of gamma H2AX focus formation and decay. The mechanisms of TE are not known. The aim of the study was to analyze the effect of hypothermia at the level of formation and decay of 53BP1 and NBS1 foci and of micronuclei (MN) in cells other than PBL. 53BP1 and NBS1 foci were analysed in order to observe differences in early and late cellular responses. Another aspect was the observation whether cells left on ice after irradiation would at all repair DNA damage.

**Methods:** U2OS were exposed at 0.8°C and 37 °C to 2 Gy of gamma radiation. Kinetics of foci formation was analyzed after 0, 5, 10,15, 30 and 60 minutes of repair time. Cells were also set up for MN, were harvested after three fixation time points: 20h, 26h and 32h of culture time. Three independent experiments were performed.

**Results:** The analysis of foci and the micronucleus scoring has not been completed at the time of abstract submission. Preliminary results show that the formation and decay of 53BP1 foci was delayed in cells exposed at 0.8°C as compared to 37°C. Cells left on ice formed 53BP1 foci.

**Conclusion:** Preliminary results demonstrate that, in contrast to human peripheral blood lymphocytes, TE is observed in U2OS cells. At present, we do not know the reason for the difference.

- Dang L1, Lisowska H, Manesh SS, Sollazzo A, Deperas-Kaminska M, Staaf E, Haghdoost S, Brehwens K, Wojcik A., RadioprotecIve effect of hypothermia on cells a mulIparametric approach to delineate the mechanisms. Int J Radiat Biol. 2012 Jul;88(7):507-14. Epub 2012 Apr 30.
- Lisowska H1, Cheng L2, Sollazzo A2, Lundholm L2, Wegierek-Ciuk A1, Sommer S3, Lankoff A1,3, Wojcik A1,2., Hypothermia modulates the DNA damage response to ionizing radiaIon in human peripheral blood lymphocytes. Int J Radiat Biol. 2018 Jun;94(6):551-557. Epub 2018 May 3.
- 3. C. Johannes, A. Dixius, M. Pust, R. Hentschel, I. Buraczewska, E. Staaf, K. Brehwens, S. Haghdoost, S. Nievaart, J. Czub, J. Braziewicz, and A. Wojcik. The yield of radiaIon-induced micronuclei in early and late-arising binucleated cells depends on radiaIon quality. Mutat.Res. 701 (1):80-85, 2010.

# P36 - Therapeutic potential of Hedgehog signaling pathway modulation for muscular repair after high local dose radiation exposure

### Nicolas Jullien<sup>1</sup>

Jérôme Pateux<sup>1</sup>, Michel Drouet<sup>1</sup>, Diane Riccobono<sup>1</sup>


**Introduction:** Civilians but also the armed forces can be injured by high dose radiation exposure, in connection with terrorist acts or accidentally. In such a situation, one of the first physiological barriers is subcutaneous musculature. Consecutive lesions to this tissue can be severe, strongly inflammatory and degenerative (cutaneous radiation syndrome; CRS). However, no satisfactory pharmacological solution is available to treat victims. It is therefore necessary to develop new therapeutic strategies to improve post-irradiation muscle regeneration.


**Methods:** Here, the objective is to evaluate the benefit of a pharmacological protocol, based on the use of recombinant Sonic Hedgehog (Shh; agonist) or Cyclopamine (antagonist), to modulate the pro-myogenic Hedgehog (Hh) signaling pathway<sup>[1,2]</sup> in differentiating mouse myoblasts (C2C12 cells) exposed to radiation (X-rays; 5 Gy). Proliferation, metabolism and myogenesis genes/proteins expression have been evaluated.

**Results:** This study shows a significant negative impact of a high radiation dose in our *in vitro* model of mouse muscle progenitors differentiation at days 0 to 7 after irradiation. Interestingly, both the activation and the inhibition of Hh pathway appear to have a therapeutic potential in post-irradiation muscle regeneration: Shh promotes the proliferation of myoblasts and their survival while Cyclopamine significantly increases cell differentiation toward mature myotubes.

**Conclusion:** The best activation/blocking sequence of this metabolic pathway remains to be investigated to stimulate both progenitors preservation and new muscle fibers synthesis after irradiation. A major scientific interest lies in such a project to improve the understanding of Hh involvement in muscular regeneration after CRS and to accumulate data for further *in vivo* studies.

- [1]. Qiu Zeng, Qining Fu et al. Cell. Phys. Biochem. 2007;43:1813-1828
- [2]. Caroline Caradu, Alexandre Guy et al. Cardiovasc. Res. 2018;114:759-770.





C2C12 cells in non differentiating (left) and differentiating culture conditions (right) at day 7

<sup>&</sup>lt;sup>1</sup> French Armed Forces Biomedical Research Institute (IRBA), Brétigny-sur-Orge, France

## *P37 - Unravelling the potential interplay of simulated spaceflight conditions: how is the skin affected?*

### Eline Radstake<sup>1, 2</sup>

Bjorn Baselet<sup>1</sup>, Sarah Baatout<sup>1, 2</sup>, Mieke Verslegers<sup>1</sup>

**Introduction:** During space travel, astronauts are continuously exposed to microgravity, ionizing radiation, and increased psychological stress. One of the organs affected by this spaceflight environment is the skin, which is subject to rashes, itches, and delayed wound healing. Furthermore, alterations in extracellular matrix proteins, thinning of the epidermis, and loss of elasticity are found after spaceflight. Yet, there is still lack of understanding how the different spaceflight stressors interact to induce these defects.

**Methods:** We used cultured primary human dermal fibroblast to investigate the cellular effects after exposure to combined spaceflight stressors, where we first exposed fibroblasts to X-rays and hydrocortisone. Endpoints included wound healing capacity, expression of type I collagen and DNA damage repair.

**Results:** We found a decreased cell migration upon wound induction and lowered expression of type I (pro)collagens (indicative for skin aging) in response to hydrocortisone, but not following radiation with 0.1-2 Gy of X-rays. Furthermore, preliminary results show increased DNA damage after irradiation which was exacerbated in irradiated fibroblasts incubated with hydrocortisone, suggesting a synergistic effect of these stressors.

Conclusion: Besides hydrocortisone and ionizing radiation (low- vs. high- LET), fibroblasts will be exposed to microgravity to investigate the possible interactive effects on wound healing. Additional endpoints will include cell survival and an in-depth investigation of extracellular matrix proteins and cytoskeleton components. Altogether, the results of this PhD project will give more insights into the effects of combined spaceflight stressors on skin dermal cells, and as such might improve the risk assessment for human deep space exploration.

<sup>&</sup>lt;sup>1</sup> Institute for Environment, Health and Safety, Radiobiology Unit, Belgian Nuclear Research Centre SCK CEN, Mol, Belgium

<sup>&</sup>lt;sup>2</sup> Faculty of Bioscience Engineering, Department of Biotechnology, Ghent University, Belgium

## P38 - Comparison of the immuno-biological response in the tumor microenvironment after FLASH or conventional electron irradiation

### Anja Brus<sup>1</sup>

Sophie Eriksson<sup>2</sup>, Elise Konradsson<sup>2</sup>, Gabriel Adrian<sup>3</sup>, Ana Carneiro<sup>3</sup>, Kristoffer Petersson<sup>4, 5</sup>, Anders E. Hansen<sup>1</sup>, Thomas L. Andresen<sup>1</sup>, Crister Ceberg<sup>2</sup>

- <sup>1</sup> Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark
- <sup>2</sup> Medical Radiation Physics, Department of Clinical Sciences, Lund University, Lund, Sweden
- <sup>3</sup> Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden
- <sup>4</sup> Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK
- <sup>5</sup> Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden

**Introduction:** Ultra-high dose rate radiotherapy (FLASH-RT) has been demonstrated to mediate a potent anti-cancer activity with reduced normal tissue toxicity in preclinical models. However, the biological effect on the immune composition in the tumor microenvironment (TME) has not been clarified. It has been demonstrated that conv-RT causes immunogenic cell death, releasing tumor antigens and increases the infiltration of cT cells, making radiation therapy a potent primer of anticancer immune response in combination with immunotherapy. Considering the observed tissue sparing properties of FLASH-RT we hypothesized that the effect on non-cancerous cells in the TME could be different compared to conv-RT.

**Methods:** The effects of FLASH-RT and conv-RT on the anti-cancer immune response were compared in a syngeneic murine cancer model, CT26. Tumors were irradiated with 8Gy of conv-RT or 8Gy FLASH-RT and the immune infiltration in the TME were evaluated 8 days after irradiation by flow cytometry.

**Results:** There was no significant difference in the viability of cancer cell between conv-RT and FLASH-RT. However, we found a significantly higher infiltration of cDC1 and cT cells in tumors treated with conv-RT compared to FLASH-RT. Interestingly, this was not associated with an increased activation based on CD86 and MHC-II expression and there was no difference in infiltration of MDSCs in the TME.

**Conclusion:** These preliminary results could indicate that FLASH-RT induces cell death by a level or mechanism that is less immunogenic. Follow-up studies to elucidate the underlying biological mechanisms and immune modulating properties of FLASH-RT at multiple time point and higher irradiation doses are therefore ongoing.

# P39 - Identification of Raman spectral biomarkers of treatment response in high risk localised prostate cancer patients receiving SABR.

### Jade Monaghan<sup>1, 2</sup>

Daniel Cullen<sup>1, 2</sup>, Dinesh Medipally<sup>1, 2</sup>, Kelly Redmond<sup>3</sup>, Ciaran Fairmichael<sup>3, 4</sup>, Suneil Jain<sup>3, 4</sup>, Aidan Meade<sup>1, 2</sup>, Fiona Lyng<sup>1, 2</sup>

**Introduction:** High risk localised prostate cancer (PCa) accounts for 15% of patients diagnosed with PCa. Stereotactic ablative body radiotherapy (SABR) offers an opportunity to increase the dose delivered to the prostate while sparing the surrounding normal tissues. After treatment, PCa patients can experience gastrointestinal and genitourinary toxicity and there is patient variability in response due to individual radiosensitivity. There is an unmet need for biomarkers to predict treatment response and potential toxicity from this treatment. Optical spectroscopic methods such as Raman spectroscopy can provide a unique biochemical fingerprint for molecules in biological samples. This study aims to identify Raman spectral biomarkers for monitoring treatment response and toxicity in SABR treated PCa patients.

**Methods:** PCa patients (n=30) were recruited as part of the SPORT High-Risk trial and blood samples were collected at baseline and at 8 time points up to 3 months post-SABR. At follow up, clinical details including prostate-specific antigen (PSA) and radiation toxicity were recorded. Raman spectra were recorded from lymphocytes and the data was analysed using MATLAB software.

**Results:** Through principal component analysis, differences in spectral features between samples before treatment and at subsequent time points were found in lipids and nucleic acids. Partial least squares-discriminant analysis provided sensitivity and specificity in the ranges of 88-100%.

**Conclusion:** Future work with these spectral signals involves modelling with treatment type and toxicity. Identification of biomarkers would allow stratification of high risk localised PCa patients according to risk of developing radiation toxicity and could provide individualised patient radiotherapy treatment.

<sup>&</sup>lt;sup>1</sup> Radiation and Environmental Science Centre, FOCAS Research Institute, Camden Row, Dublin 8, Ireland

<sup>&</sup>lt;sup>2</sup> School of Physics, Technological University Dublin, Kevin Street, Dublin, Ireland

<sup>&</sup>lt;sup>3</sup> Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK

<sup>&</sup>lt;sup>4</sup> Northern Ireland Cancer Centre, Belfast, 51 Lisburn Road, Belfast BT9 7AB, UK

## P40 - Nomogram for predicting overall survival in patients diagnosed with spinal bone metastases

### Biche Osong<sup>1</sup>

Ilknur Sanli<sup>1</sup>, Paul C. Willems<sup>2</sup>, Leonard Wee<sup>1</sup>, Andre Dekker<sup>1</sup>, Seok Ho Lee<sup>3</sup>, Johan van Soest<sup>1</sup>

Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands

Introduction: The spine is the third most common site for cancer cells to metastasize, after lung and liver. About 30 - 70% of patients with a primary tumor have metastatic spinal disease at autopsy.

Methods: A total of 250 patients with spinal bone metastases admitted to our institution from January 2014 to April 2016 were reviewed for this study. The primary tumor was restricted to breast, prostate, colon, rectal, and lung. A 5-fold cross-validation Cox proportional hazard regression model with the lasso penalty was employed for the feature selection process before establishing the prognostic nomogram. The discrimination was measured by the concordance index (C-index). A bootstrap calibration plot was used to ascertain the model's accuracy.

**Results:** Six independent prognostic factors, including age, the presence of visceral metastasis, spinal cord compression, brain metastasis, WHO performance status, and primary tumor were identified during the feature selection process for building the nomogram with the manual addition of gender. The median follow-up time for this study was 46.8 months with a 1, 3, and 6-months overall survival probability of 88%, 67%, and 53%, respectively. The C-index of the nomogram was 0.720, with a standard error of 0.02.

**Conclusion:** We established a novel nomogram that could be used to predict the survival probability of patients with spinal metastasis. We provided a digital version for flexible and easy usage (https://bich.shinyapps.io/SpinalMets/), thus helping physicians with their (shared) decision-making process and the individualized care planning of such patients.

- Aebi, Max (2005). "Spinal metastasis in the elderly". In: *The Aging Spine*. Springer, pp. 120–131.
- Bollen, Laurens et al. (2014). "Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1 043 patients". In: *Neuro-oncology* 16.7, pp. 991–998.
- Khoi, D. Than (2019). *Understanding Metastatic Spine Cancer and Spinal Tumors*. URL: https://www.spineuniverse.com/resourcecenter/spinal-cancer/understanding-metastatic-spinecancer-spinal-tumors.
- Shah, Lubdha M and Karen L Salzman (2011). "Imaging of spinal metastatic disease". In: *International journal of surgical oncology* 2011.
- Ziu, Endrit and Fassil B Mesfin (2019). "Cancer, Spinal Metastasis". In: *StatPearls [Internet]*. StatPearls Publishing.

<sup>&</sup>lt;sup>2</sup> Department of Orthopaedics and Research School Caphri, Maastricht University Medical Center, Maastricht, the Netherlands.

<sup>&</sup>lt;sup>3</sup> Department of Radiation Oncology, Gachon University, College of Medicine, Gil Medical Center, Incheon, Korea




Figure 1. Developed nomogram to predict 1, 3, and 6-months overall survival for metastatic spinal bone patients using six clinical characteristics. To use the nomogram, locate the patient's variable on the corresponding axis and draw a vertical line to the points axis, then sum the points, and bring a vertical line from the total points axis to the 1, 3, or 6 - months overall survival probability axis.

## P41 - Search for Biomarkers of Radiation-Induced Cardiovascular Disease and Pediatric Tumors

### Magy Sallam<sup>1, 2</sup>

An Aerts<sup>2</sup>, Mohammed Abderrafi Benotmane<sup>2</sup>, Sarah Baatout<sup>2, 3</sup>, Pieter-Jan Guns<sup>1</sup>

**Introduction:** Radiation therapy (RT) in breast cancer has significantly improved patient treatment outcomes contributing to a 5-year survival of around 90% in many countries. However, breast RT can cover part of the heart and major blood vessels which has been correlated with an increased cardiovascular morbidity and mortality as eventually leading to radiation-induced cardiovascular disease (CVD). Interestingly, DNA methylation alteration have been linked to both radiation and cardiovascular disease seperately. However, no previous research has focused DNA methylation alterations associated with radiation-induced CVD.

On the other hand, diagnostic computed tomography (CT) imaging ,while highly valuable, delivers significant radiation doses. Children are particularly at risk as they are more sensitive to radiation-induced cancer compared with adults and have a longer lifespan to express the delayed harmful effects. In fact, an increased risk of glioblastoma (GBM) was found in children after radiation exposure from CT scans. Hence, biomarkers for early detection of GBM are of crucial importance. Non-coding RNA have been shown to be differentially expressed in a variety of cancers including GBM. Consequently, a combined GBM biomarker panel of noncoding RNA could significantly alter disease diagnosis and monitoring.

**Conclusion:** Consequently, our research aims to discover DNA methylation biomarkers for a more accurate risk estimation of early radiation-induced CVD as well as to identify and measure microRNA/ long non coding RNA (lncRNA) markers of GBM. This research is part of MEDIRAD project which has received funding from the Euratom research and training programme 2014-2018 under grant agreement No 755523.

<sup>&</sup>lt;sup>1</sup> University of Antwerp

<sup>&</sup>lt;sup>2</sup> Belgian Nuclear Research Centre (SCK•CEN)

<sup>&</sup>lt;sup>3</sup> Ghent University

# P42 - Gene expression based signatures to predict the acute radiation syndrome after ionizing radiation - developments and challenges

### Matthias Port1

Patrick Ostheim<sup>1</sup>, Matthäus Majewski<sup>2</sup>, Michael Abend<sup>1</sup>

**Introduction:** Reliable diagnosis and triage of radiation injury patients is the key for determining appropriate guidance and therapeutic interventions after ionizing radiation accidents or attacks. Increasing threats due to proliferation of nuclear weapons, and even the possibility of improvised nuclear devices operated by terrorists challenged the conventional CBRN protection standard set within the last decades. Significant medical advances like usability of growth factors on the other hand underline the need for very early diagnosis.

**Methods:** Here we present our recent research strategy ranging from theoretical considerations on effect prediction to advanced gene signatures to predict the acute radiation syndrome after high dose ionizing radiation. Third generation gene expression signatures based on non-human-primate experiences were validated in human models.

**Results:** A small set of genes enabled us to set up a high-throughput diagnostic pathway which might be used even in large scale scenarios.

**Conclusion:** First results in the development of point of care devices will be presented. Strategies to overcome challenges like cross species differences or exon specific markers will be discussed.

### **Selected references**

Gene expression signature for early prediction of late occurring pancytopenia in irradiated baboons. Port M, Hérodin F, Valente M, Drouet M, Lamkowski A, Majewski M, Abend M. Port M, et al. Ann Hematol. 2017 May;96(5):859-870. doi: 10.1007/s00277-017-2952-7.

Validating Baboon Ex Vivo and In Vivo Radiation-Related Gene Expression with Corresponding Human Data. Port M, Majewski M, Herodin F, Valente M, Drouet M, Forcheron F, Tichy A, Sirak I, Zavrelova A, Malkova A, Becker BV, Veit DA, Waldeck S, Badie C, O'Brien G, Christiansen H, Wichmann J, Eder M, Beutel G, Vachelova J, Doucha-Senf S, Abend M. Port M, et al Radiat Res. 2018 Apr;189(4):389-398. doi: 10.1667/RR14958.1.

Impact of Inter-Individual Variance in the Expression of a Radiation-Responsive Gene Panel Used for Triage. Agbenyegah S, Abend M, Atkinson MJ, Combs SE, Trott KR, Port M, Majewski M. Agbenyegah S, et al. Radiat Res. 2018 Sep;190(3):226-235. doi: 10.1667/RR15013.1.

Rapid High-Throughput Diagnostic Triage after a Mass Radiation Exposure Event Using Early Gene Expression Changes. Port M, Ostheim P, Majewski M, Voss T, Haupt J, Lamkowski A, Abend M. Port M, et al. Radiat Res. 2019 Aug;192(2):208-218. doi: 10.1667/RR15360.1.

<sup>&</sup>lt;sup>1</sup> Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, Germany

<sup>&</sup>lt;sup>2</sup> Department of Urology, Bundeswehr Hospital Ulm, Ulm, Germany

### P43 - Health effects of cardiac fluoroscopy and modern radiotherapy in paediatrics; Harmonic

### Siamak Haghdoost<sup>1, 2, 3</sup>

Brice Freneau<sup>4, 5</sup>, Nadia Haddy<sup>4</sup>, Maria Grazia Andeasi<sup>6</sup>, Francois Chevalier<sup>2</sup>, Mats Harms-Ringdahl<sup>3</sup>, Isabelle Thierry-Chef<sup>7, 8, 9</sup>

- <sup>1</sup> Université de Caen Normandie (UNICAEN)/Archade, Caen, France
- <sup>2</sup> Cimap/Laria, Ganil facility Caen, France 3
- <sup>3</sup> Centre for Radiation Protection Research Stockholm University (SU), Stockholm, Sweden
- <sup>4</sup> Gustave Roussy (GR), Université Paris-Saclay, Villejuif, France
- <sup>5</sup> Paris-Saclay University, Paris-Sud University, CESP, INSERM, Villejuif, France
- <sup>6</sup> Genetics Research Unit, CNR Institute of Clinical Physiology, Pisa- Italy
- <sup>7</sup> Institute for Global Health of Barcelona (ISGlobal), Barcelona, Spain
- <sup>8</sup> Ciber Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- <sup>9</sup> Universitat Pompeu Fabra (UPF), Barcelona, Spain

Introduction: The use of radiation for medical diagnosis and treatment procedures has had a major impact on the survival of paediaPtric patients. However, it comes at the expense of exposure of healthy tissues to low and moderate doses of ionising radiation, which long term effects remain to be investigated in the context of rapid technology improvements. HARMONIC is a European project that started in June 2019 and aim at investigating the long term health effects of ionizing radiation exposure in children and young adults. The project encompasses six work packages (WP) including dosimetry, biology, radiotherapy and cardiac catheterization.

**Methods:** HARMONIC will set up the first European cohort with biosamples from children and young adults treated with modern radiotherapy techniques and cardiac fluoroscopy. In this presentation, the planned activities in the biology work package will be discussed. Blood and saliva samples will be collected prospectively. Plasma and saliva protein profiles will be established for each patient before, after 3 months and finally 1 year after the last exposure.

**Results:** Biomarkers of immune response, oxidative stress, ageing and activities of some DNA repair/damage signalling and oxidative stress response/immune response pathways will be investigated. These results will be related to development of adverse health effects e.g. second primary cancers, as well as cardiovascular and neurovascular disorders with the aim to provide a better understanding of the mechanisms behind the adverse response as well as to identify biomarkers that can be used to optimize the clinical outcome.

Conclusion: No conclussion yet.

# P44 - Inter-comparison of OSL response of irradiated salted crackers between Croatian and Italian laboratories for retrospective dosimetry purposes

#### Nadica Maltar-Strmečki<sup>1</sup>

Maja Vojnić Kortmiš<sup>1</sup>, Ina Erceg<sup>1</sup>, Sara Della Monaca<sup>2</sup>, Paola Fattibene<sup>2</sup>, Maria Cristina Quattrini<sup>2</sup>, Emanuela Bortolin<sup>2</sup>

**Introduction:** In retrospective dosimetry, for the radiation and nuclear (R/N) emergency if uncontrolled radiation affected many people or the environment, the information about radiation doses allows for the prediction of the biomedical consequences. Therefore, when professional dosimeters are not available, objects of everyday use can be applied as dosimeters. In such cases, the method of optically stimulated luminescence (OSL) has proved very promising.

**Methods:** The salt, following the exposure to ionizing radiation, exhibits a particularly high OSL response compared with many other materials. In this study, radiation sensitivity of salty crackers available on the market was monitored with two PSL systems in two physical dosimetry laboratories (ISS, Italy and RBI, Croatia) using the validated PSL methods. The response at two stimulation 890 nm and 470 nm have been compared.

**Results:** The results indicate that salty snacks can be used in accident dosimetry. The stimulation by 470 nm has better response, but for both stimulations detect absorbed doses are below 100 mGy. **Conclusion:** The obtained data, showed good agreement between both laboratory OSL readout suggesting additional benefit to the use of salty crackers in the retrospective dosimetry.

The study was supported by NATO Science for Peace and Security Programme, grant No. G5684.

### **Selected references**

Christiansson M, Geber-Bergstrand T, Bernhardsson C, Mattsson S, Rääf CL. RETROSPECTIVE DOSIMETRY USING SALTED SNACKS AND NUTS: A FEASIBILITY STUDY. *Radiat Prot Dosimetry*. 2017;174(1):1-5. doi:10.1093/rpd/ncw044



<sup>&</sup>lt;sup>1</sup> Ruđer Bošković Institute, Bijenička c. 54, 10000 Zagreb, Croatia

<sup>&</sup>lt;sup>2</sup> Istituto Superiore di Sanità, Viale Regina Elena 299, I-00161 Rome, Italy

### P45 - Investigation of the Self-cleaning Processes in Lake Drūkšiai from Anthropogenic Origin 14C in the Cooling Pond of the Ignalina Nuclear Power Plant

### Algirdas Pabedinskas<sup>1</sup>

Evaldas Maceika<sup>1</sup>, Rūta Barisevičiūtė<sup>1</sup>, Žilvinas Ežerinskis<sup>1</sup>, Justina Šapolaitė<sup>1</sup>, Laurynas Butkus<sup>1</sup>, Laurynas Juodis<sup>1</sup>, Rūta Druteikienė<sup>1</sup>, Vidmantas Remeikis<sup>1</sup>

**Introduction:** Considerable amounts of <sup>14</sup>C in the nuclear reactor is generated by neutrons. It accumulates in reactor components, coolant and cleaning systems, and partly is released into environment as gaseous releases and as liquid effluents (IAEA 2004). RBMK-1500 type reactors were exploited at Ignalina NPP (Lithuania): Unit 1 - 1983-2004; Unit 2 - 1987-2009. Releases from NPP accumulate in local biosphere by photosynthesis including aquatic media, as INPP used Lake Drūkšiai as a cooling pond.

**Methods:** Temporal variation of <sup>14</sup>C in lake ecosystem was examined by analysing measured radiocarbon concentration of the organic compounds (Alkali soluble-AS and alkali insoluble-AIS) derived from the layers of the lake bottom sediments (Brock et al. 2010). A sediment core was sampled in 2019 at the deepest depression of Lake Drūkšiai by using a Kajak gravity corer, sliced to 1 cm layers and <sup>14</sup>C concentration was measured of every layer. AS and AIS organic fractions of sediment samples were extracted by using acid-base-acid method, were graphitized and measured by SSAMS at Vilnius Radiocarbon facility.

**Results:** Increase of <sup>14</sup>C concentration by 60 pMC in the AS fraction and only by 5 pMC in AIS fraction was observed corresponding to the period about year 2000, followed by gradual decrease. Estimated effective half-life of the self-cleaning is 8 years.

**Conclusion:** <sup>14</sup>C concentration profile analysis of the lake bottom sediments core revealed significant impact of the Ignalina NPP on the Drūkšiai Lake ecosystem. Critical period was in 2000s, when maintenance works of the reactors were performed, followed by gradual lake recovery.

#### **Selected references**

Brock F, Higham T, Ditchfield P, Ramsey CB. 2010. Current pretreatment methods for ams radiocarbon dating at the oxford radiocarbon accelerator unit (orau). *Radiocarbon* 52: 103–112. IAEA. 2004. Management of Waste Containing Tritium and Carbon-14. Vienna.

This research was funded by a grant (No. S-MIP-19-16) from the Research Council of Lithuania.

<sup>&</sup>lt;sup>1</sup> Nuclear research department, Center for physical science and technology, Lithuania

## P46 - Long-Term 14C Activity Measurements in Tree Rings Near Ignalina Nuclear Power Plant: How it Helps to Monitor Safety of Our Environment

### Evaldas Maceika<sup>1</sup>

Algirdas Pabedinskas<sup>1</sup>, Žilvinas Ežerinskis<sup>1</sup>, Justina Šapolaitė<sup>1</sup>, Dominykas Žiemys<sup>1</sup>, Laurynas Butkus<sup>1</sup>, Laurynas Bučinskas<sup>1</sup>, Vidmantas Remeikis<sup>1</sup>

**Introduction:** Atmospheric <sup>14</sup>C is produced by natural process of cosmic radiation interaction with atmosphere as well as by anthropogenic human activities.

**Methods:** 9 pine tree cores around the INPP and 3 tree cores in background area were extracted in order to examine the annual variation and dilution peculiarities of the released radiocarbon gaseous effluents from Ignalina NPP with RBMK-1500 reactors. <sup>14</sup>C concentration in tree rings were measured covering time span of 1980-2017.

Samples were physically and chemically (BABAB) prepared, graphitized with AGE-3 coupled with elemental analyzer and measured at Vilnius Radiocarbon SSAMS facility. Paired tree core samples, taken at the unidirectional sampling sites (located to the South- 1.8 and 5.1 km; West- 2.6 and 4 km; North-East- 1.9 and 6.6 km), were examined in details by considering meteorological data records from the Ignalina NPP local meteorological station (2004-2015) in order to trace atmospheric dilution effectiveness of <sup>14</sup>C released from the 150 m height INPP ventilation stacks.

**Results:** The results showed pronounced increase of <sup>14</sup>C up to 17.8 pMC in the tree rings during INPP exploitation as well during decommission periods and allowed to trace history of elevated release events.

**Conclusion:** The constructed Gaussian atmospheric model and analysis of unidirectional samples revealed relatively high year-by-year variation of released amounts and the atmospheric dilution conditions (in average about 130%), which were caused by different frequency of atmospheric stability classes occurrence (annually averaged dilution as typical for the C and D classes).

This research was funded by a grant (No. S-MIP-19-16) from the Research Council of Lithuania.

<sup>&</sup>lt;sup>1</sup> Nuclear research department, Center for physical science and technology, Lithuania

# P47 - Low dose alpha, gamma and mixed beam radiation gene expression effects at low and high dose rates in human VH10 fibroblasts and AHH1 lymphoblasts

### Milagrosa Lopez Riego<sup>1</sup>

Pamela Akuwudike<sup>1</sup>, Lovisa Lundholm<sup>1</sup>, Andrzej Wojcik<sup>1</sup>

**Introduction:** Low and high linear energy transfer ionising radiations (IR) from natural background, occupational or medical exposures occur at low doses (LD, <100 mGy) and dose rates (DR, <6 mGy/h). Such exposures have been associated with an increased incidence of solid tumours and leukaemia, but the shape of the dose response curve is not known. Using unique radiation sources at our facility, we aim at better understanding the effects of chronic exposure to different radiation qualities at low doses and different dose rates.

**Methods:** VH10 and AHH1 cells were chronically exposed to final doses of 50-200 mGy at 1 mGy/h <sup>241</sup>Am alpha, 1.6 mGy/h <sup>137</sup>Cs gamma or a 1:1 mixed exposure and analysed just after irradiation. These were compared to the same doses after acute 13.4 Gy/h alpha and 4.1 Gy/h X-rays, analysed 24 h post-IR. Six radiation responsive genes, i.e. *BBC3*, *CDKN1A*, *FDXR*, *GADD45A*, *MDM2*, and *XPC* were analysed by qRT-PCR.

**Results:** Gene expression analyses revealed a dose dependent upregulation pattern after chronic alpha exposure in VH10, not observed after mixed beam or gamma. Interestingly, there was a trend towards upregulation of some genes in acutely alpha-irradiated VH10, yet with a lower fold change than chronic exposure. In AHH1, we observed the opposite effects, here X-rays triggered a weak dose dependent upregulation after acute but not chronic exposure.

**Conclusion:** Further experiments are needed, but we believe that in vitro experiments with low activity sources can contribute to radiation protection and knowledge of potential health effects of different radiation qualities at LD and LDR.

<sup>&</sup>lt;sup>1</sup> Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University

### P48 - Macrophage subpopulations in stereotactic radiation-induced lung injury in mice.

#### Sarah Braga-Cohen<sup>1</sup>

Jan Baijer<sup>2</sup>, Morgane Dos Santos<sup>3</sup>, Valérie Buard<sup>1</sup>, Christelle Demarquay<sup>1</sup>, Fabien Milliat<sup>1</sup>, Agnès François<sup>1</sup>

- <sup>1</sup> Laboratoire de Radiobiologie des Expositions Médicales, IRSN
- <sup>2</sup> UMRE008 Stabilité Génétique Cellules Souches et Radiations, CEA

**Introduction:** Stereotactic radiotherapy is a therapeutic alternative for 20-30% of patients with localised primary bronchial cancer and considered at high surgical risk. It is a technique of high ballistic precision, using converging small beams irradiating very small volumes. This technique allows the use of ablative doses per fraction, from 6 to 20 Gy. Despite accurate targeting, some patients develop inflammatory or fibrotic pneumopathies. The laboratory has developed a model of stereotactic pulmonary irradiation in mice allowing us to acquire anatomopathological features and to decipher mechanisms's involved. We observed an important macrophage infiltrate at the site of the focal lesion. Macrophages are immune cells which can evolve into several functional phenotypes, and are known to be involved in radiation-induced fibrotic processes. Therefore, we are interested in subpopulations of macrophages in the development of radiation-induced lung lesions under stereotactic conditions in mice.

**Methods:** To this end, lung lesions in wild type mice and CCR2 deficient mice, in which macrophage recruitment is compromised, will be compared following two radiation doses: 60 Gy and 80 Gy (3x3mm²); and at different times: 1 month and 3 months. On one hand, immunohistochemistry will determine the spatial location of macrophage sub-populations and on the other hand, by flow cytometry, we will quantify these populations.

**Results:** The flow cytometry panel has already been improved to fully identify subpopulations of macrophages in the lungs.

**Conclusion:** Moreover, we will used single cell RNAseq (10X Genomics methodology) to decipher in depth the phenotypic diversity and heterogeneity of macrophages after lung stereotactic irradiation.

<sup>&</sup>lt;sup>3</sup> Laboratoire de Radiobiologie des Exposition Accidentelles, IRSN

# P49 - The competitive relationship between cell killing and induction of carcinogenic mutations in normal cells exposed to fractionated radiation

#### Pamela Akuwudike<sup>1</sup>

Milagrosa López Riego<sup>1</sup>, Lovisa Lundholm<sup>1</sup>, Andrzej Wojcik<sup>1</sup>

**Introduction:** Predicting the risk of radiation-induced carcinogenesis at very high doses as encountered during radiotherapy is complicated by a lack of understanding of the competitive relationship between cell killing and the induction of carcinogenic mutations. It has been suggested that solving this dilemma requires consideration of both dose fractionation and the heterogeneous dose distribution across normal tissues exposed during radiotherapy. Here, we investigated this dual effect on the competition between cell death and the induction of stable carcinogenic mutations. **Methods:** An *in vitro* experiment involving a fractionation scheme similar to clinical radiation exposure during conventional radiotherapy was designed. Two normal human cell lines, fibroblasts (VH10) and lymphoblasts (AHH-1) were irradiated at four different dose gradients (mimicking the heterogeneous dose distribution across normal tissue for each fraction), 0.25, 0.5, 1.0 and 2.0 Gy per fraction. Post fractionated radiation exposure, the effects on cell growth and cell survival, DNA damage repair kinetics via gamma H2AX assay as well as accumulation of stable chromosomal rearrangements using 3-color FISH were determined.

**Results:** Cell growth was inhibited with increasing dose, yet cells recovered completely after fractionated exposure ended, also at the highest dose level. A dose-dependent increase in markers of genomic instability which are indicative of the initiation of carcinogenic events was observed, such as accumulation of unrepaired DNA double-strand breaks and accumulation of micronuclei and nuclear buds at high doses.

**Conclusion:** In conclusion, the results so far indicate that events preceding cell death and induction of carcinogenic mutations steadily increase with increasing dose without a plateau.

<sup>&</sup>lt;sup>1</sup> Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University

# P50 - The "BioPhyMeTRE" project: novel biological and physical methods for triage in radiological and nuclear (R/N) emergencies

#### Clarice Patrono<sup>1</sup>

Dina Biyakhmetova<sup>2</sup>, Emanuela Bortolin<sup>3</sup>, Sara Della Monaca<sup>3</sup>, Ina Erceg<sup>4</sup>, Paola Fattibene<sup>3</sup>, Laura Kenzhina<sup>2</sup>, Nadica Maltar-Strmecki<sup>4</sup>, Aigul Mamyrbaeva<sup>2</sup>, Valentina Palma<sup>1</sup>, Maria Cristina Quattrini<sup>3</sup>, Maja Vojnič-Kortmiš<sup>4</sup>, Fail Zhamaldinov<sup>2</sup>, Antonella Testa<sup>1</sup>

**Introduction:** The project entitled "Novel biological and physical methods for triage in radiological and nuclear (R/N) emergencies" (BioPhyMeTRE) has been recently approved within the NATO Science for Peace and Security Programme. The project focuses on innovative biological and physical dosimetry methods allowing a rapid screening/triage of potential victims by using inexpensive and user-friendly analytical procedures and devices.

**Methods:** In the "BioPhyMeTRE" project, a multi-parametric approach, by both biological and physical dosimetry methods, is used. The biological method combines the two most standardised biodosimetry methods into a more exhaustive "two-in-one" assay. The physical method focuses on the use of a low cost, portable mini photo-luminescence reader for the individual dose assessment by using personal objects.

**Results:** The novel biological and physical methods have been developed and partially tested by the laboratories participating in the project. The biological combined protocol offers the advantage of simultaneous scoring of chromosome aberrations and micronuclei on the same slide, it is therefore time-saving and inexpensive. The physical method system, designed and commercialized for irradiated food analysis, allows rapid measurements, is transportable and usable in site, even by not skilled operators. Both methods will be validated through the set-up of calibration curves and interlaboratory comparisons to verify their reliability for triage in R/N emergencies. Moreover, automation systems for the novel biological protocol will be evaluated.

**Conclusion:** The biological and physical dosimetry methods proposed in the "BioPhyMeTRE" project, once they have been fully developed and validated, could represent useful tools for the categorization of subjects overexposed to ionising radiation in R/N emergencies.


Aknowledgements: The *BioPhyMeTRE* Project is fully funded by NATO Science for Peace and Security Programme (Grant G5684).

<sup>&</sup>lt;sup>1</sup> Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), Via Anguillarese 301, 00123 Rome, Italy

<sup>&</sup>lt;sup>2</sup> Institute of Radiation Safety and Ecology (IRSE) of National Nuclear centre of Kazakhstan, Krasnoarmeyskaya st.2, 071100 Kurchatov city, Kazakhstan

<sup>&</sup>lt;sup>3</sup> Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, 00161 Rome, Italy

<sup>&</sup>lt;sup>4</sup> Ruder Boskovic Institute (RBI), Bijenička c. 54, 10000 Zagreb, Croatia



1	١
$\Gamma$	1

Abderrafi Benotmane, Mohammed P41
Abend, Michael P42
Acharya, Munjal M. I13
Adhikary, Amitava O55

Adrian, Gabriel O16, P38

Aerts, An O5, O38, P13, P24, P41

Ainsbury, Elizabeth O52

Akuwudike, Pamela P31, P47, **P49** 

Altanerova, Ursula

Andersson, Charlotte

Andersson, Martin

O43

Andresen, Thomas L.

Antoine, Gilbert

Arapi, Vasiliki

P15

Araszkiewicz, Martyna

O15

O44

P38

P25

P25

P15

Araszkiewicz, Maityna P3, 1
Arendt, Maja L. O27
Aricò, Giulia O50
Arous, Delmon P4
Azadegan, B O21
Azimzadeh, Omid O12

В

O5, O7, O8, O34, O35, O38, O41, P13, P20, P24, P37,

P41

Badie, Christophe O48

Baeyens, Ans O2, P8, P32

Baijer, Jan P48
Baiocco, Giorgio P12
Baldé, Khadidiatou O33
Ballarini, Francesca O50

Barazzuol, Lara O13, O14, O22

Barbeau, Lydie P7
Barcellini, Amelia P21
Bardiès, Manuel O6
Barisevičiūtė, Rūta P45
Barnes, Micah O19
Bartzsch, Stefan H. P22

Baselet, Bjorn	<b>O7</b> , <b>O38</b> , <b>P20</b> , P37
Bassinet, Céline	O52
Bastholm Jensen, Kristine	O27
Baulch, Janet E.	I13
Benadjaoud, Mohamedamine	O37
Benderitter, Marc	O30, O37
Benotmane, Mohammed A	O35
Bergink, Steven	O13
Bermejo, Inigo	O32
Bernhardsson, Christian	O52
Bernhardt, Peter	O31
Berrigan, Helen	O18
Beyreuther, Elke	I11, O21
Bicher, Sandra	P22
Billault, Isabelle	O54
Biyakhmetova, Dina	P50
Bláha, Pavel	О3
Bodenstein, E	O21
Bonnefoy, Nathalie	O28
Bortolin, Emanuela	P44, P50
Bottone, Maria Grazia	O9
Bottu, Heleena	O18
Braga-Cohen, Sarah	P48
Brand, Michael	I11
Bravatà, Valentina	P26
Braziewicz, Janusz	P31
Brennan, Lorraine	O18
Brons, Stephan	O24
Brossard, Clément	O37
Brouwer, Uilke	O14
Bruchertseifer, Frank	O6, O17, O28
Brus, Anja	P38
Brzozowska-Wardecka, Beata	O1, P31
Buard, Valérie	O33, O37, P48
Buckley, Amy	O18
Buckley, Croí	O18, O29
Buompane, Raffaele	P1
Butkus, Laurynas	P45, P46

Butterworth, Karl T.	<b>I9</b> , O16
Buttler, Duncan	O19
Bučinskas, Laurynas	P46
Børresen, Betina	O27

 $\mathbf{C}$ 

P28
P26
P26
O29
O17
P9
0 = 0
O50
O50 I12, P38
<b>I12</b> , P38
<b>I12</b> , P38 O9, P21

Ceberg, Crister O16, O27, P2, P38

Chaouni, Samia
P30
Chapel, Alain
O30, O37
Charalampopoulou, Alexandra
P21
Charlotte, Lepleux
P25
Chauhan, Ankit
O39
Chen, Ce-Belle
O25
Cheng, Lei
O1

Chevalier, Francois
P25, P43
Christine, Almunia
P25
Chuo Anang, Dornatien
O5
Chérel, Michel
O17
Ciamarone, Federica
O9

Ciocca, Mario O3, O9, P21

Cirrone, Guiseppe A.P. P26
Claesen, Jürgen O8

Clarke, Niamh
O18, O29
Cloet, Karlien
P32
Combs, Stephanie E.
P22, P33
Coninx, Emma
O41
Constanzo, Julie
O6, **O28** 

Coolkens, Amelie	O41

Coppes, Rob O13, O14, O22

Cornelissen, Bart I8
Cullen, Daniel P39
Cuttone, Ciacomo P26
Cuypers, Bart O8

D

D'Agostino, Emiliano P6
Dahl, Ludvig O31
Dalke, Claudia O12
Danilová, Irina P27
Danilová, Irina B. P29

Davídková, Marie P27, P29

De Jong, Marion O49, P13

De Marzi, Ludovic P30

De Mey, Valerie O2

De Saint-Hubert, Marijke O49

De Veer, Michael O19

De Vos, Winnok H O8, O35, O41

Debus, Jürgen O24
Decrock, Elke O5

Dekker, Andre O32, P40
Dekkers, Fieke O48
Delfino, Ines P9

Della Monaca, Sara P44, P50

Demarquay, Christelle O30, O37, P48

Denais Lalieve, Delphine O37 Denisov, Sergey **O55** Diana, Savu P25 Dietrich, A O21 Djonov, Valentin **I6**, O19 Dollinger, Günther O25 P34 Domański, Szymon Donetti, Marco O23 Donlon, Noel O18, O29 Dorosz, Michał P34 Dos Santos, Morgane O37, P48

Drouet, Michel

P36

Druteikienė, Rūta	P45
Dróżdż, Agnieszka	P34
Dubois, Ludwig	O36
Duchambon, Patricia	O54
Dunne, Cara	O18, O29
Dunne, Margaret	O29
Durand, Michael	O18, O29
Durante, Marco	O40 O45
Duthoo, Evi	O2, <b>P8</b>
Dutour Sikirić, Maja	Р3
E	
Eberlein, Uta	I16
Edin, Nina Jeppesen	O15, P4, P19
Eilenstein, David	O45
Ekins, Jonathan	O52
Elmros, Lotta	O56
Embriaco, Alessia	O50
Emilie, Brotin	P25
Endesfelder, David	O52
Erceg, Ina	P3, P44, P50
Eriksson, Sophie	P38
Euler-Lange, Rosemarie	O24
Ežerinskis, Žilvinas	P45, P46
F	
Facoetti, Angelica	O3, O9, <b>O23</b> , <b>P21</b>
Faget, Julien	O28
Fairmichael, Ciaran	P39
Fattibene, Paola	P44, P50
Felici, Giuseppe	P6
Feoli, Chiara	03
Fernandez-Palomo, Cristian	O19
Ferrari, Alfredo	O50
Ferrari, Beatrice	O9
Ferrarini, Michele	P21
Fida, Haris Bin	O35
Filipek, Mateusz	P31

Finck, Robert

O42

Finnon, Rosemary	O48
Forkman, Bengt	O56
Forssell-Aronsson, Eva	<b>I2</b> , O20, O44
Forte, Giusi I.	P26
Francois, Agnès	P48
Freneau, Brice	P43
G	
Gaipl, Udo	K5
Gaschet, Joëlle	O17
Gasparini, Alessia	P6
Gatin, Anouchka	O54
Geenen, Lorain	P13
Georgakilas, Alexandros G.	K1
Ghita, Mihaela	O16
Giacometti, Valentina	P28
Gialanella, Lucio	P1
Giordano, Frank A.	P17
Giuranno, Lorena	O36
Glowa, Christin	O24
Godoy, Paulo	011
Goetschalckx, Ines	O5
Gorin, Norbert-Claude	O30
Gouard, Sebastien	O17
Gram, Magnus	O44
Granger, Romain	O37
Grazia Andeasi, Maria	P43
Gregoire, Eric	O52
Groot, Arjan	O36, P7
Gryziński, Michał A.	P34
Guardamagna, Isabella	P12
Guilloux, Yannick	O17
Guipaud, Olivier	O33
Guns, Pieter-Jan	P41
Н	
Haase, R	O21
Haberthür, David	O19
Habibi, Martha	O46, <b>O47</b>

Habrand, Jean-Louis	P30
Haddy, Nadia	P43
Haghdoost, Siamak	O11, <b>P43</b>
Hamberg, Maarten	O13
Hammond, Ester	К3
Hans, Stefan	I11
Hansen, Anders E.	O27, P38
Hanson, Ingunn	<b>O15</b> , P4
Harms-Ringdahl, Mats	P43
Hausermann, Daniel	O19
Heeran, Aisling	O18, O29
Helou, Khalil	O20, O44
Herate, Cecile	P11
Herskind, Carsten	P10, <b>P17</b>
Heynickx, Nathalie	P24
Hildebrandt, Guido	O4
Hill, Mark A	O26, P18
Hinrichsen, Yvonne	O42
Hintz, Lisa	O24
Hippeläinen, Eero	P14
Hladik, Daniela	O12
Hobbie, Fabian	O13
Hoorelbeke, Delphine	O5
Hosseinpour, Parisa	O25
Hosser, Hiltraud	P10
Howell, Roger	<b>I4</b>
Hunger, Annique	O25
Hurychová, Markéta	P29
Huylebroeck, Danny	O35
Hååg, Petra	P15
I	
Ient, Jonathan	<b>P</b> 7
Iliakis, George	O46
Inalegwu, Auchi	O8
Inguscio, Chiara Rita	О9
Isaksson, Mats	O42
Ivaldi, Giovanni Battista	P21

Jain, Suneil	P39
Jarošová, Šárka	P29
Jean, Armengaud	P25
Jiang, Yuting	013
Jullien, Nicolas	P36
Juodis, Laurynas	P45
K	
Kacperek, Andrzej	P18
Kaeppler, Jakob	P7
Kalospyros, Spyridon A.	K1
Kalra, Namita	O39
Kaminskyy, Vitaliy	P15
Karaiskos, Pantelis	O46, O47
Karam, Jihad	O6, O28
Karger, Christian P.	O24, O50
Karsch, Leonhard	I11
Karyofyllis, Panagiotis	O47
Kaseva, Tuomas	P14
Kazmierczak, Urszula	P31
Kenzhina, Laura	P50
Kiltie, Anne E	O26
Kirstein, Anna	P33
Klein, Mitzi	O19
Klementová, Jana	P29
Kollaros, Nikolaos	O47
Konijnenberg, Mark	<b>K6</b> , O42
Konings, Katrien	O7
Konradsson, Elise	O16, <b>O27</b> , <b>P2</b> , P38
Korgul, Agnieszka	P5, P34
Kozlowska, Wioletta	O50
Krakowiak, Wiktoria	P35
Krause, M	O21
Kristensen, Annemarie T.	O27
Kulka, Ulrike	O52
Kumar Sah, Dhananjay	O39
Kumar-Singh, Samir	O34

Kumari, Neeraj	O39
L	
La Spada, Marianna	P21
Ladaigue, Ségolène	O33
Ladjohounlou, Riad	O6
Laguette, Nadine	O28
Laissue, Jean	O19
Lancien, Mélanie	O17
Langen, Britta	O20
Lankoff, Anna	P35
Larkin, John	O18, O29
Larsson, Malin	O20
Lasalvia, Maria	P9
Lassmann, M.	I16
Laukens, Kris	O8
Laurent, Carine	P30
Leavitt, Ron J.	I13
Lecomte, Delphine	P30
Lee, Seok Ho	O32, P40
Lefranc, Anne-Charlotte	O33, O37
Lepore, Maria	P9
Lessmann, Elisabeth	I11
Lewensohn, Rolf	P15
Leybaert, Luc	O5
Leys, Natalie	O34
Limoli, Charles L.	I13
Linard, Christine	O30, O37
Lindgren, Ola	O31
Liotta, Marco	P21
Lis, Krzysztof	P35
Lisowska, Halina	O1, P31, P35
Lonati, Leonardo	P12
Lopez-Riego, Milagrosa	P31, <b>P47</b>
Louvet, Cedric	O17
Lundh, Olle	I21
Lundholm, Lovisa	<b>O1</b> , P31, P47, P49
Lundholm, Lukas	O44
Lynam-Lennon, Niamh	O18, O29

Lyng, Fiona	P39
López Riego, Milagrosa	P49
Löck, Steffen	I11
Lühr, A	O21

M

Ma, Jun	O55
Maceika, Evaldas	P45, <b>P46</b>
Maciak, Maciej	P34
Madas, Balázs	P16
Mairani, Andrea	O50
Majewski, Matthäus	P42
Malhotra-Kumar, Surbhi	O34
Malinen, Eirik	P4, P19
Maliszewska-Olejniczak, Kamila	P5, <b>P34</b>
Maltar-Strmečki, Nadica	<b>P3</b> , <b>P44</b> , P50

Mamyrbaeva, Aigul P50 Manda, Katrin O4

Manti, Lorenzo O3, P1, P9, P26

Marcatili, Sara O6

Mariampillai, Adrian Eek P19

Markelc, Bostjan P7

Martin, Olga I5

Martinaud, Christophe O30

Martinsson, Johan O42

Mastorakou, Irene O47

Matejka, Nicole
O10, O25
Mathieu, Noëlle
O30, O37
Mattsson, Sören
O43

Mattsson, Sören O43

Maurel, Catherine O17

Mavragani, Ifigeneia V. K1

Mbouombouo Mfossa, André-Claude O35

McCormick, Paul O18, O29

McGarry, Conor P28

McMahon, Stephen J. I20, O16, P28

Meade, Aidan P39
Medipally, Dinesh P39
Mehigan, Brian O18, O29
Michaelidesová, Anna P27

Michalettou, Theodora-Dafni	K1
Mihaela, Tudor	P25

Milliat, Fabien O30, O33, O37, P48

Minafra, Luigi P26
Mohamad Mohty, Mohamad O30
Moisoi, Nicoleta P23
Monaghan, Jade P39
Moons, Lieve O35, O41

Moreels, Marjan O7
Moreno Roig, Eloy O36

Morgenstern, Alfred O6, O17, O28

Morrissey, Maria O29

Morton, Lindsay I15

Mostafavi, Mehran O55

Mothersill, Carmel I3

Munck af Rosenschöld, Per O27

Muschel, Ruth J O26, P7

Mustaciosu, Cosmin Catalin P10

Mysara, Mohamed O34, O35 Müller, J O21

N

Narayan Bhatt, Anant O39
Neefs, Mieke O34, P20

Nickson, Catherine P18 Nikitaki, Zacharenia K1

Nikolakopoulou, Aggeliki

O46, O47

Nonnekens, Julie

O49, P13

Novak, Metka

P15

Nugent, Timothy O18, O29

O

O'Sullivan, Jacintha O18, O29

Oestreicher, Ursula O52
Olko, Pawel I14
Omidali, Bahareh P14
Orlandi, Ester P21

Osong, Biche O32, P40

Ostheim, Patrick P42

Ottolenghi, Andrea	P12
Oughton, Deborah	I18

P

Peschke, Peter

Pabedinskas, Algirdas P45, P46
Pachnerová Brabcová, Kateřina P27
Palma, Valentina P50
Pantelias, Antonio K1

Pantelias, Gabriel **B&A**, O46

Papagiannis, Panagiotis O47 Parisi, Alessio 051 Parris, Toshima O20 Parsons, Jason P18 Pateux, Jérôme P36 Patrono, Clarice P50 Pawelke, Jörg I11 014 Peng, Xiaohong P9 Perna, Giuseppe Perrin, Justine 017 Perrot, Yann O49 Persson, Bertil R O56

Petersson, Kristoffer I10, O16, O26, O27, P2, P38

O24

Petersson-Årsköld, Sindra **I23** Petringa, Giada O3, P26 Pichard, Alexandre 06 P31 Plodowska, Magdalena Polgár, Szabolcs P16 Popescu, Roxana-Cristina P10 Port, Matthias P42 Porzio, Giuseppe P1

**O6**, O28 Pouget, Jean-Pierre Pour Khavari, Ali 011 Pouzoulet, Fréderic P30 Pringle, Sarah 014 Prise, Kevin M. **K2**, P28 Pucci, Gaia **P26** Pullia, Marco O23, P21 Płódowska, Magdalena P35

Q

Quattrini, Maria Cristina	P44, P50
Quintens, Roel	O8, <b>O35</b> , O41
Quitoco, Monica	O33
R	
Radstake, Eline	P37
Radu, Mihai	P10
Rai, Yogesh	O39
Ramadan, Raghda	O5
Redmond, Kelly	P39
Reijonen, Vappu	P14
Reindl, Judith	O10, O25
Remeikis, Vidmantas	P45, P46
Ricciardi, Valerio	O3, <b>P1</b> , <b>P9</b>
Riccobono, Diane	P36
Ritter, Sylvia	O40, O45
Rizzo, Marzia	O11
Roeder, Kim Carola	O45
Roos, Per	I17
Rosa, Enrico	O3
Rossi, Sandro	O23
Rouard, Hélène	O30
Ruan, Jia-Ling	O26
Rudigkeit, Sarah	O25
Russell, Emily	P28
Russo, Giorgio	P26
Ruud, Martine	P19
Ryan, Anderson J	O26
Rykkelid, Anne Marit	P19
Rääf, Christopher	O42
S	
Saager, Maria	O24
Sabatier, Laure	P11
Sache, Amandine	O37
Sakamoto-Hojo, Elza	O11
Sala, Paola	O50

Sallam, Magy	P41
Salli, Eero	P14
Sami, Ahmad	P17
Sammer, Matthias	O25
Sanli, Ilknur	P40
Savazzi, Simone	O23
Savio, Monica	P12
Savoca, Gaetano	P26
Savolainen, Sauli	<b>I19</b> , P14
Savu, Diana Iulia	P10, P23
Scherthan, H.	I16
Schickel, E.	O40
Schilling, Daniela	P33
Schmid, Thomas E.	O25, P22, P33
Scholz, Michael	O45
Schroeder, I. S.	O40
Schrunner, Stefan	P4
Schröder, Annemarie	<b>O</b> 4
Schröpfer, Leo	P22
Schumann, S.	I16
Schültke, Elisabeth	<b>I7</b>
Schürer, Michael	I11, O21
Seymour, Colin	I3
Shcherbakov, Viacheslav	O53
Shubbar, Emman	O20, O44
Siamak, Haghdoost	P25
Sicard-Rosell, Cécile	O54
Sichel, François	P30
Simon, Jean-Marc	O30, O37
Sioen, Simon	P32
Sjögreen Gleisner, Katarina	O31
Smart, Sean C	O26
Smit, Timo	O40
Smyth, Lloyd	O19
Sobota, Daniel	P31
Soest, Johan van	O32, P40
Sofiev, Alexey	P14
Soni, Aashish	O46

Soni, Ravi	O39
Sonia, Hem	P25
Souli, Maria P.	K1
Spetz, Johan	O20
Squiban, Claire	O30, O37
Stefan, Dinu	P30
Stevens, Piet	P6
Sticht, Carsten	P17
Stivala, Lucia Anna	P12
Stouten, Sjors	O48
Straticiuc, Mihai	P10
Struelens, Lara	O49
Suckert, T	O21
Sundlöv, Anna	O31
Svensson, Johanna	O31
Syljuåsen, Randi	P19
Szary, Karol	P35
Sémont, Alexandra	O30
T	
Tabarelli de Fatis, Paola	P21
Tabarelli de Fatis, Paola Talpur, Rubab	P21 P23
Talpur, Rubab	P23
Talpur, Rubab Tamborino, Giulia	P23 <b>O49</b>
Talpur, Rubab Tamborino, Giulia Tapio, Soile	P23 O49 O12
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges	P23 O49 O12 O37
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela	P23 O49 O12 O37 P23
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan	P23 O49 O12 O37 P23 O31
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I.	P23 O49 O12 O37 P23 O31 K1, O46, O47
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I. Testa, Antonella	P23 O49 O12 O37 P23 O31 K1, O46, O47 P50
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I. Testa, Antonella Teulon, Isabelle	P23 O49 O12 O37 P23 O31 K1, O46, O47 P50 O6
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I. Testa, Antonella Teulon, Isabelle Thiede, Bernd	P23 O49 O12 O37 P23 O31 K1, O46, O47 P50 O6 O15
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I. Testa, Antonella Teulon, Isabelle Thiede, Bernd Thierry-Chef, Isabelle	P23 O49 O12 O37 P23 O31 K1, O46, O47 P50 O6 O15 P43
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I. Testa, Antonella Teulon, Isabelle Thiede, Bernd Thierry-Chef, Isabelle Thompson, James	P23 O49 O12 O37 P23 O31 K1, O46, O47 P50 O6 O15 P43 O26
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I. Testa, Antonella Teulon, Isabelle Thiede, Bernd Thierry-Chef, Isabelle Thompson, James Torgue, Julien	P23 O49 O12 O37 P23 O31 K1, O46, O47 P50 O6 O15 P43 O26 O6
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I. Testa, Antonella Teulon, Isabelle Thiede, Bernd Thierry-Chef, Isabelle Thompson, James Torgue, Julien Trappetti, Verdiana	P23 O49 O12 O37 P23 O31 K1, O46, O47 P50 O6 O15 P43 O26 O6 O19
Talpur, Rubab Tamborino, Giulia Tapio, Soile Tarlet, Georges Temelie, Mihaela Tennvall, Jan Terzoudi, Georgia I. Testa, Antonella Teulon, Isabelle Thiede, Bernd Thierry-Chef, Isabelle Thompson, James Torgue, Julien Trappetti, Verdiana Tremi, Ioanna	P23 O49 O12 O37 P23 O31 K1, O46, O47 P50 O6 O15 P43 O26 O6 O19 K1

Tymińska, Katarzyna	P5, P34
U	
Unger, Kristian	I1
V	
Vachelová, Jana	P27
Valvo, Francesca	P21
Valérie, Rofidal	P25
van Buuren-Broek, Fleur	O13, O22
van den Berg, Annette	O36
van der Rest, Guillaume	O54
van Hoey, Olivier	O52
van Ijcken, Wilfred FJ	O35
van Luijk, Peter	O22
Vasileiou, Christine	K1
Veldwijk, Marlon R.	P10
Verduyn Lunel, Sjoerd	O48
Verellen, Dirk	P6
Vermeer, Jenny	P7
Vermeulen, Stephanie	O2
Verreet, Tine	O35
Verslegers, Mieke	O34, O35, <b>O41</b> , P37
Viktorsson, Kristina	P15
Vila, Isabelle	O28
Villagrasa, Carmen	O49
Vissink, Arjan	O14
Vojnić Kortmiš, Maja	P44, P50
Vojnovic, Borivoj	O26
von Neubeck, C	O21
von Törne, Christine	O12
Vondráček, Vladimír	P27
Vooijs, Marc	O36, P7
Voshart, Daniëlle	O13, <b>O22</b>
Voudris, Vasilis	O47
Vozenin, Marie-Catherine	<b>K</b> 4
Vral, Anne	O2, P8, P32
Vromans, Els	O5

Waldner, Lovisa	O52
Waluś, Martyna	P34
Wansleeben, Carolien	O36
Wee, Leonard	P40
Wenz, Frederik	P17
Werin, Sverker	O56, I22
Wiliński, Maciej	P34
Willems, Paul C.	P40
Wilppu, Ulla	P14
Woda, Clemens	O52
Wojcik, Andrzej	O1, O52, <b>P31</b> , P47, P49
Wojtania, Grzegorz	P5
Wouters, Shari	O34
Wu, Yi	O14
Wójcik, Andrzej	P35
Węgierek-Ciuk, Aneta	P35
Y	
Yliperttula, Marjo	P14
Z	
Zahradníček, Oldřich	P27
Zanzonico, Pat	OL1
Zhamaldinov, Fail	P50
Zíková, Martina	P29
Å	
Åkerström, Bo	O44
Åkesson, Anna	O31
Š	
Šapolaitė, Justina	P45, P46
Šegota, Suzana	P3
Ž	
Žiemys, Dominykas	P46